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1 Introduction 
 
1.1 Background 
 
It would be interesting to know whether S. H. Cohen and H. W. Boyer anticipated the 
impact of their 1973´s discovery, that genes can be combined and arranged in new order in vitro, 
on today´s spectrum of modern pharmaceuticals. Since then, the development of protein 
pharmaceuticals has undoubtedly been boosted by the advent of recombinant DNA technology. 
Thereby, the large-scale production of recombinant DNA based vaccines, antibodies, functional 
regulators, enzymes and the like became possible. And the scientific world is still in move: in June 
2000, U.S. President Clinton announced the completion of the first survey of the entire human 
genome. As a consequence, a better understanding of the molecular basis of diseases and the 
disclosure of new targets for proteinic drugs took center stage of pharmaceutical scientists´ hopes 
and expectations. Under these conditions, biopharmaceutical technology is considered to enjoy a 
magnificent prospect. The world market in recombinant drugs – struggling for US$ 1.2bn in 1985 
– totaled US$ 27bn in 2001 and is forecasted to almost double to US$ 50bn in 2010.  
However, this growth phenomenon would level to a minor degree if the ground has been 
less well prepared: tremendous effort was put on the fields of pharmaceutical analytics and 
protein drug stabilization during the last two decades. High-sophisticated analytical methods 
accompany drug development and are a prerequisite to appropriate drug´s R&D programs.  
Both areas, protein analytics and protein aggregation interfere with each other in a most 
exciting way: on the one hand, the identification of intrinsic and extrinsic factors that contribute 
to the stabilization of protein drugs has provided valuable information for stabilizing protein 
pharmaceuticals (Wang, 1999). On the other hand, insufficient stabilization, facilitating 
aggregation processes, has to be unveiled in earliest stages in order to commence adequate 
counter measurements. Hence, pharmaceutical industries try to implement advanced up-to-date 
analytical techniques in aggregation identification and quantification.  
The major obstacle to an overall quantification of protein aggregates is obvious: protein 
aggregates can be soluble or insoluble in nature, and most commonly – and for the 
pharmaceutical analyst most challenging – they do exist in parallel. Due to the underlying 
principles of the methods applied in aggregation analysis, either the soluble or the insoluble 
aggregate fraction can be separated and quantified. Quantification of insoluble aggregate 
specimen – often subsumed under particulate matter – is commonly performed by turbidity 
measurements or particle counting techniques, e.g., via light obscuration or Coulter principle. 
Moreover, filtration and centrifugation procedures may be applied to separate insoluble 
aggregates from soluble, native protein. 
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Referring to soluble aggregates, (polyacrylamide) gel electrophoresis (PAGE) and high 
presssure liquid chromatography (HPLC) are state-of-the-art techniques. While accurate 
determination of the aggregate amount subsequent to PAGE separation via densitometric 
detection is delicate, HPLC proved to be a sound method for soluble aggregate analysis. In case 
of aggregate determination based on size, the size-exclusion (SE) mode of HPLC is to be applied, 
whereas in reversed-phase (RP) mode isoforms of aggregates or covalent and non-covalent 
aggregates can be differentiated (Perlman and Nguyen, 1992; Shahrokh et al., 1994). However, 
both methods lack the possibility to analyze dissolved samples aside undissolved samples.  
Almost coevally, the field-flow fractionation (FFF) technique entered the analytical stage 
in the 1960s, but with by far less success (Giddings, 1966). Considering the FFF´s low 
recognition, the development that has taken place since then resulting in a diversity of different 
FFF methods – albeit promoted by only a few supporters – is all the more remarkably (Coelfen 
and Antonietti, 2000). That range of various FFF techniques was established in the early years, by 
this extending the assortment of sample components amenable to FFF separation considerably, 
i.e., encompassing a width from the lowest nm range up to ~100 µm. Given the sample 
dimensions in the arena of pharmaceutical protein drugs - varying between 1 – 10 nm by native 
state peptides and proteins, the two-digit nm range of soluble aggregates and several microns of 
insoluble aggregates –, FFF may be considered as ideal candidate for analysis of complex protein 
samples. However, only recently the optimization of FFF methodology and instrumentation, 
most notably of the subtechnique asymmetrical flow FFF (AF4) has taken place and should pave 
the way for a broader application in the pharmaceutical industry. 
 
1.2 Rationale of this work 
 
The major aim of this work was to comprehensively evaluate the applicability of AF4 in 
pharmaceutical protein analytics. Soluble and insoluble protein aggregates were to be separated 
from native protein monomers in a reproducible way in one single run. For a rational assessment 
of the results, AF4 data were compared to established methods in protein aggregation analysis, 
mainly SE-HPLC and light obscuration technique. To gain maximum information on the 
fractionated specimen, AF4 was to be coupled on-line with multi-angle light scattering (MALS).  
Furthermore, the general applicability of AF4 in other closely related fields of 
pharmaceutical analytics was to be investigated and the provided data were to be assessed. 
Therefore, separation tasks in the field of parenterals and nanocolloidals were approached 
presently considered to be impractical or, at least, highly challenging. 
The investigations in protein aggregation analysis were augmented with an approach to 
optimize the liquid formulation of a therapeutic antibody. Via adequate selection of stabilizers 
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and assessment of appropriate excipient concentrations aggregation tendencies of the antibody 
were to be minimized.  
 
1.3 Organization of this thesis 
 
This thesis is divided into two main sections. The THEORETICAL SECTION starts 
with a general FFF overview in Chapter 2. In particular, inherent AF4 parameters and separation 
principles are presented. In Chapter 3 the phenomenon of protein aggregation is reviewed. 
Besides, prevalent theories on aggregation are discussed and means of aggregation quantification 
are set out. Chapter 4 focuses on the application of multi-angle light scattering in protein 
analytics and extensively surveys the theoretical aspects. The theoretical section is summarized in 
Chapter 5. 
Chapter 6, which illustrates and exemplifies the evaluation of AF4 applicability in protein 
aggregation analytics, launches the EXPERIMENTAL SECTION. The following chapters 
present exclusive examples of how AF4 can be favorably applied to selected tasks in 
pharmaceutical analytics, e.g., analytics of antibody solutions in siliconized syringes (Chapter 7), 
gelatin nanoparticle characterization (Chapter 8), and particulate matter identification in 
parenterals (Chapter 9). The subject protein aggregation is specifically targeted by a laboratory 
case study described in Chapter 10. Besides a short review on formulation strategies of liquid 
protein pharmaceuticals an approach to reduce aggregation biases of a therapeutical antibody is 
presented. Chapter 11 summarizes the experimental outcome, aims for appropriate conclusions 
and puts the results into perspective. Chapter 12 is adressed to listen special and continuative 
literature referred to in the thesis. 
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2 The family of field-flow fractionation (FFF) techniques 
 
2.1 Introduction and underlying principles 
 
FFF occupies an unique niche in the field of analytical fractionations because it is the 
only technique being capable to separate materials over the entire colloidal size range with high 
resolution (Giddings, 1993). However, FFF operators agree that one major obstacle to a 
widespread FFF utilization is due to its greatest asset. That asset is its versatility, and – as in daily 
life – versatility comes with a price: there is no simple formula for choosing the proper FFF 
technique for a given application. Moreover, one has to understand the underlying mechanisms 
of the fractionation to approach successfully a separation problem by means of FFF (Jonsson, 
2001). The fundamental principle of FFF is illustrated in Fig. 1.  
An external field forces the sample components to accumulate at different levels in a 
channel. Since the flow velocities of the carrier liquid streaming through that channel correlate 
with those level heights, the sample components are transported with different speed, resulting in 
a component separation. However, this view would simplify matters in an unjustifiable way. 
The sample separation is performed inside a narrow ribbon-like channel. This channel 
typically reveals dimensions of ±50 cm in length and ±2 cm in width, whereas the channel heigth 
can vary between 50 µm and 500 µm. From the inlet, a carrier liquid is pumped through the 
channel, establishing a parabolic flow profile (laminar Newtonian flow) as in a capillary tube, 
propelling the samples towards the outlet (Huang, 1999; Bos and Tijssen, 1995). Perpendicular to 
the direction of the carrier liquid flow an external field is applied, forcing the sample components 
to accumulate at one of the channel walls, termed accumulation wall. Under “normal mode” or 
“Brownian mode” conditions, the sample components can be considered as non-interacting 
point masses, with their center of gravity near to the accumulation wall (van Asten, 1995). Due to 
the established concentration gradient, a diffusion flux in reverse direction, i.e., back into the 
interior of the channel, is induced according to Fick´s law. As a consequence of the two rivaling 
parameters – the exerted field of force and the opponent diffusion flux – a steady-state profile is 
laminar inlet
flow channel
laminar outlet
field of force
Fig. 1. Schematic separation principle of FFF.
Chapter 2. The family of field-flow fractionation (FFF) techniques 
 5
generated, and the equilibrium distributions of the sample components across the channel can be 
expressed by a mean layer thickness x, as illustrated in Fig. 2 (Coelfen and Antonietti, 2000; 
Giddings, 1991). Those analytes (like a) with distributions nearest to the accumulation wall are 
positioned in the slowest flow laminae of the parabolic laminar flow. Accordingly, they gradually 
separate from analytes (like b), which are positioned at more elevated levels in the channel, 
therefore eluting with faster laminae.  
Consequently, FFF can be considered as a hybrid of chromatography and field-driven 
methods such as electrophoresis and ultracentrifugation (Pauck  and Coelfen, 1998; Li et al., 
1990). Like chromatography, FFF is an elution technique with inherent differential flow 
displacement phenomena. On the other hand, like ultracentrifugation, FFF separation is based on 
an applied gradient or field of force.  
Since that field of force is opposed by sample diffusion processes, the sample 
concentration c (relative to the wall concentration c0) approaches an exponential function of the 
mean layer thickness x remote from the accumulation wall (Martin and Williams, 1992) 
 
 
where U represents the drift velocity of the sample induced by the external field. The diffusion 
coefficient D can be related to the frictional coefficient f by the Stokes-Einstein relationship  
 
 
 
where k is Boltzmann´s constant and T is the temperature.  The drift velocity U is correlated to 
the force F, which is exerted on the sample, by U = F/f. Furthermore, the parameter l =D/│U│ 
is introduced, with l representing the average sample-wall distance. Consequently, the relationship 
 
 
field of force
flow
parabolic
profile
bottom wall
a
b
x
w
Fig. 2. Schematic representation of the separation of two components a and b via FFF 
across the parabolic flow profile within the channel.  
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can be derived, expressing that the samples will be positioned proximate to the accumulation wall 
(low l) when exposed to vigorous forces. In order to provide optimal values of l, i.e., to guarantee 
appropriate sample levels for FFF experiments, the intensity of the external field can be varied. 
Accordingly, F can be altered proportionally and the precedent condition to ensure efficient FFF 
operations can be met: w >> l. As the FFF accessories kits available provide almost any “w”, the 
wide application range of FFF becomes evident. Eq. (3) can be extended by the dimensionless 
parameter λ, leading to  
 
 
 
where λ is a synonym for the retention ratio R, i.e., the retention time of an unretained 
sample component t0 to the retention time of a retained sample component tr, or equivalently in 
terms of retention volumes V0/Vr. It is important to refer to the relationship tr = F given by Eq. 
(4), thereby implicating that the retention time of sample components can be assessed as desired 
by exerting expedient force intensities. Large analytes with inherent low values of their diffusion 
coefficients D will offer only slight resistance to exerted force intensities. In contrast, smaller 
analytes such as peptides or low molecular weight (lmw) proteins will counterbalance even 
extensive force fields, due to their high D values. This explains why it is usually more delicate to 
separate small sample specimen via FFF than to fractionate larger samples. As it will be shown in 
the experimental section, F can be increased to a level at which the elution of high molecular 
weight (hmw) samples is totally blocked. By monitoring of the channel effluent by adequate 
detection systems, the retention times of the analytes can be determined and sample 
compositions can be elucidated by straightforward FFF experiments. 
The magnitude of F, which can be applied on the sample specimen, depends on the 
experimental arrangements of the various FFF techniques, i.e., the kind of field that is installed. 
Primarily four prominent FFF fields, introduced in Chapter 2.2, have become most relevant for 
scientific research - and are applied to an increasing extent in industrial practice (Janca, 1992). 
The common feature of all FFF subtechniques is the parabolic flow profile of the carrier liquid as 
the driving parameter of separation.  
To keep up with completeness: a significant number of FFF techniques have been 
developed. However, some of those – although justified by special applications – attract scant 
attention or are to be qualified as “exotic”. Therefore, these techniques are described in the 
literature only sporadically, e.g., acoustic or photophoretic FFF (Coelfen and Antonietti, 2000). 
Fw
kT
w
l
V
V
t
t
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==== 00λ (4) 
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2.2 FFF techniques and modes of operation 
 
Since the theoretical fundament of Sedimentation FFF (SFFF) was grounded in the late 
1960´s and put into practice shortly thereafter, SFFF may be deemed one of the oldest FFF 
techniques (Yang et al., 1974; Berg and Purcell, 1967). SFFF experiments are performed in a 
channel constituted by two closely spaced parallel surfaces. When this channel is rotated in a 
centrifuge, dissolved and suspended analytes - which are more dense than the ambient mobile 
phase - are forced to migrate towards the outer wall. Correspondingly, if the sample is less dense 
than the ambient liquid, “floating” phenomena are to be observed, and those sample components 
accumulate at the inner wall, as illustrated in Fig. 3.  
The limiting particle size for retention in SFFF depends on the maximum speed of the centrifuge, 
i.e., on the gravitational field exerted, and on density differences. Via modern SFFF equipment 
with inherent gravitational forces exceeding 100,000 g a broad range of materials of biological 
and industrial interest can be characterized. Furthermore, the aqueous carrier density can be 
varied towards lower densities by adding organic liquids. Vice versa, the density will increase if 
salts or sugars are added to aqueous liquids or if water is added to organic fluids, resp. (Moon, 
2000; Kirkland et al., 1983). The theoretical principles of SFFF are summarized by Eq. (5) 
 
 
 
with G symbolizing the centrifugal/gravitational acceleration, |∆p| the density differences 
between the sample components and the solvent used, and d the effective spherical diameter of 
the sample component. Due to the high resolution potential of SFFF, typical applications are the 
 
Fig. 3. Sedimentation FFF: Due to ultra-
centrifugation, the separation is based on 
density differences between analyte specimen 
and the carrier liquid. Note that “floating” 
analytes (z) opposite the bands of denser 
samples (x, y), enabling fractionation of 
“floating” and “sinking” components 
simultaneously. 
6
3 ρπ ∆= GdF H (5) 
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characterization of soil and sediment colloids, the separation of biopolymers and 
macromolecules, or cell sorting (Williams et al., 2002; Chen and Beckett, 2001; Kirkland et al., 
1980). 
Thermal FFF (ThFFF), is considered to be the oldest of all FFF methods. As a matter 
of fact, research in thermal diffusion started in 1856, when Ludwig observed the selective 
migration of compounds towards colder regions (Tyrell, 1961). In the 1960´s, ThFFF was at first 
applied for the separation of polystyrenes; its broad applicability for the fractionation of various 
polymers was demonstrated in 1978 (Thompson et al., 1967; Giddings et al., 1978). The channel 
design of ThFFF is shown in Fig. 4.  
By exerting a large temperature difference across the channel the thermal diffusion effect 
is employed to concentrate the sample components – typically polymers and colloids – at the 
cold wall. Under normal operation, this temperature difference between the hot wall, heated with 
electric cartridges, and the water-cooled cold wall encompasses 100 °C. The applicability of 
ThFFF in aqueous systems is restricted due to the weak thermal diffusion of polymers in water. 
Therefore, particles and lipophilic polymers are favorably characterized in organic media 
(Schimpf, 2000a). Given the background of the numerous assumptions and approximations 
inherent to ThFFF, this method is judged to be the most complicated FFF subtechnique, though 
the effective driving force |F| per analyte can be defined by the basic correlation 
 
 
where DT is the thermal diffusion coefficient (Coelfen and Antonietti, 2000). Although 
considerable effort is invested in the subject, e.g., by the development of micro-channels with 
increased speed and resolution power, ThFFF will not gain acceptance in pharmaceutical 
analytics because of its inherent drawbacks due to the underlying principles. However, ThFFF 
occupies an niche in the spectrum of hmw polymer characterization, what is to be attributed to 
its unique separation mode (Lou, 2003; Janca, 2002; Sibbald et al., 2000). 
cold wall 
copper plate
hot wall 
copper plate
parabolic 
flow 
profile a
b
Fig. 4. Basic illustration of an ThFFF channel. Note that the sample components, e.g., 
lipophilic polymers, accumulate at the cold channel wall.  
dx
dT
D
DkTF T= (6)
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In terms of its analytical properties, the electrical FFF (elFFF) is discussed 
controversially. The prevalent elFFF channel design utilizes two graphite plates, which serve a 
dual role of both channel wall and electrode, separated by a Teflon spacer (Caldwell and Gao, 
1993). Exposing the ~150 µm wide channel to only a few volts gives rise to substantial effective 
field strengths in the order of 100 – 200 Vm-1. To achieve fields of comparable strength in 
capillary electrophoresis, 20 – 30 kV are to be provided. Moreover, electrophoretic separations 
lack the possibility to differentiate between particles of different size, but with similar surface 
charge density (Tri and Caldwell, 2000).  
Since the electrical field E is related to the drift velocity U of a sample component with 
the electrophoretic mobility µe by U = µeE, the force F exerted on the sample can be expressed as 
 
 
with regard to Eq. (3). What speaks in favor of the method is the simplicity of applying 
and programming E, as does the absence of any moving parts. The other side of the elFFF medal 
is labeled with two major disadvantages: the electrode polarization limitates the carrier solutions 
which can be applied and, as a consequence, the sample materials that can be characterized by the 
technique (Caldwell, 2000a). Additionally, conductivity differences between the analytes and the 
carrier liquid influence the retention, what means, that sample concentration affects the data 
obtained (Palkar and Schure, 1997a; Palkar and Schure, 1997b; Coelfen and Antonietti, 2000). A 
trend is evident, that more effort will be put into further development of other FFF 
subtechniques.  
The significant difference between Flow FFF (FlFFF) and the FFF subtechniques 
introduced above is that the separation field of force is established by a second stream of carrier 
liquid, pumped in vertical direction to the axial flow stream, as illustrated in Fig. 5.  
Ew
D
eµλ =
(7)
upper channel wall – cross-flow in
accumulation wall – cross-flow out
membrane
parabolic
flow profile
di
ffu
si
on
c r
os
s 
f lo
w
f
Fig. 5. Schematic representation of a Flow FFF channel. The position of sample specimen is 
determined by two independent flow streams, i.e., the axial carrier liquid flow and the vertical  
cross flow, propelling the sample components towards the accumulation wall.  
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In SFFF, TFFF and elFFF, the sample separation is induced by external physical or 
chemical fields. Contrarily, in FlFFF this field is to be characterized as “internal”. The FlFFF 
experiments are performed in a symmetrical set-up, in which the channel walls consist of two 
porous frits. This “symmetrical” system was developed in the mid1970s (Giddings et al., 1976). 
The lower wall is covered by an ultrafiltration membrane, permeable only by carrier liquid, not by 
sample components. Provided by a separate pump, the cross flow enters the channel via the 
upper channel wall, crosses the channel interior and finally passes the accumulation wall, 
subsequent to passing an ultrafiltration membrane.  
As the separation only relies on differences in diffusion coefficients, FlFFF is the most 
applicable FFF subtechnique. The wide applicability was demonstrated in characterizations of 
analytes ranging from solutes with inherent molar masses of ~500 g/mol and dimensions of <2 
nm up to particles with dimensions of 100 µm (Dycus, 1995). The lower size limit is determined 
by the molecular weight cut-off of the ultrafiltration membranes (~1 kDa), whereas the upper 
size limit is assessed by a threshold of about 20% of the channel height w (Williams, 2000).  
The driving force of FlFFF separations, exerted on the analytes by the cross flow, can be 
mathematically expressed as 
 
 
with dH being the hydrodynamic diameter of the sample, and where the linear cross flow velocity 
|U| can be classified as an experimental parameter. Eq. (8) reveals that – since U is exerted on 
each compound with identical intensity – the separation of sample components is only due to 
their inherent dimensions, i.e, their diffusion coefficients D.  
The theoretical FlFFF principles were introduced in 1976 and, in the subsequent years, a 
broad variety of samples was exemplarily separated by means of FlFFF, covering polystyrene 
latexes, various proteins, viruses and macromolecules (Lee and Lightfoot, 1976; Giddings et al., 
1977; 1978b; 1978c). In retrospect, the further development of FlFFF seems predicted, 
confirming the golden rule of science: new techniques attract more successful experiments, 
successful experiments attract more users, more users contribute new ideas. In case of FlFFF, 
Wahlund and Giddings helped to get a new idea accepted: the idea of an asymmetrical FlFFF 
channel set-up. 
 
2.3 Asymmetrical flow field-flow fractionation (AF4) 
 
The first approach to the AF4 principle was ventured in 1986, but due to technical 
“teething troubles” of that system, the actual break-through of AF4 can be set to 1987 (Granger 
et al., 1986; Wahlund and Giddings, 1987). AF4 draws a significant distinction to FlFFF in 
D
UkT
UdUfF === πµ3 (8)
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revealing only one permeable wall, so that the carrier liquid can leave the channel solely via the 
accumulation wall to generate a cross flow.  
 
2.3.1 Channel set-up 
 
In contrast to symmetrical FlFFF, the upper wall in AF4 consists of transparent plexiglas 
(polymethylmethacrylate, PMMA), nonpermeable to the solvent (Fig. 6). The transparency of the 
upper wall allows visual observation of the channel interior, helping to cope with trouble-
shooting during experiments or enabling visual monitoring of colored sample separation. Due to 
the obvious differences between upper and bottom wall, “asymmetrical” was prefixed to the term 
AF4. 
Consequently, the cross flow rate through the accumulation wall – comprising a ceramic 
frit covered by an ultrafiltration membrane – is induced by the constant loss of axial flow 
occurring with the transport of carrier liquid along the channel. This leads to a continuous 
decrease in the volumetric flow rate, i.e., the flow velocity, of the horizontal flow while 
approaching the outlet of the rectangular channel (Wahlund, 2000). In case of using very thin 
channels with low volumetric capacities in order to speed up separations, applying high cross 
flow rates results in fatal low outlet flow rates. During separation, this phenomenon has to be 
taken into account in order to avoid mis-assigning of sample characteristics due to the observed 
elution times. To compensate these undesired effect, a trapezoidal channel geometry was 
innovated, where the breadth decreases ongoing towards the channel outlet (Fig. 6). Within short 
time, the trapezoidal channel proved superior to the traditional rectangular geometry, and is 
almost exclusively applied now (Litzén and Wahlund, 1991; Coelfen and Antonietti, 2000).  
channel base collector 
block 
sample inject upper wall 
(plexiglas) laminar 
flow inlet 
distance pin 
channel 
volume 
spacer, 
excised inside 
laminar 
flow outlet 
Fig. 6. Schematic presentation of the AF4 channel assembly.
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Due to the variety of material qualified for channel composition, AF4 – as the other FFF 
subtechniques – can be operated with aqueous and organic solvents. The suitability of wall 
materials such as polycarbonate, polyethylene, aluminium or stainless steel have been examined 
(Kirkland, 1992). Appropriate holes for both carrier inlet and outlet and sample injection tubing 
can be drilled easily through the walls. The introduction of modern materials such as PMMA not 
only broadened AF4 applicability, but also initiated the development of innovative channel 
construction: traditionally, spacers were sandwiched between both walls, dimensioning a definite 
channel height due to their gage. Channel shape, e.g., rectangular or trapezoidal, was assessed by 
an outline cut in the spacer material, for instance polyester like mylar, teflon or polyimide (Miller, 
1996). Contrarily, the new way of channel construction is as simple as effective: via engraving an 
appropriate cavity - with desired depth and geometry - direct into the upper wall, the required 
channel volume capacity is provided. The wall block, with the cavity underside, is placed on the 
ultrafiltration membrane, which overlies the ceramic frit. Accordingly, fumbling with spacers 
becomes redundant – an agreeable way how rationalization meets analytical practice.  
The minimum usable spacer thickness, i.e., the cavity depth, is determined by the 
compressibility of the ultrafiltration membrane (Jensen et al., 1996; Giddings et al., 1992). When 
the channel is bolted together, the membrane is compressed in regions direct contacting the 
spacer and the upper wall, respectively. On the other hand, in unaffected areas the membrane 
maintains its original thickness and now protrudes into the channel. Amplified by membrane 
swelling phenomena, this determines a threshold for spacer thickness minima (Williams, 2000). 
As outlined before, thin channels normally advance separation. Referring to this, applying 
thin channels is afflicted with a severe drawback, namely the increased probability of 
interferences with the laminar forward flow profile as a consequence of membrane corrugations. 
As illustrated in Fig. 7, the process of separation happens in immediate vicinity of the membrane.  
Considering that in normal mode separations the analyte specimen are positioned in 
lamina levels not exceeding 5 µm distance off the membrane, the importance of smooth, 
unruffled membrane surfaces becomes evident. 
Fig. 7. Schematic representation of AF4 flow conditions close to the ultrafiltration membrane.
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During separation, the sample components are subjected both by an axial flow vector – 
as a result of the laminar forward flow – and by a transversal flow vector, arising from the cross 
flow (Wittgren, 1997). If the sum of the vector net effect is falsified by sterical – and referring to 
AF4 principles, also theoretical - barriers, reproducibility, accuracy and power of the fractionation 
process is critically corrupted. This, in combination with the imperative of sample-membrane 
compatibility, led to a rushing demand for various membrane materials. The prevalent 
ultrafiltration membranes have meanwhile to withstand fierce competition by microporous 
membranes, since the latter provide a flat surface, marginal compressibility, high flux and low 
cost.  
Proper selection of membrane material is a condition precedent to sufficient AF4 
separation. The most popular materials are cellullose derivatives, poly(ether)sulfone, 
polycarbonate, polyamide, acrylic copolymers, fluoropolymers, polyethylene and polypropylene.  
Since the samples are prevented from leaving the channel with the cross flow by the 
membrane, its cut-off properties crucially influence potential sample loss and sample recovery. It 
is known that the nominal cut-off value only refers to an estimation of the smallest analyte 
retained by the membrane, far apart from a precise specification. Consequences arising therefrom 
can be for good or for bad: sample specimen with molar masses as low as 6.5 kDa have been 
observed to be retained by membranes with declared nominal pore sizes of 50 nm (Benincasa 
and Giddings, 1992). Otherwise, membrane permeability may provide optimal conditions in the 
analysis of lipoproteins and pharmaceutical colloids, where co-analytes like lmw plasma proteins 
present aside would interfere analytics, but are displaced from the samples by passing the 
membrane (Li and Giddings, 1996).  
 
2.3.2 Consideration of theoretical principles 
 
Due to the rectangular channel geometry in FlFFF, the velocity U of the cross flow 
stream can be related to the cross flow rate Vc by  
 
 
where b represents the width and L the length of the channel. Given the background that both 
Vin - i.e., the carrier liquid volume entering the channel - and Vout values may accurately be 
assessed via flowmeater measurements, Vc is experimentally accessible via Vc= Vin – Vout. 
Unfortunately, matters in AF4 are complicated by asymmetrical channel design and trapezoidal 
channel geometry associated with non-uniform flow velocities.  
To obtain U in the vertical x-direction in AF4, the basic Eq. (9) has to be rewritten to  
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where |u0| is the cross flow velocity at the accumulation wall and x is the sample-wall 
distance. A constant cross flow provided, the mean flow velocity <v> in the horizontal z-
direction can be expressed in rectangular AF4 channels via 
 
 
where <v>0 is the flow velocity of the carrier liquid at the channel inlet. In trapezoidal 
channels, the area of the accumulation wall A(z) from the inlet up to z - with b(z) representing 
the channel width at z – is dispositive for both t0 and the channel volume V0, aliased the void 
volume. With b0 and bL as the channel widths at 0 and L, b(z) is assessed by 
 
 
 
Accordingly, A(z) can be expressed as 
 
 
 
and the horizontal average flow velocity results in 
 
 
 
Utilizing Eq. (4) and Eq. (13), to can be calculated by 
 
 
 
where z` is the distance from the inlet to the focusing point, Vc the cross flow, Vout the 
outlet flow rate, V0 the void volume and y the area excluded by the tapered inlet end. Given the 
known parameters t0, Vc, V0 and w, furthermore the experimentally assessed tr, and assuming the 
approximation R = 6λ, the diffusion coefficient D can be obtained directly via  
 
 
 
Moreover, by applying the Stokes-Einstein relationship – referred to in Eq. (3) - the 
hydrodynamic diameter dH of sample specimen can be assessed 
 
 
 
where η is the solvent viscosity.  
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Therefore, AF4 not only enables the fractionation of sample components, but also can be 
utilized for concomitant size determination of the fractionated specimen. These AF4 features can 
be applied for the characterization of complex samples, for instance, to separate and size-
determine 70S ribosomes of Escherichia coli and the analogous 30S and 50S subunits (Nilsson et 
al., 1996). However, since the truth of the tr values determined has always to be scrutinized, e.g., 
due to sample-membrane interactions potentially biasing AF4 data, the assessment of sample 
dimensions by means of AF4 theory per se took a back seat in recent years. Other sophisticated 
size-assessing detection systems, such as multi-angle light scattering (MALS), are to be preferred 
(Wyatt, 1993).  
All mathematical considerations outlined above apply exclusively for what is often 
referred to as the “normal” or “Brownian” mode of FFF: sample specimen behave as point 
masses whose sizes are insignificant compared to the dimensions of the sample specimen zone. 
Consequently, sample retention becomes a unique reflection of the size, i.e., the hydrodynamic 
radius, and the diffusion coefficient (Caldwell, 2000b).  
The larger the sample specimen, the less valid this approach becomes. In case particle 
sizes increase to a level where they are no longer negligible compared to the channel height, their 
retention has to be considered as a reflection of their inability to approach infinitely closely to the 
accumulation wall (Giddings, 1978d). Because the centers of gravity of large particles can 
approximate the wall not closer than the particle radius, the net result of this protrusion into the 
parabolic flow profile is that migration becomes forwarded in relation to particle size (Fig. 8). 
Thus, the order of separation is reversed, and that phenomenon is called “steric” mode 
effect (Min et al., 2002). The transition between normal and steric FFF mode depends on both 
particle size and channel height and is to be assessed for standard separation parameters at ~1 
µm. 
(To leave the Ariadne´s thread of AF4 matters for reasons of correctness: this steric 
exclusion observed in areas adjacent to walls is an important parameter in other separation 
dHs
dHl
small
particle
large
particle
particle
velocity vectorparabolic flow profile
Fig. 8. Schematic representation of the steric mode FFF principle. Sample specimen are 
prevented from approaching the accumulation wall closer than half of their hydrodynamic 
diameter dH. Due to their greater migration velocity vector, larger particles elute prior to smaller 
particles. 
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contexts, e.g., hydrodynamic chromatography or in size exclusion chromatography, where it 
accounts for the Casassa model (Dos Ramos and Silebi, 1993; Casassa and Tagami, 1969)). 
However, that is only half of the truth: it has been discovered early, that steric particles 
do not migrate with direct contact to the wall surface – due to their high sensitivity to driving 
forces of the vertical field of force - but are positioned at elevated levels due to the role of 
hydrodynamic lift forces (Caldwell, 1979). These results were substantiated by data revealing that 
large diameter particles are migrating at levels more distant from the accumulation wall than 
smaller particles, eluting in steric mode, too (Moon et al., 1999). The situation in which steric 
mode is combined with hydrodynamic lift forces is termed hyperlayer mode. Fig. 9 depicts the 
forces affecting a sample eluting in hyperlayer mode. 
It is to be noted that the hyperlayer mode does not change the elution order of the steric 
mode, i.e., larger hyper-layered particles do elute prior to smaller hyper-layered particles, which in 
turn elute prior to steric particles very proximate to the accumulation wall.  
These matters may be associated with the ascending force of airplanes due to the wing 
airfoils, what can be interrelated to those phenomena. Particles under laminar flow in thin tubes 
have long been known to experience velocity-dependent hydrodynamic lift forces directed away 
from the tube wall (Caldwell, 2000b). Early observations of this phenomenon include the so-
called Fahraeus-Lindquist effect, which describes the depletion of blood cells from areas 
proximate to the endothel during the blood-flow through capillary vessels (Fahraeus, 1929).  
However, the nature of hydrodynamic lift forces and hyperlayer mode are still only poorly 
understood. The expedient, although oversimplified, Eq. (18) relates the retention ratio R in 
steric mode FFF to the particle size dH: 
 
 
Fig. 9. Schematic representation of the forces affecting a large particle eluting in hyperlayer 
mode. The traction towards the wall due to the vertical field of force is opposed by 
hydrodynamic lift forces FLift. The laminar parabolic flow drags the particle at hyper-layered levels 
towards the channel outlet.  
parabolic flow profile
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where γs represents a steric correction factor related to the hydrodynamic lift forces. It 
can be derived from Eq. (18) that the retention time of sample specimen is decreased by thinner 
channels, like in normal mode separations. 
 
2.3.3 Operational procedures 
 
Basically, the AF4 experiment can be divided into three stages: sample injection, sample 
focusing, and the fractionation step. Identical to conditions in HPLC, the sample volume 
designated to AF4 analysis is gauged by using sample loops with inherent loop volumes spanning 
10 – 100 µl. Considering prevalent AF4 channel capacities ranging between 200 and 1000 µl, to 
inject 100 µl sample entails that a considerable part of the channel volume will be replenished by 
the sample, not to mention void volumina of the injection capillaries. In a worst case scenario, 
the injected sample would fill the channel completely. Starting fractionation subsequently would 
implicate a situation, in which some of the sample components were positioned directly adjacent 
to the flow inlet and the sample injection port, while the rest of the sample would populate areas 
towards the flow outlet. Fractionations based on those preliminary conditions would suffer 
insufficiency and peak broadening (Fig. 10). 
 
 
 
 
 
 
 
 
 
 
Furthermore, the sample specimen are to be positioned in their steady-state equilibrium 
levels before being eluted, in order to optimize fractionation quality. Referring to that, in virtually 
any FFF subtechnique a focusing step – often termed focusing/relaxation step – must be 
performed prior to separation. Due to this focusing/relaxation process, sample material that is 
distributed widely throughout the channel interior is forced into a narrow “band” from which 
proper separation is possible (Giddings, 1990). Unlike other forms of FFF, the field of force in 
AF4 can not be controlled independently of the axial flow. Therefore, sample focusing to narrow 
bands – to minimize band broadening of the detection signals – and sample arrangement in 
steady-state equilibrium profile has to be achieved simultaneously.  
sam ple 
injection
flow inlet flow outlet
Fig. 10. Sample distribution within an AF4 channel subsequent to the injection step. 
accumulation wall
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To meet this premise, an opposing stream of carrier liquid is pumped into the channel 
from the outlet end additionally to the flow through the inlet port. As a consequence, the sample 
specimen are focused at a predetermined point in the vicinity of the sample injection port and the 
carrier liquid exits the channel via passing the membrane (Fig. 11, Fig. 12). A position ~5 mm 
downstream from the inlet port is deemed an adequate location for sample focusing, since 
otherwise, one has to accept the consequences of flow inhomogeneities: surface protuberances of 
both flow inlet port and sample inlet port may interfere with the axial parabolic flow profile and 
may foster artifacts (Wahlund, 2000).  
Referring to Fig. 11 and Fig. 12, the dependence of successful AF4 separation on 
optimal focusing/relaxation becomes evident. Although the assessment of necessary 
focusing/relaxation times was approached mathematically, this calculation is considered to 
inhere some uncertaincies due to the necessity of assumptions (Moon and Myers, 2000). 
Therefore, for quality monitoring of focusing/relaxation, the utilization of colored 
macromolecular samples such as cytochrome-c and ferritin is feasible (Wittgren et al., 1996). 
Besides, the ideality of flow lines and channel leakage can easily be controlled by color 
indicator substances like bromophenol blue (BPB). 
flow from  
channel 
inlet
inversed 
flow from  
channel 
outlet 
sam ple 
injection
Fig. 11: Schematic diagram of sample specimen arrangement subsequent to focusing/ 
relaxation. Note that analytes are focused to a narrow band and arrange at level heights 
 related to their diffusion coefficients. 
accumulation wall 
axial 
parabolic 
elution 
flow
accum ulation wall
field of force
Fig. 12. Situation in the channel at an early stage of separation: since sample components  
arrange at different lamina levels after focusing/relaxation, sample specimen disband  
right from separation start. 
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Set to action concomitantly, the intensities of both axial forward flow and cross flow 
determine the retention time of analytes. If samples to be fractionated are very polydisperse, a 
high cross flow must be applied in order to separate the least retained analytes, e.g., to 
counterbalance their high diffusion coefficients. As a consequence, well-retained specimen would 
elute after an excessively long period (Coelfen and Antonietti, 2000). 
In contrast to separation methods with rather stringent separation modes like (SE-) 
HPLC, the cross flow intensity in AF4 can be changed and programmed arbitrarily during 
separation. This programming consists of intentionally and systematically varying the cross flow 
rate – and commensurate herewith, the axial forward flow rate also has to be adapted. Already in 
the first paper, the concept of programming FFF runs was proposed and implemented shortly 
afterwards (Giddings, 1966; Thompson et al., 1969). 
Recently, the delivery of facts in terms of programming by FFF practitioners was 
increasingly accompanied by the concepts of theoreticians – a fruitful symbiosis: not only were 
FFF data evaluated in terms of matching available theories, but were applied to create new ones. 
Those in turn gave rise to technical innovations, e.g., a trapezoidal channel geometry. By means 
thereof, experimental facts were set, again demanding for appropriate underlying principles. 
From this “who was first: hen or egg”-race a wide mathematical arsenal evolved, including step, 
linear, parabolic and exponential functions, a special class of power functions capable of yielding 
almost constant relative resolutions, and data analysis algorithms (Moon et al., 2002; Williams et 
al., 2001; Williams and Giddings, 1994). 
The actual cross flow intensity is simply to quote %-values. For instance, the term 
10% cross flow means, that 10% of the elution medium entering the channel are pumped off 
through the ultrafiltration membrane. Therefore, if the laminar flow profile at the channel outlet 
is set to be 1.0 mL/min, consequently a flow volume of 1.1 mL/min has to enter the channel via 
the flow inlet in order to enable a 10% cross flow rate. Morever, basically all state-of-the-art 
detection systems applied in monitoring elution of fractionated analytes – i.e., 
spectrophotometry, refractive index, light scattering and fluorescence detection units – are prone 
to artifact measurements due to (rapid) change of system parameters, i.e., discharge shifts of cell 
flow. Referring to that, the channel outlet flow volume has to be maintained constant during the 
whole experiment.  
In this manner, even complex AF4 fractionation conditions can be expressed both 
comprehensively and briefly.  
 
2.3.4 Applications of AF4 
 
Confronted with the task to review AF4 applications, it is to be accentuated that AF4 is not a 
state-of-the-art method, neither in industries nor in scientific research. A general survey of the 
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published literature, e.g., in terms of AF4 in protein analysis, is completed within short time, 
revealing a low two-digit number of extensive scientific publications. In contrast, to perform the 
same in terms of SE-HPLC means to become assailed with thousands of articles. This indicates 
that AF4 applications mainly originate for special – not to say unusual – analytical tasks. Due to 
the lacking of package material within the channel, fractionations are performed under moderate 
conditions, avoiding both shear stress and high system pressures. This predestines AF4 for 
characterization of hmw analytes, prone to artifacts due to experiment conditions, e.g., shear 
degradation and upper exclusion limit of the separation technique applied.  
Referring to this, AF4 was mainly employed to study conformational changes, 
aggregation tendencies and hmw ratios of macromolecules, which are utilized in pharmaceutical 
and chemical industries, such as ethylhydroxyethyl cellulose, carrageenans and starch 
polysaccharides (Andersson et al., 2001; Roger et al., 2001; Wittgren et al., 1998). Furthermore, 
AF4 was employed to characterize amphiphilic polymers, where the usefulness of SE-HPLC is 
limited because of interactions between hydrophobic polymer segments and the stationary phase. 
Consequently, the aggregation of amphiphilic graft copolymers, essential for  the stabilization of 
interfacial structures, was analyzed via AF4 as well as the aggregation of pullulan derivates 
(Wittgren et. al. 1996; Duval et al., 2001).  
The second main field of AF4 application represents the analysis of dissolved sample 
components aside undissolved particles. Moreover, the size limit of samples amenable to AF4 
separation can be risen to the µm range, allowing the separation of nanoclusters, nanocolloids, 
microparticles and even cells.  
In case of nanocolloids, AF4 was used for analysis of polyorganosiloxane nanoparticles 
dispersed in a complex mixture in the presence of excess surfactant (Jungmann et al., 2001). 
Additionally, the FFF potential for degradation-free separation was applied to provide analytes 
with extremely narrow size distributions for subsequent high-precision measurement of analyte 
dimensions via MALS. In this respect, the superiority of AF4/MALS over established methods 
like transmission electron microscopy (TEM) was shown (Wyatt and Villalpando, 1997).  
The challenging task to separate dissolved and undissolved sample components via AF4 
was repeatedly performed, e.g., by examining the distribution of a lipophilic drug within human 
plasma or when characterizing lipoproteins originating from human blood (Madorin et al., 1997; 
Li and Giddings, 1996). In particular, the potential of AF4 was demonstrated in the separation of 
lipoprotein particles of coronary artery disease patients (Park et al., 2002). 
Without doubt, the exertion of AF4 in vaccine control is one of the most promising 
applications. The surface features of deactivated bacteria or viruses affect the immunoresponse to 
bacteria- or virus-associated antigens. Therefore, sorting and characterization of deactivated 
bacteria or viruses is an important way of quality control for whole-cell bacterial or viral vaccines 
and was demonstrated by using AF4 only recently (Fraunhofer et al. 2003, Reschiglian et al., 
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2002). In this context, also the separation of plasmids and plasmid fragments, and the 
determination of acid phosphatase in cultivation media via AF4 have to be subsumed (Wahlund 
and Litzén, 1989; Litzén et al., 1994).  
Furthermore, the amounts of ribosome and ribosome subunits were determined via AF4 
as well as the assessment of tRNA levels in bacterial cells (Nillson et al., 1996; Arfvidsson et al., 
2003). 
The general acceptance of HPLC in protein characterization reduces the significance of 
AF4 therein. Although a variety of proteins have been analyzed by means of AF4, almost without 
exception the aim of those studies was to demonstrate the basic applicability of AF4 in protein 
separation rather than to approach and elucidate an analytical problem in particular (Fraunhofer 
et al., 2001; Giddings, 1993). The characterization of wheat flour protein by SE-HPLC and AF4 
is one of the few examples of an extensive case study, wherein AF4 was applied. Unfortunately, 
AF4 data were not comparable to SE-HPLC data, as samples were either characterized solely via 
SE-HPLC or AF4 (Ueno et al., 2002).  
Conversely, due to their unimodal mass-distributions, protein monomers are considered 
ideal systems to control AF4 set-up or evaluation.  
Commensurate with the nowadays increased ecological awareness, AF4 is employed 
accumulatively in analytics of environmental particles and macromolecules. This development is 
instanced by the characterization of humic substances and the separation of colloidal organic 
matter from river waters (Benincasa et al., 2002; Benedetti et al., 2002). 
An extensive register of AF4 applications, encompassing published results prior to 1999, 
can be found in the literature (Coelfen and Antonietti, 2000; Jonsson, 2000). 
 
To predict some future trends of AF4 applications is delicate, since there are reasons 
legitimizing a pessimistic as well as an optimistic rating.  
The main argument of the “bears” is the low recognition of the brand itself. Within the 
vast majority of analytical laboratories, the term AF4 is not associated with a powerful separation 
technique with wide applicability, but more with a black box. Consequently, the routine analysis 
of samples is performed with state-of-the-art methods, resulting in data which can be assessed in 
correlation with data formerly obtained by the same established methods. Moreover, allowing 
new methods to take roots is synonymous with additional expenses on time, employees and 
money. Finally, present established methods are subject to constant optimization, be it propelled 
by the users of by the manufacturers. The outcome is an increase in accuracy and applicability of 
present established analytical methods. 
Falling into line with the “bulls”, the increasing demand for new analytical methods may 
fertilize AF4 development. Three trends may be anticipated. One is certainly to combine AF4 
with absolute detection techniques like MALS or other methods like inductively coupled plasma 
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(ICP) or electronspray mass spectroscopy. Thereby, a convenient identification of the separated 
analytes by assessment of molar mass, hydrodynamic radius or chemical composition is possible.  
Another development with much potential is to couple several FFF separation 
mechanisms to a kind of multidimensional FFF. Since this technique combines the assets of 
several FFF methods, all possible data of each individual FFF technique would contribute to 
sample information obtained from one single experiment.  
Probably the greatest potential for AF4 progress lies in the development of advanced 
membranes. Sample specimen are brought in immediate vicinity to the membrane during 
separation, facilitating possible sample-membrane interaction. Bearing in mind the low sample 
concentrations of many biotechnological products, there is a tremendous need for new 
technologies of protein compound identification and quantification. In this regard, the 
development of immunoassay-membranes, masked with antibodies that are highly specific to the 
target compound within the sample, is highly promising. Since those membranes can be tailored 
in any desired way, the high potential of such kind of membranes in interacting with specific 
organic (and anorganic) analytes becomes evident. Consequently, accuracy, sensitivity and 
applicability of AF4 may be boosted. 
Considering that FFF was introduced to analytical science in the late 1960s and was long 
kept in a rather shadowy existence, by regarding the development in the last decade it is to be 
assumed that diversity and potential of FFF methods probably will experience an upturn in the 
years ahead. 
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3 Protein aggregation in liquid protein pharmaceuticals 
 
3.1 Introduction 
 
Products of modern pharmaceutical biotechnology represent a very significant fraction of 
today´s total pharmaceutical market. The rapid development not only of simple replacement 
proteins, e.g., recombinant insulins and blood factors, but also engineered protein 
pharmaceuticals was particularly facilitated by technical innovations in molecular biotechnology 
and protein chemistry. Thus far, some 88 recombinant proteins/monoclonal antibody-based 
products have gained marketing approval within the European Union (EU), accounting for a 
36% share of all new EU drug approvals since 1995 (Walsh, 2003). As the vast majority of 
protein drugs are administered through injection, the stability of proteins in dissolved state is a 
critical concern. Committed to the development of elegant formulations as well as patient 
acceptance, pharmaceutical scientists increasingly offer protein drugs in liquid formulations, 
thereby avoiding costly lyophilized products. 
Subsequent to application, the protein drug still is opposed to an environment that is 
predominantly aqueous: a typical cell contains 70-85% water and the extracellular space of most 
tissues is composed of 99% thereof. Even the brain, with its complex arrangement of cells and 
myelinated structures, comprises a ~80% water content (Saltzman, 2001). Consequently, to 
accomodate protein drugs with a broad portfolio of stabilizing parameters may be considered the 
formulator´s task. Therefore, sufficient protein stability in liquid formulations is a criterion of 
utmost importance. Unfortunately, protein drugs don´t care about that. 
Instability of peptides and proteins can be originated by two pathways: chemical and 
physical. Chemical instability can be deemed to take center stage in relevant scientific articles 
reviewing protein instability (Wang, 2000; Wang, 1999; Schoeneich et al., 1997; Cleland et al., 
1993; Manning et al., 1989). In many cases, chemical degradation reactions can proceed 
simultaneously in proteins, thus complicating the revelation of one prime chemical degradation 
reaction. Contrarily, the prevalent scientific opinion hallmarks aggregation to be the most 
common process of physical instability (Wang, 1999; Cleland et al., 1993). Consequently, this 
capter focuses on the protein aggregation phenomenon. 
 
3.2 Chemical instability 
 
Notable progress has been made in elucidating the link between protein structure and 
chemical instability. Basically, chemical instability can be defined as any process which comes 
along with protein modification by bond formation (e.g., oxidation) or – most commonly - by 
bond cleavage (e.g., hydrolysis).  
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In the majority of cases, hydrolytic reactions in proteins affect the side-chain amide 
groups of asparagine (Asn) and glutamine (Gln), and the peptide bond on the C-terminal side of 
an aspartic acid (Asp) or a proline (Pro) residue, when it is in the penultimate position from the 
N-terminal end (Goolcharran et al., 2000a). As Asn residues deamidate generally more rapidly 
than Gln residues, Asn hydrolysis is exemplified below in detail (Schoeneich et al., 1997). Acidic 
conditions provided (pH < 4), the prevalent reaction with an Asn residue involves direct attack 
of water on the side-chain amide carbonyl carbon resulting in the formation of an Asp residue. 
On the other hand, at neutral or basic conditions (pH > 6) the predominant reaction with an Asn 
residue involves cyclic imide formation with subsequent attack of water on one of the two 
carbonyl carbon atoms, yielding Asp and isoaspartic acid residues in an approx. 1 to 4 ratio (Fig. 
13) (Patel and Borchardt, 1990). 
The exogenous factors influencing the deamidation rate are of dazzling array: besides 
temperature, buffer specimen, buffer concentration and ionic strength are critical parameters. 
Bicarbonate and glycine buffers appear to catalyze deamidation as well as buffers based on 
phosphate in a 0 – 20 mM range (Tyler-Cross and Schrich, 1991; Tomizawa et al, 1995). On the 
contrary, a thorough analysis revealed that the deamidation rate of Val-Asn-Gly-Ala was not 
influenced by the variation in buffer component concentration, encompassing a 0 – 50 mM range 
of phosphate and carbonate (Lura and Schrich, 1988). The list of investigations dealing with the 
Fig. 13. Schematic representation of Asn residues deamidation pathways.
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relationship between buffer components and deamidation rate may be prolonged arbitrarily 
(Goolcharran et al., 2000b; Tomizawa et al., 1995b, Capasso et al., 1991). Anything provided by 
experiments, science still misses a golden rule regulating this matter and, consequently, room for 
speculation prevails. One theory suggests, that phosphate ions, or other buffer ingredients, could 
act on the aqueous solvent to increase basicity of water molecules without forming free 
hydroxide ions, thereby affecting deamidation (Brennan and Clarke, 1995). However, data 
corroborating this hypothesis has not yet been published. 
Equally, the effects of ionic strength on deamidation appear to resist easy 
generalizations. In protein solutions with neutral or alkaline pH, ionic strength effects on 
deamidation are evident: e.g., the catalytic activity of phosphate is decreased in the presence of 
salts (Johnson and Aswad, 1995; Tomizawa et al., 1995b). Interestingly, NaCl has been shown to 
protect less against deamidation than salts like LiCl and Tris HCl. 
Other exogenous factors influencing deamidation include the effect of organic 
cosolvents, e.g., ethanol and glycerol, for obvious reason: embedded in a medium with reduced 
dielectricity, the protein or peptide bond nitrogen would be less likely to ionize. As the anionic 
bond nitrogen is necessary in the formation of the cyclic imide, a low dielectric medium is 
considered to retard the progress of deamidation (Bummer and Koppenol, 2000). This topic was 
approached in recent years, employing a hexapeptide (Brennan and Clarke, 1993). As expected, 
the lower dielectric constant media resulted in clearly lower deamidation rates of the Asn residue. 
Furthermore, the deamidation rate is affected by endogenous factors, e.g., by the 
primary sequence of the protein. It was found early that Asn residues seem more prone to 
deamidation than Asp (Robinson and Rudd, 1974). In this regard, amino acid residues on the 
amino side of Asn have only minimal effect, regardless of parameters like charge and size. 
Otherwise, characteristics of the carbonyl side residues are decisive for the deamidation rate. 
Increasing both size and branching of the residue side chain minimizes the deamidation rate ,in 
some cases as much as 70-fold relative to a Gly residue. Consequently, Asn-Gly is considered the 
most labile sequence (Powell, 1996). It is hypothesized that bulky residues succeeding Asn may 
inhibit sterically the formation of the succinimide intermediate in the deamidation reaction. 
Additionally to deamidation, proteins may undergo other non-enzymatic hydrolysis pathways, 
e.g., degradation of proteins yielding a diketopiperazine (DKP) and a truncated protein (Fig. 14). 
Fig. 14. Diketopiperazine formation resulting in degradation of N-terminal sequences with 
inherent penultimate Pro residues. 
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The mechanism of DKP formation commences with a nucleophilic attack of the N-
terminal nitrogen on the carbonyl carbon of the peptide bond between the second and the third 
amino acid residues in the primary sequence. A precedent condition for this degradation process 
is Pro representing the penultimate residue in N-terminal sequences. This intramolecular 
aminolysis reaction was observed for a number of pharmaceutical proteins and is catalyzed in 
both acidic and basic conditions (Goolcharran et al., 2000c; Straub et al., 1995; Battersby et al., 
1994). In the latter case, the DKP cyclization can be minimized by avoiding general base catalysts 
such as phosphate or acetate buffers. 
Degradation of Asp residues represent the third major hydrolytic protein degradation 
pathway. Principally, the Asp stability is conditioned by its position in the primary sequence (Ota 
and Clarke, 1989). One degradation pathway takes place via Asp-to-isoAsp interconversion, 
propelled by a cyclic imide intermediate state similar to that represented in Fig. 13. The other 
pathway proceeds via amide bond hydrolysis of Asp and adjacent amino acids. Under moderate 
acidic conditions, the rate of peptide bond hydrolysis next to the Asp residue is by at least two 
orders of magnitude greater than the hydrolysis of other peptide bonds, where Asp is not 
involved (Oliyai and Borchardt, 1993; Goolcharran et al., 2000a). Although the impact of the 
primary sequence on Asp degradation is considerable, it is short of the effect on Asn residue 
deamidation. Nevertheless, the greater the steric bulk of the amino acid adjacent to Asp, the 
more the hydolysis rate is decreased. For instance, in terms of cyclic imide formation at pH 7.4, 
the half-life of a sequence containing Asp-Ala exceeds that of the Asp-Gly analog by factor 7 
(Stephenson and Clarke, 1989).  
Besides hydrolysis, oxidation is the other major pathway of protein degradation. 
Facing a broad variety of possibilities to initiate oxidation, the formulator´s assignment may be 
compared to the task of Sysiphos: even excipients like the polyether surfactant polysorbate 80 – 
without doubt one of the most utilized stabilizing agents in liquid protein formulations – have 
been convicted of releasing peroxide, a potent oxidizing protein cross-linking agent (Ha et al., 
2002; Jaeger et al., 1994).  
In general, protein oxidation is to be attributed to photochemical, metal ion catalyzed, 
high energy γ-radiation, or organic additive sources. Even sonication appears to promote the 
generation of reactive oxygen specimen (Bummer and Koppenol, 2000; Riesz and Kondo, 1992). 
Protein oxidation is – due to its importance - topic of intense research, and yet new information 
trickles scarcely.  
Independent of the cause of oxidation induction, the basic principle implicates the 
interconversion of oxygen to (few) key reactive oxygen specimen, which react with the protein. 
The most potentially oxidizable sites of proteins are the side chains of His, Met, Cys, Trp, Arg 
and Tyr (Daniel et al., 1996; Stadtman, 1993). For instance, Met residues are easily amenable to 
oxidation by atmospheric oxygen in vials containing only 0.4% oxygen (Richards, 1997).  
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Metal catalysis is the most instanced oxidation phenomenon, as many pharmaceutical 
processes such as protein/peptide synthesis and subsequent purification, bulk storage and dosage 
form storage may provide conditions which facilitate metal-catalyzed oxidation (Cleland et al., 
1993; Manning et al., 1989). Trace levels of metal ions such as Fe(III) and Cu(II) are often 
implemented unintentionally to pharmaceutical systems, e.g., via buffer reagents (Li et al., 1995). 
Reduced by prooxidants, the metal ions then provide reactive oxygen specimen via interaction 
with oxygen. Prooxidative agents present in formulations may be buffer component 
contaminants or excipients added originally in antioxidative terms, e.g., ascorbic acid (Li et al., 
1995b). Even the victim is to be convicted complicity, since side-chains of the amino acids Tyr, 
Trp and Cys may operate as prooxidants (Timmins et al., 1982).  
Both photooxidation and autooxidation are minor sources for fostering protein 
degradation.  
As only few pharmaceutical proteins are photosensitive, little is published dealing 
with light-induced protein oxidation. Amino acids found to be most susceptible of 
photooxidation are His, Trp, Met and Cys (Halliwell and Gutteridge, 1989). Of more interest are 
the photosensitizing features of stabilizing excepients. For instance, the photolytic degradation of 
proteins such as antibodies has been observed in the presence of non-ionic surfactants (Lam et 
al., 1997; Brot and Weissbach, 1991). In case of polysorbate 20, it was concluded that the excited 
polysorbate may initiate photooxidative reactions via interaction with oxygen to form singlet O2, 
resulting in a metsulfoxide formation (Duenas et al., 2001).  
Autooxidation as direct reaction between ground state oxygen in triplet state and 
singlet ground state proteins and peptides is unlikely, as both components differ in the 
appropriate electron spin directions. Assuming air-saturated and metal- and peroxide-free buffers, 
the approximate half-life of the most labile amino acid residues was calculated to be 80 years for 
Cys and over 107 years for Met (Schoeneich et al., 1997). Referring to his, many of the so-called 
cases of autooxidation observed for proteins are most likely due to metal-catalysis or other 
sources (Goolcharran et al., 2000a).  
Other chemical pathways of protein degradation are of lower importance, although a 
broad portfolio may be compiled by searching the literature. Instances thereof encompass 
isomerization, succinimidation, non-disulfide crosslinking, beta-elimination, conversion, 
racemization or more circuitous pathways like deglycosylation and maillard reactions. Further 
information on the mechanisms and consequences of chemical protein degradation is provided 
by the review articles cited in the introduction of this chapter. 
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3.3 Aggregation – a consequence of physical instability 
 
3.3.1 Random walks 
 
Proteins successfully cope with even harsh conditions in order to maintain stability: in 
nature they can be found at conditions ranging from –40 °C to 115 °C and from ~1 pH to 11 
pH, respectively (Jaenicke, 1991).  
Referring to this, the pharmaceutical formulator´s task to make long-term stability 
data of protein drugs available - covering 12 months at minimum at drug submission - seems 
simple: at 30 °C ± 2 °C and 65% rh, valid for most territories (ICH Draft, 2002). However, 
unequally challenging tasks account for unequal facilities. Whereas the formulator basically has to 
rely on his experience, proteins in vivo are provided with a sophisticated quality control system in 
order to guarantee proper folding and stability subsequent to synthesis (Fig. 15).  
 
Fig. 15. Cell situation scheme of a globular protein. After synthesis on the ribosome, the protein 
is assumed to fold in the endoplasmatic reticulum (ER) and to be secreted from the cell. Under 
certain conditions, proteins may at least partially unfold and become prone to aggregation. N, I 
and U refer to native, partially folded (intermediate) and unfolded protein states, respectively. QC 
refers to the quality control systems which prevent incompletely folded proteins being secreted 
from the ER, mainly comprising chaperones and proteases. Chaperone binding and release of 
folding intermediates allows proteins to reach their native conformation. As aggregated proteins 
are relatively resistant to proteolysis, chaperones promote proteolysis indirectly by maintaining 
misfolded proteins in an unaggregated state (Wickner et al., 1999) (illustration with friendly 
permission of Oxford Center for Molecular Sciences, UK). 
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Despite these cellular controls, a range of debilitating human diseases is associated 
with protein misfolding events that result in the malfunctioning of the cellular machinery. Most 
attention has been focused on a group of diseases where proteins or protein fragments convert 
from their soluble forms with intact helical folding to insoluble fibrils or plaques. The final forms 
of these aggregates often reveal a well-defined fibrillar nature, known as amyloids (Fig. 16).  
 
One remarkable protein feature – considering the dependence of native conformation on 
function – is that the native state is only marginally stable relative to denatured states, facilitating 
subsequent aggregation phenomena. As this is valid for proteins in vivo and in pharmaceutical 
dosage forms, to understand the basic principles of denaturation and aggregation is of crucial 
importance for the formulator in order to minimize or – at  best – to avoid negative 
consequences concerning drug formulation. 
 
3.3.2 Thermodynamics 
 
Unlike small pharmaceutical drugs, where physical instability is rarely encountered except 
for poorly water-soluble compounds, proteins, because of their unique ability to adopt three-
dimensional forms, tend to undergo a number of structural changes, independent of chemical 
modifications (Akers and Defilippis, 2000). Thereby, the tertiary structure of proteins is conveyed 
by two kinds of noncovalent interactions: hydrophobic interactions, which mainly represent 
hydration effects of nonpolar groups, and electrostatic interactions, e.g., ion pairs, weak polar 
interactions, H bonds and van der Waal forces (Anderson et al., 1990). Bearing in mind that the 
free energy change for the unfolding/denaturation reaction of proteins is minimal – 5-10 
Fig. 16. Molecular model of an amyloid fibril 
derived from the SH3 module of PI3 kinase 
via cryo electron microscopy. Amyloid fibrils 
are known to be rich in β-structure, giving 
rise to the α-helix-to-β-sheet transition of 
proteins with originally largely helical 
conformation. The fibril consists of four 
twisted “protofilaments”, forming a hollow 
tube with approx. 60Ă in diameter, and 
reveals a characteristic cross-β-structure, 
generally considered to be requisite for 
protein aggregates subsumed to amyloids. 
Today, some 20 human proteins have been 
found to form amyloids, which are 
associated with diseases like Creutzfeld-
Jakob, Alzheimer´s, Huntington´s, or 
Parkinson´s diseases (illustration with 
friendly permission of Dobson, 1999).  
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kcal/mol – the impact of even slight changes of enthalpic and entropic parameters on protein 
stability becomes evident (Pace et al., 1996; Jaenicke, 1990).  
In order to approach this matter, most articles are predicated on a trivial two-state 
model with an inherent equilibrium between the native (N) and the denatured states (D).  
Physiological conditions provided, the equilibrium constant K for unfolding can be 
expressed as K = [D]/[N] and utilized for the derivation of the change in Gibbs free energy 
(irrespective of intermediate state specimen):  
 
 
wherein R represents the gas constant and T the absolute temperature. K may be inserted in the 
van´t Hoff equation, yielding the temperature coefficient of the equilibrium constant via 
 
 
Consequently, by combination of Eq. (19) and Eq. (20) the change in Gibbs free energy can be 
related to the temperature: 
 
 
where ∆H and ∆S symbolize enthalpic and entropic changes (typically 50 – 200 kcal), 
respectively, at the same temperature at which ∆G is evaluated. Since the small changes in free 
energies associated with the transition from N to D are the difference of large values, the 
difference in free energy is very sensitive to small perturbations in the attractive and repulsive 
intermolecular interactions (Bummer and Koppenol, 2000). The temperature dependence of ∆H 
and ∆S is defined by the heat capacity change, ∆Cp, between native and denatured states. For 
most proteins, ∆Cp reveals a large value, reflecting the restructuring of solvent subsequent to 
protein unfolding (Robertson and Murphy, 1997).  
Combining Eq. (20) and Eq. (21) in terms of ∆Cp, Eq. (22) can be derived, generally 
referred to as the modified Gibbs-Helmholtz equation.  
 
 
 
Accordingly, the value of ∆G is the fundamental stability parameter of a protein. As Eq. 
(22) is based on the two-state model, values derived therefrom are only valid for proteins lacking 
N (native) D (denatured)
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stable folding intermediates. However, most small globular proteins were shown to correspond 
to this prerequisite, as they usually fold within milliseconds or even less (Kristjánsson and 
Kinsella, 1991; Lumry et al., 1966).  
On the other hand, definite conditions provided, unfolded state intermediates may be 
stable for considerable time and reveal significant amounts of residual secondary structure. This 
was shown to be the case for some pharmaceutically relevant proteins, e.g., human growth 
hormone (Bam et al., 1996). (In this regard, scientists successfully gave proof of their sense for 
neologisms: striving towards denomination of those intermediates, the term “molten globule 
state” was coined, thus avoiding the oxymoron “durable intermediates”.) (Shortle, 1996; Goto 
and Fink, 1989)  
In order not to lose the plot of thermodynamics: the large and positive ∆Cp observed 
in protein denaturation is primarily due to exposure of nonpolar groups. Over 80% of the 
nonpolar side chains such as Ala, Val or Phe are buried in the interior of the intact folded protein 
and are exposed to the surface after unfolding (Pace, 2001).  
The molar enthalpy of protein denaturation, ∆H, may be either positive or negative at 
low temperatures, but increases notably with temperature. As the propulsive power for protein 
unfolding is the increased conformational entropy in aqueous solution, ∆S is expected to be 
positive. Consequently, -T∆S forces the Gibbs free energy ∆G to become negative and thus 
forwards unfolding. 
In this respect, the special situation of ∆G=0 deserves attention: in that case, 50% of 
the protein molecules are unfolded, and the correlative temperature is defined as the unfolding or 
melting temperature Tm. For the majority of proteins, Tm values range between 45 °C and 70 °C 
(Wang, 1999). Extreme high Tm values are exhibited by proteins in hyperthermophilic bacteria, 
where Tm can exceed 100 °C (Jaenicke, 1996).  
Two important caveats are to be noted in the use of Tm, often prompting 
misunderstandings. The first disaccord is that proteins are assigned specific Tm values, which 
characterize the proteins individually – what is not correct per se. For human and bovine 
albumin, two Tm values can be determined, indicating the existence of a molten globule state. 
Contrarily, dog and rabbit albumin  reveal only one transition (Kosa et al., 1998). Moreover, the 
parameters temperature, pH or the analytical technique used can influence the number of 
transitions obtained, exemplified by differential scanning calorimetry (DSC). Prior to DSC 
deconvolution, two protein melting transitions may be yielded, whereas subsequent to 
deconvolution three unfolding transitions can be determined, accounting for three individual 
protein domains (Remmele et al., 1998).  
The second misunderstanding refers to the relationship between Tm and general 
protein stability, represented by the Gibbs free energy ∆G. Is is widely assumed that any change 
of structure which leads to increased Tm should result in a commensurate gain in general stability. 
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E.g., in case of the pharmaceutical protein rt-plasminogen activator Tm was found to be about 66 
°C. In the presence of arginine, which stabilized the protein in solution, Tm shifted to 71 °C 
(Pearlman and Nguyen, 1992). Yet, thermodynamics – substantiated by experimental data - does 
not evaluate any particular relationship between Tm and ∆G at a given temperature (Knapp et al., 
1998; Dill et al., 1989). 
However, both rise and decrease of temperature may lead to a shift of ∆G (Fig. 17).  
Whereas unfolding due to heat is driven principally by the loss of polar contacts and a 
gain in conformational entropy of the protein chain, cold denaturation is based on the weakening 
of the hydrophobic effect upon cooling (Privalov and Gill, 1988). For the overwhelming majority 
of proteins, the temperature of cold denaturation is far below the freezing point of aqueous 
solutions. As a practical matter, at the temperature of maximal stability (Ts), generally between –
10 °C and 35 °C, protein unfolding entropy is zero and the native structure is solely stabilized by 
the enthalpy factor (Pace and Laurents, 1989).  
 
3.3.3 The aggregation process 
 
The formation of soluble and insoluble protein aggregate specimen is based on either 
covalent or non-covalent interactions. Covalently linked protein dimers or specimen of higher 
order are due to chemical reactions between the protein molecules. Because the aggregate origin 
is generally not evident, unfortunately the term “aggregation” is employed to describe this 
process, which should rather be termed “polymerization”. As protein aggregates often represent 
Fig. 17. Scheme of changes in entropy (∆S) and Gibb´s free energy (∆G) of protein unfolding 
as a result of temperature alteration.Tm is the temperature at which the free energy difference  
between the native and the unfolded state is zero, and represents the cold and heat denatura- 
tion temperature. At Ts the native state stability is maximal and ∆S is zero. 
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a potpourri of various covalently and non-covalently bound components, the term “aggregation” 
is universalized (Constantino et al., 1994). 
Furthermore, the terms denaturation, aggregation, precipitation and coagulation – 
although describing closely linked phenomena – have to be specified. Denaturation refers to both 
reversible and irreversible structural changes in native proteins resulting in altered solubility 
properties. However, the primary structure stays intact. If denaturation occurs far away from the 
isoelectric point (IP), the denatured protein remains in solution with only slight tendency to form 
aggregates.  
Generally, the item aggregation is used to differentiate between association or assembly 
with regard to quaternary structure formation on the one hand, and side reactions due to kinetic 
partitioning between correct folding and incorrect scrambling of subunits, on the other (Jaenicke, 
1995). The macroscopic equivalent of aggregation is precipitation (Manning et al., 1989). 
Precipitation may be brought intentionally by either complex formation or multi-component 
solutions, e.g., by salting out with salts or fractionation with mixed solvents. 
Coagulation of proteins is defined as an increase in particle size caused by denaturation 
and subsequent separation from the solution or gelation, often by means of elevated temperature 
(Jaenicke, 1997). 
Protein aggregation can occur from a conformational intermediate or from more 
extensively unfolded (completely denatured) protein molecules, where hydrophobic residues are 
exposed to the aqueous solvent. The initial stages of aggregation are quite specific in the sense 
that they involve the interaction of structural subunits of one molecule with “corresponding” 
hydrophobic surface areas of structural subunits of a neighboring molecule. Two sites can be 
sufficient, in which case the aggregation most likely propagates in a linear fashion forming long 
fibres. Anyhow, the process will yield larger aggregates, whose sizes will eventually exceed the 
solubility limit (Brange, 2000). Hydrophobic interaction, i.e., the reluctance of nonpolar groups to 
be exposed to water, is prevalently deemed the primum mobile for protein unfolding and 
subsequent aggregation (Franks, 2002). 
A variety of physical parameters can contribute to the aggregation process, as they 
facilitate the exposure of hydrophobic protein sites. The fragile balance of exposed and buried 
hydrophobic sites – propelling unfolding and aggregation if outbalanced - may be interfered by 
temperature, ionic strength, shaking, ultrasound or exposure to interfaces (Patro and Przybycien, 
1996).  
Basically, there is a continuous kinetic competition between refolding into the protein 
native state and reactions towards high-order aggregates. As aggregation is generally 
concentration-dependent, and since at higher concentrations aggregation dominates over 
refolding, there is obviously a sword of Damocles hanging over high-concentrated formulations. 
However, it is to be noted that the risk of product loss due to potential adsorption phenomena 
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on packaging material increases at low drug concentrations, i.e., <1 mg/mL. Hence, a statistically 
greater portion of protein drug has access to the adsorptive surface area of the package container 
(McLeod et al., 2000). 
Moreover, in event of highly dosed liquid protein formulations not only the aggregation 
rate, but also the size of protein aggregates may increase, resulting in possible precipitation 
phenomena (Roefs and De Kruif, 1994). If so, the aggregate nuclei have grown into primary 
particles, which may agglomerate and result in visible particulate matter. These primary particles, 
typically with dimensions ranging between 100 and 200 nm, correspond to approximately 1000 
protein molecules, according to protein molecular weight (Glatz, 1992). 
Aggregation reversibility and nature – i.e., covalent or non-covalent – can be 
characterized by means of denaturants such as GdnHCl, urea and sodium dodecyl sulfate (SDS). 
Principally, aggregation is irreversible and due to covalent processes if the protein aggregates can 
not be solubilized in those agents (Allison et al., 1996; De Young et al., 1993). 
An aggregate feature often in the fore is the formation of long fibres, especially if 
aggregation is due to thermal denaturation. In this case, the aggregates reveal an intermolecular 
hydrogen-bonded, antiparallel β-sheet structure, comparable to that illustrated in Fig. 16 (Dong et 
al., 1995). The thermally induced α-helix-to-β-sheet conversion was verified early on the basis of 
poly-L-lysine and subsequently demonstrated for a variety of proteins such as calcitonin, 
fibronectin or other proteins whose native folds are largely helical (Timasheff et al., 1967; Dong 
et al., 1995; Sunde and Blake, 1997). 
 
3.3.4 Theories on aggregation 
 
In contrast to the detailed information about proteins, relatively little is known about the 
thermodynamics of the aggregated protein state and the kinetics and mechanisms of its formation 
(Randolph et al., 2002). However, many theories on aggregation have been proclaimed, were 
expanded and upgraded, and some of them were binned.  
Most theories assume imperative protein denaturation prior to aggregation. Historically, 
research on protein aggregation first led to the proposal that protein aggregates originate from 
the totally unfolded, denatured state. It was found that (thermally induced) protein aggregates 
feature an antiparallel β-sheet structure, regardless of the initial secondary structural composition 
of the native proteins (Dong et al., 1995). Consequently, proteins have to unfold completely, i.e., 
to abandon their secondary structure, before aggregation occurs. 
The next historical leap in insight into aggregation involved “molten globule” protein 
intermediates. Associated herewith is the maintenance of secondary protein structure, albeit the 
tertiary structure is vastly perturbed due to destabilizing ambience. Effectually high 
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concentrations provided, e.g., >1 mg/mL, molten globules readily form aggregates (Uversky et 
al., 2001). This implicates that aggregation may eventuate from only partially unfolded states. 
To confuse the matter further on, most recently it was found that even under solution 
conditions not disrupting tertiary structure and thermodynamically greatly favoring the native 
state, proteins can aggregate and even precipitate (Kim et al., 2000). Accordingly, the native 
conformation is accredited a dynamic structure, such that at any instant in time an ensemble of 
specimen exists with a distribution of structural expansion/compaction. Aggregates derived 
thereof arise from components which reveal an expanded structure, compared to the most 
compact conformations present. 
This conclusion is substantiated by the status of proteins in thermophilic bacteria, 
generally considered practically insusceptible to aggregation. Here, a slightly denser packing in 
native proteins is observed compared to the density of ubiquitary proteins (De Decker et al., 
1996).  
These renewed efforts to define theories and to determine aggregation processes were 
both permitted and fueled by the demonstration that aggregation proceeds through specific 
pathways (Speed et al., 1996). Thereby, a rationale for repudiation of the nonspecific 
coaggregation dogma has been provided and the conceptual bias that aggregation is a random 
process has been removed. 
The theory, that the native protein conformation has a dynamic structure is supported by 
the energy landscape theory and the folding funnel concept, respectively (Fig. 18). 
Fig. 18. „Rugged energy landscape“ of 
protein folding for a small protein site 
with a preferred directionality towards an 
unique native state. E and Q refer to the 
solvent-averaged energy and the fraction 
of native-like contacts, respectively. The 
fluctuations ∆E and the stability gap 
δ∆Es between the misfolded or molten 
globule states and the native state are 
functions of the order parameters. 
Unique folding is assessed by local 
secondary and tertiary contacts as well as 
hydrogen bonds within the stability gap. 
If correct folding is opposed, the 
directionality is inversed and the proteins 
reveal denatured states, prone to 
aggregation phenomena (Jaenicke, 1999).
Beginning of helix formation 
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There is evidence from NMR data that even under extreme denaturing conditions a 
certain amount of native residual protein structure prevails (Wilson et al., 1996). As a 
consequence, the denatured state comprises a large number of noticeably different conformations 
in rapid equilibrium with each other. In the framework of folding delineation as the descent in an 
energy landscape, native protein sites would populate the tapered terminal area of the landscape. 
Each native protein state is assigned a specific trap, with minimal distances between stabilizing 
secondary and tertiary contacts. Conversely, unfolded and aggregated protein sites would 
populate sub-states in the funnel-part of the landscape that are characterized by distances 
between stabilizing sites in the range of many Ǻngstroms (Chahine et al., 2002).  
One major obstacle in establishing a universally valid aggregation theory can be ascribed 
to the heterogeneity of aggregation peculiarities. Aggregation can be characterized as an 
unimolecular/intramolecular process (e.g., β-elimination) as well as a multimolecular/ 
intermolecular process (Chang et al., 1996). Consequently, aggregation may or may not follow 
first-order-kinetics, as proved by experimental data (Wang, 1999; Pikal et al., 1991). However, this 
matter is still discussed controversely, exemplified by the investigations on pancreas RNase: 
thermally induced inactivation was found to be strictly of first order or unimolecular kinetics. The 
researchers assigned protein aggregation in general a necessarily first-order kinetic and a 
polymolecular pathway. As a consequence, they innately ruled out aggregation as the cause of 
inactivation (Ò Fágáin, 1995).  
A quite simple, though target-oriented, attempt is to approach underlying principles of 
protein aggregation by employment of colloidal aggregation models. Accordingly, both native 
protein monomers and denatured aggregates are considered to act like colloids, with inherent 
diameters between 1 and 1000 nm and dispersed in solution (De Young et al., 1993b).  
Basically, the DLVO theory accounts for steric and electrostatic repulsions and van der 
Waals attractions between particles in solution. Referring to this, DLVO provides a simple 
framework for describing the thermodynamics and kinetics of colloidal stability and aggregation 
(Russel et al., 1989). According to the Smoluchowski theory, the kinetics of protein aggregation 
depends on the diffusion coefficient, particle number and particle radius (Rosenqvist et al., 1987). 
This theory has been successfully employed to model protein aggregation (Fig. 19).  
Considerable progress has been made in terms of understanding protein aggregation by 
introducing theories which draw a comparison between parameters contributing to protein 
stability and parameters forwarding protein unfolding and aggregation, respectively. The mean-
field lattice theory posits an equilibrium between denatured and aggregated states of proteins 
(Fields et al., 1992). The lattice model implicates the aggregate state to be composed of 
amorphous protein polymer plus solvent, and that the driving forces are hydrophobic interaction, 
advancing aggregation, and conformational and translational entropies, which foster 
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disaggregation. The theory predicts that at sufficiently high protein concentration precipitation 
proceeds, whereby the solubility limit represents the lowest concentration at which this occurs.  
An integral part of the lattice model is the determination of upper and lower 
temperatures, assessing dissolved-undissolved protein phase boundaries. For instance, cooling at 
low temperatures leads to a loss of the translational entropy, favoring aggregation. More 
important at low temperatures is the weakening of the hydrophobic interaction upon cooling, 
what forwards dispersion of the protein polymer in the solvent. Hence, principally, proteins 
could be dissolved by cooling at adequate temperatures. However, this temperatures are 
predicted to be below the freezing point of water. Due to the temperature dependence, the phase 
boundaries can undergo remarkably large shifts with very small changes in copolymer 
composition. The practical consequence of this is that the change of a single amino acid of a 
protein can cause precipitation or can cause an insoluble protein to become soluble, vice versa 
(Fields et al., 1992). 
Two years ago, the manifold ensemble of theories was enriched by an article of Pace, 
causing a stir within the prevalent point of view of most researchers (Pace, 2001). According to 
Pace, the burial of an polar amide group is deemed to contribute more to protein stability than 
the burial of an equivalent volume of nonpolar -CH2- groups. Since about 1960, the latter 
parameter was considered to contribute the lion´s share to protein stability (Kauzmann, 1959). 
However, Pace construed several studies as the desolvation penalty for burying peptide groups to 
Fig. 19. Free energy dependence on aggregate size. Pursuant 
to Smoluchowski theory, protein particles stick so strongly 
to the aggregate that the rate-limiting step is diffusion of the 
particles to the aggregate cluster. In this regard, it is 
important how one monomer attachment influences the 
next, and whether aggregate groth is (a) simple, (b) 
nucleation controlled or (c) exponential. Simple growth (a) 
occurs when each monomer addition is favorable to about 
the same degree, independent of the size of the growing 
aggregate. The free energy per added monomer is negative 
(favorable) and is of comparable amount for each monomer. 
Larger aggregates are favored but smaller ones are also 
populated, particularly at early times. In nucleation 
controlled growth (b), e.g., protein crystallization, the free 
energy of adding monomers is positive when the aggregate is 
small. Consequently, small aggregates are unfavorable. In 
exponential growth (c), the addition of each unit is more 
favorable than for the preceding unit, e.g., the Ca2+-induced 
aggregation of α-casein occurs via exponential aggregation 
kinetics followed by Smoluchowski aggregation (De Young 
et al., 1993). 
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be considerably smaller than thought hitherto. Contrarily, hydrogen bonding and van der Waals 
interactions of peptide groups in the tightly packed interior of folded proteins are more 
favorable. The fraction of space occupied by atoms is 0.75 in protein interiors – outranging the 
0.71 packing of close packed spheres – and regions containing hydrogen-bonded polar groups 
may be more tightly packed than regions containing nonpolar side chains. As a consequence, van 
der Waals interactions among groups in the interior of a folded protein will be more favorable 
than the interactions of the same groups with water in the unfolded protein (Fleming and 
Richards, 2000; Honig, 1999). Therefore, improved van der Waals interactions have a large share 
in the enthalpy of protein folding. This theory was supported by investigations demonstrating 
that protein stability can not be increased by replacing groups forming a buried hydrogen bond 
by different combinations of hydrophobic residues (Maxwell and Davidson, 1998).  
Given the background of the low solubility of glycine peptides, it may be concluded 
that water is a relatively poor solvent for the peptide backbone. This raises the question of 
whether solvophobicity of the backbone in water has been overlooked as a contributor to the 
collapse and folding of proteins – all the more, because reduced packing density and increased 
solvophobicity of the protein backbone facilitate protein aggregation subsequent to unfolding 
phenomena. At present, science is digesting these notions, as neither Pace nor the supporters of 
the contribution of nonpolar group burial to protein stability have published further arousing 
details. 
The accumulating number of observations of three-dimensional protein domain 
swapping has prompted speculations as to its impact on aggregation phenomena (Fig. 20).  
Fig. 20. Basic principles in domain swapping. 
The term domain is not used in a strict sense, as 
proteins habe been reported to swap entire 
tertiary globular domains as well as domain 
elements such as α-helices or β-sheet strands. (A) 
Simplified representation of a protein monomer 
and a domain-swapped dimer. The exchanging 
parts of the structure form a new interface in a 
domain-swapped oligomer, highlighted in red. 
(B) Structures of monomer and domain-swapped 
dimer; the domain swapping C-terminal β-strand 
and the hinge loope are shown in red. (C) 
Illustration of open-ended and close-ended 
domain swapped oligomers, exemplifying 
aggregation processes induced by domain 
swapping (with friendly permission of Rousseau 
et al., 2003). 
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Originally proposed to be a mechanism for the emergence of polymeric proteins, an 
increasing amount of data solidify its potentiality to foster misfolding and aggregation. Basically, 
three-dimensional domain swapping – the term was introduced in 1994 - is a process by which 
one protein molecule exchanges a domain with an identical partner (Bennet et al., 1994).  
Referring to this, transient aggregation was observed during refolding of several proteins, 
and was ascribed due to domain swapping (Silow et al., 1999). Additionally, a correlation between 
domain swapping propensity and the rate of heat aggregation of proteins was stated (Rousseau et 
al., 2001). Domain swapping is also attributed to play a role in the processes of prion and amyloid 
formation, substantiated by crystallization data of prion protein, for instance (Knaus et al., 2001). 
As research strongly focuses on understanding protein aggregation due to self-association, it is to 
be expected that domain swapping will gain increasing attention (Rousseau et al., 2003). 
Considering the diversity of theories available, the development of an overall theory in 
terms of aggregation is to be deemed unlikely. If at all, this theory will be a patchwork of several 
theories available, and each protein aggregation problem will have to be approached individually.  
 
3.3.5 Quantification of the aggregation rate 
 
“To be aggregated or to be unfolded” seems to be the Hamlet´s question for protein 
samples analyzed in terms of physical instability. As protein aggregation involves precedent 
unfolding, a definite classification of techniques in methods monitoring the 
unfolding/denaturation process and methods quantifying the aggregation rate is not always 
unambiguously. 
This inherent method ambiguity can be exemplified by (fourier transform) infrared 
spectroscopy (FT-IR). Today, FT-IR is the most widely employed technique in order to assess 
the secondary structure of proteins (D´Auria et al., 1997). The investigated parameter is the C=O 
stretching vibration of the peptide moiety, which is weakly coupled with the in-plane N-H 
bendings and the C-N stretching vibrations (Takeda et al., 1995). Induced by different secondary 
structures, e.g., α-helix, β-sheet or loops, C=O stretching vibrations are covered by the amide I 
region (1620 – 1690 cm-1). In order to increase IR resolution and assess secondary protein 
structure more accurately, fourier self-deconvolution and second or fourth derivation have been 
applied (Goormaghtigh et al., 1994). On the other hand, intermolecular hydrogen-bonded β-sheet 
structures are a common characteristic of protein aggregation, mainly represented by a low-
frequency band around 1620 cm-1 (Dong et al., 1995b). This structural composition occurs 
regardless of the pristine composition of the secondary structure of native proteins. Therefore, 
this band can be used - among other bands – to quantify protein aggregation in both aqueous and 
solid states (Wang, 1999). Moreover, FT-IR can be applied to estimate protein Tm values via 
analysis of amide I band intensities (Bischof et al., 2002; Chehin et al., 1998). 
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As regulatory authorities generally limit the potential consequences of protein aggregation 
- e.g., particulate matter contamination –, the formulation scientists usually focus on aggregation 
rate determination rather than to analyze unfolding phenomena. Furthermore, inactivation of 
proteins may occur without disruption of the tertiary structure and proteins highly prone to 
unfolding phenomena do not necessarily exhibit a pronounced tendency to aggregate (Cowan, 
1997). Thus, aggregation per se is generally scrutinized by the scientists more intensively than 
protein unfolding. Among the various methods applied in aggregate quantification, PAGE and 
SE-HPLC are the most widespread techniques. Both techniques monitor the increase of protein 
size during aggregation. 
The popularity of SE-HPLC is based on its high reproducibility, simplicity of operation 
and the ability to satisfactorily estimate protein molecular weight averages (Olivia et al., 2001). 
For instance, newly cloned proteins, especially those generated subsequent to large-scale 
sequencing, may exist in solution optionally in monomeric or oligomeric forms. By means of SE-
HPLC the solution consistence may easily be verified (Wen et al., 1996). Unfortunately, protein 
or aggregate size can be overestimated by SE-HPLC if the protein is not spherical - e.g., but 
highly-coiled - and its Stokes radius exceeds that of a globular protein (Kuhlman et al., 1997). 
While SE-HPLC assesses the total amount of aggregates based on size, reversed phase HPLC 
(RP-HPLC) can intergrade covalent and non-covalent aggregates or differentiate between various 
isoforms of protein aggregates (Sharokh et al, 1994; Perlman and Nguyen, 1992). However, 
filtration or centrifugation of the samples prior to HPLC analysis imposes the significant 
constriction of HPLC to be limited for the determination of soluble aggregates.  
Referring to PAGE, the distinction between covalently and non-covalently (ionic) bound 
soluble aggregates is possible via reducing and non-reducing PAGE (Reubsaet et al., 1998). E.g., 
by reducing SDS-PAGE the covalent binding of G-CSF was shown to be primarily due to 
disulfide linkages via intermolecular disulfide scrambling (Bartkowski et al., 2002). Both reducing 
and non-reducing SDS-PAGE can be combined in two-dimensional electrophoresis, where the 
first dimension is a non-reducing run and the second dimension is a reducing one. Quantification 
of the separated aggregate fractions is usually performed densitometrically (Petruccelli and Anon, 
1995). Though, this method lacks accuracy, as the utilized dying agents, e.g., Coomassie Blue, 
reveal an affinity for both proteins and gel material. 
As the two methods complement one another, SE-HPLC and SDS-PAGE frequently are 
employed in parallel for meanwhile three decades (Maekawa et al., 2003; Skjelkvale and Duncan, 
1975).  
Light obscuration and Coulter technique are state-of-the-art methods for subvisible 
particle counting in protein parenterals with inherent lower detection limits of ~1 µm and ~0.4 
µm, respectively. As the aggregation process theoretically can run the gamut from nm range – at 
early stages of the aggregation process – to the subvisible µm range, maybe resulting in visible 
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association/precipitation products, particle counting techniques disclose protein instability 
tendencies relatively late – compared to methods like SE-HPLC or PAGE. In this regard, analysis 
of particulate matter in protein parenterals via light obscuration mainly is targeted on particles 
due to surface abrasion of package material during the manufacturing process rather than on 
protein particles due to aggregation processes (Borchert et al, 1986). On the other hand, Coulter-
based measurements were successfully applied in analysis of hemoglobin aggregation and 
assessing size distributions of protein particles due to precipitation (NcNulty et al., 1994; Rohani 
and Chen, 1993). Generally, data of aggregation processes obtained by light obscuration closely 
correlate with data derived from Coulter technique, as both methodes detect aggregation 
tendencies in protein shelf-life studies concomitantly with identical sensitivity (Fraunhofer et al., 
2003). 
The turbidimetric method is used to estimate the amount of protein aggregate by 
measuring the optical density of a sample based on light scattering in the near UV or visible 
region, where proteins do not reveal any absorption (Kelley and McClements, 2002; Wang et al., 
1996). Given the background that soluble aggregates do not necessarily lead to opalescent or 
turbid protein solutions, whereas smallest amounts (<1%) of insoluble aggregates may cause 
turbidity with subsequent particulate matter, neither particle counting techniques nor turbidity 
measuring enables accurate quantification of aggregation rates (Hoffmann, 2000). One further 
aspect that has to be taken heed of is the potential intrisic turbidity of highly-concentrated 
protein solutions, e.g., antibody formulations, which can exhibit protein concentrations exceeding 
100 mg/ml. Additionally, opalescence/turbidity of liquid protein pharmaceuticals may be due to 
packing material such as siliconized rubber closures (Gebhardt et al., 1996). Thus, solution 
turbidity may not automatically be equated with protein aggregation. 
In the last decade, a variety of new experimental techniques have been introduced in 
protein aggregation monitoring. However, many of those techniques still have to provide 
evidence of their general applicability in aggregation analytics. E.g., antibody mapping can be 
employed to detect early aggregation intermediates and to assess aggregation intensity (Betts and 
al., 1999). Referring to this, quasi-elastic light scattering (QELS) was shown to be also suited for 
resolving initial stages of the aggregation process and aggregate quantification (Walsh et al., 
1997). Whereas fluorescence spectroscopy (FS) per se is prevalently used to investigate protein 
unfolding, FS can be applied to assess the aggregation intensity in combination with dying agents 
such as bis-anilino napthalene sulfonic acid (BIS-ANS) (Azuaga et al., 2002; James and 
Bottomley, 1998). Besides the aggregation rate, by means of ANS fluorescence also structure and 
conformational plasticity of protein aggregates can be determined (Kundu and Guptasarma, 
2002). However, as the exposure of hydrophobic core surfaces in the course of aggregation 
processes does not essentially correlate with the aggregation rate, this method reveals a major 
drawback - folding events can potentially be mistaken as aggregation events (Finke and Jennings, 
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2001). Moreover, the temperature dependent ANS fluorescence may only be observed in case of 
measurable turbidity of protein solutions (Andersen, 2002). 
Analytical ultracentrifugation (AUC) may also provide valuable results in terms of protein 
aggregation (Arakawa et al., 1999). Besides identification of individual aggregated protein 
specimen, AUC can be applied to quantify the aggregation rate (Whittingham et al., 2002; Liu and 
Shire, 1999). Further methods applied in the evaluation of aggregation intensities encompass 
atomic force microscopy and electron diffraction (Nichols et al., 2002; Serpell et al., 2000).  
In reviewing the information above, the conclusion arrives that present established 
methods of protein aggregate quantification inhere one major restriction: they enable the 
quantification of only soluble aggregates, thereby jettisoning insoluble aggregates or vice versa. 
Given this background, one candidate with great potential for aggregate quantification is AF4, as 
this method can analyze both aggregate specimen.  
The separation of protein monomer from oligomers and soluble lmw aggregates via AF4 
was principally demonstrated in 1993 (Litzén et al., 1993). Subsequently, AF4 was shown to be 
capable of analyzing soluble hmw aggregates of glutenin (Wahlund et al., 1996). Only recently, 
the overall-applicability of AF4 in protein analytics was successfully demonstrated by 
comparative studies addressing soluble aggregate quantification and particulate matter analysis – 
compared to SE-HPLC and light obscuration, respectively (Fraunhofer, 2002d). However, 
research still lacks an extensive study on the use of AF4 in protein analytics – comprising relevant 
parameters such as sample recovery and elution order. Consequently, Chapter 6 attends to those 
matters. 
Finally, it should be stressed that instability/aggregation studies of pharmaceutical 
proteins generally are accompanied by activity assays. Yet, bioassays inhere several drawbacks, 
e.g., low reproducibility, labor-intensity, unability in detecting only slight activity alterations. 
Furthermore, in many cases a tailor-made bioassay is to be created based on the protein´s 
function (Wolfbeis et al., 2002; Hsu et al., 1995). In practice, bioassays therefore are employed in 
combination with other analytical techniques to assess protein stability such as SE-HPLC for 
soluble aggregate quantification and light obscuration, seizing insoluble aggregates and particulate 
matter, respectively.  
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4 Multi-angle light scattering (MALS) in protein analytics 
 
4.1 Introduction 
 
Light scattering is an everyday occurrence of our life, that becomes apparent for instance 
in the color of the blue sky, red sunsets or the phenomenon of rainbows. Simplifying the latter, 
the raindrops function as scattering angular filters, and due to the properties of water there is 
enough angular spread ending up in colorful visions. Light scattering analytics has found it´s way 
into branches of science and research with an impact only scarcely imaginable some years ago, 
e.g., pharmaceutics, medicine, bioengineering and meteorology (Hodgson, 2000). The upturn of 
light scattering appliance was fueled by the plethora of analyte information accessible, comprising 
molecular weight, radius of gyration, hydrodynamic radius, size distribution, shape and internal 
structure and even analyte interactions. 
Two general techniques employing light scattering exist: dynamic light scattering (DLS), 
often referred to as PCS or quasi-elastic light scattering (QELS), and static or so-called classical 
light scattering (SLS). In DLS a laser is focused into the solution volume containing the (in most 
cases colloidal) analytes and the scattered light is collected over a small angle. Both phase and 
polarization of the light scattered are determined by size, shape and conformation of the analyte 
molecule (Brown, 1993). Thereby, the fluctuation of the scattered light intensity determined by 
the detector is closely related to the extent of random Brownian motion and, consequently, 
temperature-dependent (Hodgson, 2000). From these fluctuations an autocorrelation function is 
derived, which is inverted for assessment of analyte diffusion coefficient and analyte size, in case 
that the analytes are spherical. The use of DLS for off-line batch characterizations has extensively 
been reviewed in the literature (Borcovec, 2002; Will and Leipertz, 2001; Finsy et al., 1992). 
Although the application of DLS as on-line detection method during chromatographic sample 
separations was approached, this procedure inheres a major drawback: the DLS measurement 
normally fails to keep pace with the rate of sample specimen elution. Thus, unfavorable stop-flow 
modes of the separation method have to be accepted (Claes et al., 1992).  
On the other hand, SLS is targeted on quantification of the scattered light intensity as a 
function of the scattering angle. By spacing several discrete photo-detectors around the flow-cell 
in a multi-angle geometry, measurements can be performed over a broad range of angles, 
resulting in a SLS-subtechnique called multi-angle light scattering (MALS) (Fig. 21). Thereby, 
both molecular weight and size of analytes can be determined absolutely, i.e., independently of 
the elution volume and without the need of calibration or assumptions concerning chemical and 
steric structure of the analyte. Furthermore, the light scattering intensity is monitored in the 
microsecond time range, thus drawing a major distinction to DLS, where monitoring is 
performed in second time range. Hence, SLS is applicable to on-line detection subsequent to 
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fractionation processes. In contrast to the rather low resolution of DLS in analyzing bi- or 
multimodal systems, MALS was shown to accurately resolve analyte subpopulations that differ by 
much less than a factor of two in mean size (Korgel et al., 1998). Due to its ability to elucidate the 
steric structure of sample components, MALS is increasingly applied to investigate conformation, 
unfolding, and both glycosylation and aggregation rate of proteins (Filenko, 2000). Assets and 
drawbacks of SLS and MALS, respectively, have repeatedly been published (Wyatt, 1998; Hallett, 
1996; Schnablegger and Glatter, 1993). 
Generally, the theory governing the light scattering process resembles the theory 
underlying the scattering by X-rays and neutrons, even though light and X-rays are 
electromagnetic radiation with different wavelengths while neutrons hold mass (Chu and Liu, 
2000). Thus, besides SLS and DLS, similarly sophisticated techniques arise in protein analytics 
such as small-angle X-ray scattering (SAXS), wide-angle X-ray diffraction (WAXD) and small-
angle neutron scattering (SANS), which can be applied in conformational studies of putatively 
fully unfolded protein states (Millet et al., 2001; Koch et al., 2001). 
 
4.2 Theoretical aspects 
 
The theoretical cornerstones of light scattering were developed early by Raman, Debye, 
Mie, Lorenz and Zimm (Raman, 1927; Zimm, 1948; Wriedt, 1998). Even Einstein adressed the 
light scattering phenomenon during his time as associate professor at Zurich by explaining light 
scattering from pure liquids as a result of density fluctuations (Einstein, 1910, 1911). 
The fundamental equation relating the intensity of scattered light and molar masses of 
analytical scatterers was pioneered by Zimm in 1948, 
 
where θ is the angle between the incident and the scattered rays and Rθ expresses the excess 
Rayleigh ratio of the light scattered from a dilute solution/suspension of analytes, i.e., the excess 
of scattering of the molecular solution/suspension above that scattered by the solvent itself. 
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θ
Fig. 21: Schematic principle of MALS 
detection. Several photo-diodes are 
spaced around a flow-cell, which is 
irradiated by laser light. The multi-angle 
geometry of the diodes enable a simul-
taneous detection of scattered light over 
a wide range of scattering angles (θ), 
typically varying from 10° to 160°. 
cA
MR
Kc
w
22
1
)(
+=θ
(23)
Chapter 4. Multi-angle light scattering (MALS) in protein analytics 
 45
Pertaining to that, R0 is proportional to the fraction of incident light that is scattered by the pure 
solute without interference. A2 represents the second virial coefficient and MW indicates the 
molar mass of the analyte. At low concentrations c, the term 2A2c in Eq. (23) may be negligible. 
K represents a physical constant according to 
 
 
 
where n0 is the refractive index of the solvent, NA marks Avogadro´s number, dn/dc 
signifies the refractive index increment of the analyte in solution or suspension, and λ0 indicates 
the vacuum wavelength of the incident light. In analytical practice, the refractive index increment 
is easily amenable via use of refractive index detection systems. Basically, Eq. (23) is valid for any 
type of analyte, provided that the radial axis of the analyte does not exceed ~20% of the 
wavelength of the incident light. If the analyte reveals larger dimensions, the scattering emanating 
from various parts of the analyte will exhibit a difference in phase and the isotropic scattering 
profile will shift towards anisotropic behavior (Fig. 22).  
Thereby, the extent of the phase difference depends on the scattering angle and intensifies 
when the observation angle is increased – while the difference remains unchanged at θ = 0 (Witt-
gren and Wahlund, 1997b). In order to compensate Eq. (23) for the decrease in scattering power 
due to phase difference phenomena, a special form factor P(θ) is introduced (Zimm, 1945), 
 
 
 
where <r²G>1/2 represents the root mean square radius. This quantity is often referred to as radius 
of gyration, although it has no connection with any rotation or moment of inertia. By employing 
the form factor P(θ), Eq. (23) changes into 
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Fig. 22: Dependence of analyte size on light scattering characteristics: if the analyte diameter (d) 
exceeds λ/20, the light scattering profile is modified towards anisotropic scattering, i.e., light is 
scattered particularly in forward direction. As a consequence, at lower angles (θ) the intensity of 
scattered light increases. 
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Consequently, by assessing the scattering intensity at different angels and analyte 
concentrations, via Eq. (25) and Eq. (26) MALS can provide information about molecular mass, 
the radius of gyration and the second virial coefficient of analyte components.  
It is important to emphasize that in case of small analytes with inherent diameters <λ/20 
- e.g., immunoglobulin monomers of the subclass G reveal diameters of 5.2 nm - the detection of 
scattered light intensity at one single angle is sufficient for accurate molar mass determination. 
According to Fig. 22, antibody monomers scatter light in all directions with identical intensity, 
regardless of the detection angle. Referring to this, the form factor P(θ) may be applied as 
“scattering function” in order to describe the dependence of scattered light profile on the angle 
of detection. In case of small analytes, this dependence can be expressed in a straight line, 
indicating an isotropic mode of scattering (Fig. 23). Since the line slope is closely correlated to the 
scatterer´s diameter and as the scattering functions are to be extrapolated towards conditions 
with θ = 0, one single detector placed at an optional angle enables accurate mass determination. 
However, in case of larger analytes - e.g., hmw protein aggregates with diameters exceeding λ/20 
– the scattering function is to be expressed by higher-order functions. As a consequence, several 
breakpoints are to be assessed to determine the scattering function and to render extrapolation 
towards a θ = 0 situation possible. Thus, several photo-detectors have to be placed at various 
angles. 
 
If MALS is combined with separation systems such as HPLC or AF4, the theory outlined 
above may be applied to gain further information. As this modus operandi enables to gauge the 
scattering intensity in each small slice i of the fractionated sample via 
 
parameters such as molecular mass distribution, radius of gyration distribution and different 
averages of the molecular mass are made accessible (Shortt et al., 1996). Furthermore, the 
Fig. 23: Dependence of the form factor 
P(θ), often referred to as scattering function, 
on scattering analyte dimensions. The larger 
the analyte, the greater the angular variation 
of the scattered light intensity. Note that 
P(0°) = 1 is imperatively. 
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concentration in each individual slice is different and the number of slices may be considered to 
be discretionary, thus, the amount of analyte in every slice is guaranteed to be low (Wittgren and 
Wahlund, 1997). Consequently, the term 2A2c in Eq. (27) and Eq. (23) may be neglected, thereby 
improving accuracy of the calculated data. 
A graphical respresentation of the extrapolation of Eq. (27) can be achieved by plotting 
Kc/Rθ versus sin²(θ/2) for each (θ, c) point measured (Fig. 24). The extrapolation towards θ = 0 
yields 1/M at the point of ordinate intersection, whereas the slope of the fitted straight line 
expresses the root mean square radius per Eq. (25).  
Principally, the standard data reduction equipment required is a straight edge, a pencil and 
a firm eraser. As a matter of fact, this was the state-of-the-art treatment of data when Zimm 
originally developed that technique (Wyatt, 1993). In case of assessing small analytes with 
inherent low molecular weights, data treatment applying a Zimm plot is prevalently esteemed: the 
extrapolation towards 1/M is then targeted on high values, what is conducive for data 
interpretation verity. Vice versa, analyzing large sample components – i.e., sample specimen 
beyond 100 nm in diameter and thus exceeding λ/20, since established wavelengths of MALS 
instruments average ~600 nm – involves a reciprocal Zimm plot, generally termed Debye plot 
(Debye, 1944; 1947). 
Thereby, Rθ/Kc is plotted versus sin²(θ/2). Accordingly, the extrapolation towards θ = 0 
yields M/1 – and as M represents a large value, even unprecise extrapolation results in only slight 
aberrations concerning experiment fidelity.  
For further particulars it is to be referred to reviewed literature (Buchholz and Barron, 
2001; van de Hulst, 1996; Wyatt, 1993).  
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Fig. 24. A Zimm plot derived from a MALS experiment with simultaneous assessment of the 
scattered light intensity at 18 individual angles. The ordinate intersection indicates the reciprocal 
molar mass value, and the line slope represents the root mean square radius of the analyte. 
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As outlined in Chapter 3, the protein drug formulation scientist is strongly interested in 
early-stage detection of protein aggregation. In this regard, light scattering can be deployed as 
reconnaissance tool: the presence of even slightest amounts of (hmw) aggregates in the 
formulation is reflected by a disproportional intense light scattering signal. This gives the 
formulator a competitive edge (Fig. 25). 
 
Therefore, the coupling of MALS with (semi-)chromatographic separating techniques 
such as SE-HPLC enables a highly sensitive detection of aggregate specimen in protein solutions. 
As demonstrated in Chapter 10, this feature of SE-HPLC/MALS can facilitate early-stage 
detection of protein instabilities in different protein drug formulations. 
 
4.3 MALS in laboratory practice: on-line combination with FFF or HPLC 
 
It is generally accepted that light scattering is the method of choice for assessing the size 
of analyte ensembles, provided that all analytes reveal exactly the same size (Wyatt, 1998). In that 
case, the ensemble of identical analytes generate a light scattering pattern the same as that of a 
single analyte molecule, but amplified proportional to the particle number present in the 
investigated scattering volume. Until analytical samples could be separated, e.g., by HPLC, light 
scattering measurements assessed solely weight average molecular weights and number-average 
square radii. The often underestimated pitfalls inherent to that limitation are reflected by one 
Fig. 25: Relationship of protein aggregate mass ratio and according share of the total scattered 
light. The protein monomers reveal a 2.2 nm diameter and account for 99.95% of the protein 
mass present in the sample. On the contrary, the average size of aggregate specimen is assessed 
to be ~80 nm. Though the aggregates total to solely 0.05% of protein mass present, they cause 
28% of the intensity of overall scattered light, thus underlining the sensitivity of the method 
(illustration with kind permission of Alliance Protein Laboratories, CA, USA). 
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issue of Applied Optics, that was (almost exclusively) devoted to light scattering (Bohren and 
Hirleman, 1991). 
For FFF/MALS coupling basically any FFF subtechnique is qualified. The pioneering 
experiment was performed in 1991, when MALS was combined with Sd-FFF (Wyatt, 1991). 
Later on, the first successful coupling of MALS with Flow-FFF was performed in order to 
determine molar mass distributions of polystyrene particles and dissolved dextranes (Roessner 
and Kulicke, 1994). The results were compared to SE-HPLC/MALS data, thus demonstrating 
the general applicability of FFF/MALS to separate sample components in the range where SE-
HPLC fails due to the existence of an exclusion boundary. These findings were substantiated by 
the characterization of ultra-hmw polymers via SE-HPLC, Th-FFF and MALS, as SE-HPLC per 
se was demonstrated to consistently underestimate the molecular weight of the samples (Lee and 
Kwon, 1995). Even in connection with MALS, the accuracy of molar mass determination via SE-
HPLC was limited due to the deficiency of SE-HPLC to provide monodispersity in each data 
slice. Recent investigations performed by means of AF4/MALS aiming at the characterization of 
ultra-hmw components of synthetic and natural polymers may also be subsumed to this matter 
(Wahlund et al., 2002). 
As a consequence, MALS is preferentially applied to characterize hmw and particulate 
sample specimen fractionated via precedent FFF separation. E.g., polystyrene latices and various 
swellable core-shell sub-micron particles were assigned (thermal) diffusion coefficients, surface 
structure and radii of gyration by associating MALS with Th-FFF and AF4, respectively (Mes et 
al., 2001; Frankema et al., 2002). A challenging analytical task was approached when molar mass 
distributions of polymer aggregates in solutions containing flocculants were evaluated via Flow-
FFF and MALS (Hecker et al., 1999).  
Pertaining to pharmaceutics, MALS can be employed to accurately analyze colloidal and 
particulate systems running the gamut from nm to µm range. E.g., heterogeneous mixtures of 
cationic lipid-DNA colloidals can be characterized in terms of shape and size distribution 
subsequent to separation via Flow-FFF (Lee et al., 2001).  
As HPLC enjoys a state-of-the-art prevalence, a broad spectrum of applications in 
combination with MALS may be itemized. Most notably, synthetic polymers are characterized 
routinely in both aqueous and organic solvents (Himel et al., 2003). In particular, the 
characterization of block copolymers is to be quoted, as copolymers gain increasing importance 
in (colloidal) drug carrier design (Zhang et al, 2003; Liu and Tsiang, 2003). Referring to this, the 
successful determination of molar mass, polydispersity and storage stability of hyaluronan in 
commercial intra-articular injectable preparations may be instanced (Adam and Gosh, 2001).  
Commensurate with AF4 applications in protein analytics, HPLC/MALS primarily is 
applied for characterization of aggregated hmw specimen (Southan and MacRitchie, 1999). In 
case of fibroblast growth factor, MALS contributed substantially to the elucidation of multimer 
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formation pathways due to varying oxidation conditions (Astafieva et al., 1996). Additionally, the 
characterization of proteins incorporated within colloidal drug carriers like liposomes or the 
analysis of liposomes per se was effectively approached applying MALS (Wang et al., 2002). 
In order to add to the information provided, UV-spectrophotometry and refractive index  
(RI) detection are normally associated with MALS. With regard to protein analytics, assessment 
of protein concentration can easily be performed via UV-spectrophotometry, whereas the degree 
of glycosylation of proteins is advantageously determined by RI detection. This ternary detection 
set-up enabled the extensive evaluation of oligosaccharide conjugate vaccines by means of SE-
HPLC/MALS (Jumel et al., 2002).  
A more detailed listing of MALS applications comprising the period before 1999 – 
focusing on the coupling with FFF - can be found in the literature (Coelfen and Antonietti, 
2000). In general, MALS is expected to have a cumulative stake in future analytics. Up to 1997, 
only few MALS applications were published, whereas there is an exponential increase ever since. 
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5 Summary 
 
Despite more than two decades of intense research, the pharmaceutical formulation 
scientists still miss a generally-valid, rational procedure to ensure adequate protein drug stability. 
Thereby, protein stabilization is often hampered by a very subtle balance between native 
conformation and denatured states. The most prevalent outcome of physical instability is protein 
aggregation. In this regard, considerable progress has been made in understanding the complex 
combination of circumstances leading to aggregation, particularly facilitated by modern advanced 
analytical techniques capable of accurately assessing the rate of protein aggregation.  
 
Field-flow fractionation (FFF) is introduced in Chapter 2 as a family of analytical 
techniques with broad application range. Although pioneered almost four decades ago, FFF was 
adopted in analytical laboratories only recently to an increasing extent, mainly due to 
perfectioning of inherent system parameters. The most prominent FFF subtechniques, their 
mode of operation and basic theoretical principles are expounded. A large subsection is devoted 
to AF4, the main technique applied in this thesis for assessing the degree of protein aggregation 
in liquid formulations and for approaching challenging tasks in pharmaceutical analytics. Besides 
the AF4 channel set-up, the individual separation steps involved in an AF4 experiment are 
outlined. Particularly with regard to applications presented in the Experimental Section, the basic 
modes of AF4 sample elution are described. In a concluding part, selected applications of AF4 
are highlighted, thus offering a general survey of the published literature - though pharmaceutical 
applications are accentuated.  
 
Chapter 3 attends to protein stability in pharmaceutical liquids. Introductorily, a 
description of the main chemical degradation pathways is presented – primarily hydrolysis and 
oxidation. The following section summarizes the wealth of information on protein aggregation 
available via a multiplicity of scientific articles. The aggregation phenomenon is elucidated in 
thermodynamical terms, thereby instancing caveats and misunderstandings which the matter 
inherently encounters. Consequently, the aggregation process per se is illustrated, dealing with 
issues such as molten globule states and fibre formation, for instance. Eminent emphasis is laid 
on reviewing prevalent aggregation theories extended in the literature. Contrarily to the dazzling 
array of theories being at the reader´s disposal, little to no insight is provided in many articles on 
how the individual theory is to be put into correlation with other theories available. Accordingly, 
colloidal aggregation models are discussed in comparison to lattice models or domain swapping. 
Additionally, the controversial issue of polar group burial and nonpolar group burial, respectively, 
in the course of their contribution to protein stability and native state maintenance is reasoned. 
Finally, analytical methods commonly utilized in quantification of protein aggregation are 
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itemized and evaluated in terms of applicability, accuracy and inherent drawbacks. Thereby, one 
point of concern is the differentiation between methods capable of soluble aggregate analytics 
and insoluble aggregate/precipitate characterization, respectively.  
 
Chapter 4 is a synopsis of multi-angle light scattering (MALS) in protein analytics. 
Initially, scope and underlying principle of both general light scattering techniques – i.e., dynamic 
and static mode - are defined. Given the background of its importance to analytical case studies 
outlined in chapters later on, the presentation of theoretical aspects of MALS is focused therein. 
The difference between isotropic scattering and anisotropic scattering and the employment of 
both scattering profiles in terms of absolute molar mass assessment and size determination are 
presented. Furthermore, the sensitivity of MALS concerning high-molecular weight or particulate 
specimen is explained. The chapter is completed with a list of exemplary MALS applications in 
combination with FFF and SE-HPLC, respectively. 
 
Throughout the Theoretical Section strong emphasis was put on aligning the presented 
topic with scientific references. In order not to inappropriately outrange the scope of the thesis, 
an extensive reference list is provided in Chapter 12, indexing relevant special and continuative 
literature. 
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6 AF4 as analytical tool in protein aggregation analytics 
 
6.1 Introduction 
 
Considered more a bibelot of a few supporters rather than an effective separation 
method, FFF for long time was ascribed only minor importance in the arsenal of powerful 
analytical separation methods, especially when compared to popular techniques inhering similar 
application ranges, e.g., (SE)-HPLC and electrophoresis. Contrarily to the variety of distributors 
of HPLC equipment, in the field of FFF the analytical scientist for many years was dependent on 
one commercial manufacturer (FFFractionation LLC, Salt Lake City, USA). In many laboratories 
the standard FFF apparatus accounting for the development of new applications in most cases 
was a provisional do-it-yourself construction. However, things were on the move, and at present 
the analytical scientist is facing three manufacturers of commercially available FFF systems 
(Consenxus GmbH, Ober-Hilbersheim, Germany; Postnova Analytics, Landsberg/Lech, 
Germany (merged with FFFractionation in 2001); Wyatt Technology Corp., Santa Barbara, USA).  
Driven by the firms´ impetus to increase the FFF technique´s recognition, several articles 
were published, focusing thereby on the broad applicability of AF4 particularly in protein 
analytics and attending to the assets of AF4 compared to SE-HPLC (Wyatt Technology, 2002; 
Hansen and Klein, 2001; Jiang et al., 2000). Unfortunately, as with many other publications in this 
field, parameters such as reproducibility, sample recovery, elution order, etc., were not discussed 
in detail.  
It is the aim of this chapter to comprehensively evaluate the general applicability of AF4 
in protein analytics. Furthermore, new applications with the potential to have a considerable stake 
in the future are presented, including the possibility to invert the AF4 elution order in normal 
mode separations. Additionally, AF4 data on various proteins are compared to SE-HPLC data. 
As the discussion of experimental results often refers to figures or tables, the data are discussed 
extensively where appropriate. The chapter is concluded by a summarizing discussion. 
 
6.2 Evaluation of general AF4 applicability in protein analytics 
 
6.2.1 Materials and methods 
 
All AF4 experiments presented in this thesis were performed with an HRFFF-10.000 
AF4 system, comprising separation channel, pumps accounting for injection flow, forward flow 
and cross flow, in-line solvent filter (0.1 µm, PTFE), degaser (PN75) and autoinjection system 
(PN5200) (all from Postnova Analytics, Germany) (Fig. 26). Except stated otherwise, the channel 
height was 350 µm, the flow rate at the channel outlet was 1.0 mL/min, the sample loop held 100 
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µL and the applied ultrafiltration membrane consisted of regenerated cellulose with a 5 kDa cut-
off (Postnova Analytics, Germany, and Nadir Filtration GmbH, Wiesbaden, Germany, resp.). 
The AF4 system was connected to a ternary detection system, combining MALS, UV-
spectrophotometry and RI detection. MALS was performed by a miniDAWN®TristarTM with a 
30 mW GaAs linearly polarized laser emitting 690 nm wavelength light and using three angles in 
order to detect scattered light (45°, 90°, 135°)(Wyatt Technology, USA). UV-spectrophotometry 
was performed at 280 nm wavelength (SpectraSystem UV 1000, Thermo Separation Products, 
Germany). Values of protein dn/dc were determined with a deflection type differential RI 
detector (∆n-1000, λ = 620 nm, WGE Dr. Bures, Dallgow, Germany). If not specified differently, 
the carrier medium consisted of 20 mM dibasic phosphate, pH 7.5.  
Comparative study AF4 versus SE-HPLC: SE-HPLC was performed applying two 
different columns (column I: TSKgel G3000SW, Tosoh Biosep GmbH, Stuttgart, Germany, 
column pressure during operation 24 bar; column II: superose 6 HR 10/30, Amersham 
Biosciences Europe GmbH, Freiburg, Germany, column pressure during operation 7 bar), 
sample loop 20 µL, flow rate 0.5 mL/min, in-line degassing was performed (SCM1000, Thermo 
Separation Products, Germany). Due to overlapping of experiment time column I was connected 
solely to UV280-spectrophotometry. AF4 parameters: channel height 500 µm; an initial 80% cross 
flow rate was maintained for 20 min, then linearly minimized to 0% within 3 min; system 
pressure during 80% cross flow was 4 bar, without cross flow 2 bar; sample loop 100 µL, forward 
flow rate 0.6 mL/min. Carrier liquid for SE-HPLC and AF4 were identical to BSA solution 
medium (refer to Section 6.5), BSA samples were not diluted prior to injection, all experiments 
were performed in triplicate (n=3). 
Prior to the AF4 fractionation steps, blue colored dextran was applied to monitor flow 
line ideality, contingent channel leakage, time-period of sample injection and focusing 
performance. As illustrated in Fig. 27, the intense color of the sample enables a convenient 
AF4 channel
autoinjection 
system
pump units
detection 
units
Fig. 26. AF4 system with channel, autoinjection system and detection units (UV, RI). Via pumps, 
the flow rates of forward flow, cross flow and sample injection flow are regulated. 
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control thereof. Subsequent to the focusing process, the elution step transports blue dextran in 
form of a colored band towards the channel outlet, visualizing the forward flow velocity. Blue 
dextran was shown to adsorb only moderately to capillary material, PMMA wall material and 
cellulosic membranes – thus, a consecutive short-time (<2 min) separation run with buffer liquid 
guarantees a total wash-out of the indicator analyte and provides immaculate channel surfaces.  
Vice versa, the permeability of the applied ultrafiltration membrane may be demonstrated 
by means of colored lmw components such as bromophenol blue (BMP). During focusing, the 
BMP will gradually pass the membrane pores. Sufficient focusing time provided, the BMP will 
eventually vanish in total. Referring to this, a typical range for the focusing/relaxation time 
encompasses 30 – 180 s, whereas a representative injection time is 60 s using a 50 µL injection 
Fig. 27. Monitoring of sample injection and subsequent focusing of blue dextran in an AF4 
channel; channel width 13 mm. a) Beginning injection via the sample injection port, blue 
dextran streaming towards the channel outlet. The forward flow inlet is placed at the end of 
the tapered channel, hidden by the brown fitting of the injection port. b) Initiation of sample 
focusing/relaxation. The densifying blue region in the middle of the picture indicates z`, used 
in Eq. (15). z` is assessed by the flow rate ratio of both focusing flows originating from 
channel inlet and channel outlet. c) Optimum of focusing/relaxation. The band representing 
blue dextran, extending over 80 mm prior to focusing, is narrowed to <1 mm. 
 
a 
b 
c 
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loop and a sample feed rate of 0.2 mL/min. The final fractionation step normally takes 10 – 30 
min, although high-speed separations lasting <5 min have been described (Reschiglian et al., 
2002). Often esteemed as linchpin of every successful AF4 experiment, the fractionation step 
simply leverages the accomplishments of the precedent focusing step, as far as the positioning of 
sample specimen in their steady-state equilibrium levels is concerned. In order to prove the 
quality of the channel configuration and the influence of different cross flow intensities on the 
analyte elution profile, the scrutinity via standard samples is well-established (Wahlund, 2000). 
 
6.2.2 Results 
 
The efficacy of an AF4 system can be investigated by monitoring the resolution of the 
different sample components, e.g., of accurately defined mixtures of polystyrene latex colloids or 
particles (Wright et al., 2001; Wahlund and Zattoni, 2002). Likewise, proteins represent ideal 
standard analytes, since the composition of each native monomer – concerning primary and 
secondary structure – is identical, thereby ensuring an unimodal size distribution. Based 
thereupon, the 440 kDa protein ferritin is often employed, as ferritin usually exhibits a 
constitution profile of monomers aside several oligomers (Wahlund, 2000). Equally, human or 
bovine serum albumin (HSA/BSA) may be used, due to its inherence of considerable amount of 
dimer (~10%) and higher-order oligomers/aggregates. Additionally, the amount of higher-order 
specimen can easily be increased by protein stressing, e.g., via 60 °C storage for 3 d of HSA lyo-
philisate, yielding accretions from 9.3% up to 29% for dimer and from 2.5% to 11.9% for trimer 
and higher-order specimen (Moreira et al., 1992). As illustrated in Fig. 28, HSA can favorably be 
employed to demonstrate the correlation between cross flow intensity and efficacy of resolution.  
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Fig. 28. Fractionation of HSA at different AF4 separation conditions. Note the correlation 
between increasing cross flow strength and prolonged elution time/resolution power. 
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When 0% cross flow is applied – i.e., no parameters provoke sample retainment – the 
HSA sepecimen are eluting concomitantly, unifying in one symmetric peak in subsequent UV280 
detection. Contrarily, when subjected to increasing cross flow intensities, the analytes elute more 
sluggishly and the peak symmetry changes towards a tailing profile. With 55% cross flow, sample 
elution is prolonged onward and analyte fractionation is performed, visualized by several UV280 
peaks. According to the theoretical principles of normal-mode separation, smaller analyte 
specimen elute prior to larger analytes – hence, it may be deduced, that the peaks derived from 
75% cross flow conditions represent HSA monomer, dimer and trimer, eluting within 15 min. 
Subsequently, higher-order oligmers may be detected.  
Fig. 28 gives rise to the question of both peak identification and the whereabouts of hmw 
aggregates. Referring to the first, the molecular weights of HSA specimen may be determined by 
PAGE; yet this involves the interpretation of data derived from different analytical techniques, 
facilitating potential data misinterpretation. On the other hand (knowledge on dn/dc values of 
the protein provided), each peak can be assigned the appropriate analyte molar mass via 
simultaneous MALS/UV-detection. Therefore, the HSA dn/dc value was determined off-line by 
RI analytics, applying concentrations in the range of 1-5 mg/mL. Via plotting (ni – n)/ci versus ci 
and extrapolating to zero concentration, dn/dc was determined to be 0.173 mL/g (with ni being 
the refractive index at concentration ci and n representing the refractive index of the carrier 
liquid). This value is in good agreement with formerly published data, where HSA dn/dc values 
were assessed 0.168 and 0.175 mL/g, respectively (Stuting and Krull, 1990). Accordingly, on-line 
molar mass determination of the fractionated specimen enables the unambiguous identification 
of analytes. 
The sensitivity of larger analytes on high cross flow rates potentiates immobilization of 
hmw aggregates upon the ultrafiltration membrane. Thus, performing the experiment with 75% 
cross flow conditions even for long periods – e.g., for 10 hrs – renders no hmw aggregate elution. 
As a consequence, sample retainment is to be decreased by reducing the cross flow after elution 
of separated oligomers, i.e., after 20 min. Subjected to this separation conditions, HSA can be 
separated in monomer, dimer, trimer, tetramer and higher-order oligomers within 20 min. 
Subsequently, by gradually minimizing the cross flow rate within short time, the resolution power 
of the system is decreased and a soluble (hmw) aggregate fraction can be detected (Fig. 29).  
Due to the possibility of flow programming, a broad repertoire of separation conditions 
is provided, comprising a broad molar mass application range (Fig. 29). The challenging aspect of 
AF4 flow programming is to maintain a delicate balance between optimal separation parameters 
– contributing to resolution power and low experiment times – and a “controlled system crash” – 
induced by irreversible sample immobilization on the membrane due to ultra-high cross flow 
rates. Optimizing a separation generally involves increasing the resolution of the analyte specimen 
and/or decreasing the analysis time. Unfortunately, in most prevalent analytical techniques – 
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including AF4 – resolution and analysis time are competing factors. As a consequence, the 
forward flow rate of the carrier can not be increased at random without sacrificing resolution. 
Therefore, a trade-off exists between resolution and analysis time (Schimpf, 2000c). 
Ultimately, flow rates are limited by either pump specifications or the resulting rise of 
channel pressure. Low elution rates, e.g., <0.4 mL/min, imply the risk of peak broadening due to 
a growing impact of the well-known Eddy diffusion phenomenon (Giddings, 1960). 
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Fig. 29. Fractogram of HSA characterization applying 0% and 75% cross flow intensities, 
respectively. Minimizing the 75% cross-flow to 0% after 20 min enables elution of hmw 
aggregates, revealing molar masses of >106 Da. MALS enables convenient UV data 
interpretation, assigning calculated masses to the peaks of monomer (66.9 kDa), dimer (133.8 
kDa) and trimer (204 kDa), matching the theoretical values. Note that the UV signal of 0% 
cross flow analysis unifies all HSA specimen, running the gamut from monomer to hmw 
aggregates. Due to the merger of scattered light from both hmw aggregate and lower-order 
specimen, the calculated mass maximum does not exceed 106 Da.  
Fig. 30. Separation of HSA, applying 75% (left) and 85% cross flow rates (right). Although 
AF4 separation theory correlates intense cross flow rates with increased resolution, the dimer 
at 85% cross flow conditions is separated less efficacious from adjacent monomer and trimer 
than at less stringent conditions. This is mainly to be ascribed to sample-membrane 
interactions. 
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Furthermore, field strengths are finite due to the potential interaction of sample 
components with the ultrafiltration membrane as they are forced into more concentrated zones 
upon the membrane. Thus, increased cross flow rates do not necessarily lead to a gain in 
resolution power. In fact, if cross flow intensities exceed a definite threshold, this detracts from 
resolution, although sample retainment is prolonged (Fig. 30). 
Besides resolution power, the amount of sample – either minimally required or maximally 
acceptable - amenable to AF4 separation appraises the applicability of AF4 in protein analytics. 
In general, a sample size of 1-50 µg is appropriate for most materials, whereas lower values are 
considered to be more favorable when the detection system inheres sufficient sensitivity (Moon 
and Myers, 2000). It is known that long-chain molecules are subject to considerable entanglement 
even at low mass concentration levels – thus making retention time and elution profiles 
dependent on concentration (Caldwell et al., 1988). On the other hand, anionic polymers were 
shown to reveal a tendency for high-loaded samples (30 µg) to elute earlier than small sample 
loads (5 µg) (Benincasa and Giddings, 1992). Consequently, the relationship protein load – 
elution profile was evaluated by analyzing 5 µg and 500 µg HSA, respectively (Fig. 31).  
  
 
As outlined above, the influence of sample load on elution time is discussed 
controversially. The findings in Fig. 31 are consistent with earlier work (Giddings et al., 1978c). 
Generally, because AF4 separation passes off in a very thin region with high sample 
concentration near the ultrafiltration membrane, the protein molecules may interact, what affects 
the diffusion coefficients, increases the viscosity and thus is regarded to prolong retention time 
(Benincasa and Giddings, 1992). 
On the other hand, repulsion/interaction between analyte molecules can increase the area 
required for optimal separation – as a consequence, the equilibrium of distribution may be 
displaced towards higher, and therefore faster, flow laminae (Moon and Myers, 2000). Moreover, 
1,E+04
1,E+05
1,E+06
1,E+07
0 10 20 30
time (min)
m
ol
ar
 m
as
s 
(g
/m
ol
)
0,00
0,01
0,02
0,03
0,04
U
V signal (V)
1,E+04
1,E+05
1,E+06
1,E+07
0 10 20 30
time (min)
m
ol
ar
 m
as
s 
(g
/m
ol
)
0,00
0,25
0,50
0,75
1,00
U
V signal (V
)
Fig. 31. Characterization of HSA samples with 5 µg load (left) and 500 µg load (right). In both 
experiments MALS assigned the monomer 67 kDa (1), the dimer 134 kDa (2) and the trimer 204 
kDa (3). Concerning elution time, HSA specimen elute slightly differently: the 5 µg load trimer 
fraction finishes detector passage at 13.9 min, compared to 14.8 min of the 500 µg sample. 
Experiment conditions: 0.6 mL/min forward flow, 75% cross-flow (0-15 min, then linearly 
lowered to 0% at 22 min); UV-detector sensitivity dimmed by factor 2.5 in right figure.  
(1) 
(3) (1) (2) 
(2) (3) 
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the value of diffusion coefficients is deduced from infinite dilution, and as the fractionation of 
highly-loaded samples is involved with a more pronounced vertical concentration gradient, this 
additionally contributes to a more elevated steady-state position of the samples. Despite the 
variety of all theoretical scenarios, it is to be noted, that the elution profile of samples with 
concentrations varying by two orders of magnitude is in effect congruent, substantiated by the 
experimental data (Fig. 31).  
As outlined in Table 1, the detected mass distribution among monomers, dimers and 
aggregates of high- and low-loaded samples vary, but can be assessed in reproducible way.  
Thereby, high-loaded sample analysis is associated with inherent greater ratios of higher-
order specimen, especially hmw aggregates. Since both samples were drawn from HSA stock 
solutions with concentrations of 50 µg/mL and 5000 µg/mL, respectively, this discrepancy 
appears reasonable: the general dependence of the aggregation rate on protein concentration has 
been repeatedly reported (Wang, 1999). 
 
mass distribution (%) 5 µg sample load 500 µg sample load 
monomer 74.2 70.1 
dimer 15.6 16.5 
≥trimer 8.6 10.3 
hmw aggregates 1.6 3.1 
 
 
In summarizing the results, the applicability of AF4 in protein characterization appears 
feasible. Protein sample specimen can be separated with sufficient resolution in reproducible way. 
Furthermore, the coupling of AF4 with MALS, UV- and RI-detection facilitates both data 
interpretation and evaluation.  
 
 
 
 
 
Table 1. Mass distribution among HSA specimen in terms of 100-fold difference in sample load 
(n=5, Srel for all data <2.3). 
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6.3 Parameters of fractionation 
 
6.3.1 Sample recovery 
 
The practicability of any separation method depends ultimately on its capability for the 
conversion of analyte specimen into separated fractions. In this regard, the evaluation of sample 
component recovery – i.e., the system´s ability to fractionate complex samples without a 
significant loss of content – is of utmost importance in order not to run the risk of a concomitant 
loss of information.  
Principally, the term “absolute recovery” is to be differentiated from “relative” or “linear 
recovery”. The first is defined as the mass percentage of an injected sample that is recovered 
from the separation system (Williams and Giddings, 2000). In contrast, relative/linear recovery 
attends to the recovery of a sample component in amounts being proportional to – but not 
necessarily equal to – their levels in the original sample. It is obvious that without detection 
systems granting access to mass calculations – e.g., MALS – the absolute sample recovery can not 
be determined. 
In case of AF4, sample loss may be the result of sample transport through the 
ultrafiltration membrane or of adsorption to the membrane (Beckett et al., 1988). As both 
phenomena are enhanced by direct contact and/or interaction of sample components with the 
ultrafiltration membrane, intensity and duration of cross flow and focusing step have a crucial 
impact on sample recovery. However, optimum conditions provided, the pursuit of absolute 
recovery values of almost 100% is not illusive (Fig. 32).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32. Elution profiles of an immunoglobulin sample with >99.9% native monomer content in 
the original bulk solution. The color of the solid UV280 lines and the MALS signals (dots) refer to 
cross flow intensities of 0% (red), 10% (blue), 20% (green), 30% (black) and 40% (grey). Ratio of 
AUC280 40% / AUC280 0% = 0.996; membrane cut-off 1 kDa; focus step was abandoned. 
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As demonstrated in Fig. 32, increasing cross flow rates do not mandatorily imply lower 
recovery rates due to adsorption processes and/or sample passage through the ultrafiltration 
membrane. The investigated 150 kDa immunoglobulin was shown to reveal a >99.9% native 
monomer content, demonstrated by RP-HPCL, SE-HPLC and circular dichroism analysis 
(Abbott, 2000). The impact of the exerted cross flow rates is reflected by prolonged elution times 
and peak broadening. MALS proves the immunoglobulin to exhibit unimodal mass distribution, 
regardless of the cross flow intensity applied. Because of the combination of concentration 
sensitive UV detection and molar mass sensitive MALS detection, sample recovery can be 
specified in terms of mass values. It is important to note that the AF4 system utilized was well-
conditioned and potential adsorption effects were overcome due to constant operation: when 
analyzing polymers, the total adsorption of sample components on fresh membranes repeatedly 
was reported (Benincasa and Giddings, 1992). Though, subsequent experiments will yield 
increasing recovery rates, as the channel surface areas prone to adsorption are small and 
conditioning can be provided with minimal protein quantities, typically ~10 µg (Coelfen and 
Antonietti, 2000; Towns and Regnier, 1991). The influence of the injected sample mass on 
absolute recovery rate is demonstrated in Table 2. 
 
cross-flow intensity 0% 10% 20% 30% 40% 
10 µg sample load 99.7 99.4 98.9 98.3 97.5 
50 µg sample load 99.9 99.7 99.4 99.1 98.7 
100 µg sample load 99.9 99.7 99.5 99.2 98.9 
As outlined, lower sample recoveries correlate to decreasing sample loads and intensified 
cross flow rates. Due to the relatively high molar mass of the immunoglobulin and the 
commensurate sensitivity on field strength, even moderate separation conditions entail notable 
retainment. Increasing the resolution power further on gives rise to complete sample 
immobilization upon the membrane. E.g., exerting 80% cross flow for 2 hrs yields recoveries of 
less than 10%. Referring to this, sample loss due to high field strengths was often reported as 
empirical fact (Jiang, 1994; Ratanathanawongs and Giddings, 1992; Li et al., 1990).  
Besides adsorption, membrane parameters such as material and permeability influence 
sample recovery. In this realm, the affinity of proteins for membrane adsorption can often be 
attenuated by well-advised choice of carrier liquid, e.g., in terms of pH and both salt and 
surfactant content (Barman and Moon, 2000).  
Contrarily, sample loss through the membrane can only be depleted by membrane cut-off 
specifications and not by so-called soft parameters such as carrier liquid composition. For 
Table 2. Influence of sample load of a 147 kDa immunoglobulin on absolute recovery rate; 
membrane cut-off 1 kDa; n = 5, Srel for all data <0.89; experiment time 15 min, focusing step was 
abandoned. 
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instance, a 15% loss of cytochrome C (13 kDa) or a 4% loss of BSA have been reported for 
cellulose membranes with 5 kDa cut-off, whereas 15% of a γ-globulin sample (160 kDa) passed a 
100 kDa cut-off membrane (Williams and Giddings, 2000; Li et al., 1991). Based on that, the 
recoveries of a 147 kDa immunoglobulin versus membrane cut-off values were investigated 
(Table 3).  
 
cross-flow intensity 0% 10% 20% 30% 40% 
1 kDa cut-off 99.8 99.6 99.3 99.0 98.6 
5 kDa cut-off 99.8 99.6 99.4 98.9 98.5 
10 kDa cut-off 99.8 99.5 99.3 98.7 98.3 
 
 
 
Referring to Table 3, only slight differences of the recovered sample masses can be 
detected. Subjected to low cross flow rates (≤20%), the immunoglobulin is recovered always with 
identical rates, regardless of the applied membrane. However, increasing the field strength results 
in greater sample loss, which is maximal in case of 10 kDa cut-off membranes and in effect 
identical for membranes with 1 kDa and 5 kDa cut-off, respectively. The data appear reasonable, 
as the protein accumulation upon the membrane increases with greater flow rates – accordingly, 
the membrane with the greatest permeability reveals the most pronounced sample loss. 
Whereas the impact of cross flow intensities on sample recovery already has been 
reported, no extensive study was performed investigating the influence of the focusing step 
thereon. Bearing in mind that during focusing the analyte specimen are concentrated within a 
narrow band with close contact to the membrane – as both opposing focus flows meet at the 
focusing point z´ and mainly pass the membrane there – this appears remarkable. Furthermore, 
since both focusing length and intensity are attributed decisive influence on the quality of the 
subsequent separation, AF4 operators may tend to elongate the focusing step (Coelfen and 
Antonietti, 2000). 
The theoretical membrane cut-off expresses a situation, where 90% of an analyte with a 
molecular weight identical to the cut-off value are retained by the membrane (Poeppelmeyer, 
2002). Though, both effective membrane cut-off and membrane adsorption were characterized 
to be governed by analyte size, shape, surface charge and the solution conditions (Balakrishnan et 
al., 1993). Accordingly, proteins may differ in their recovery rates. 
In order to approach that problem, identical mass amounts of several proteins were 
injected into the channel and subjected to various focusing periods. Since the influence of focus 
strength per se was attended, the subsequent elution step was performed without cross flow. As 
illustrated in Fig. 33, focusing notably affects protein recovery, whereby the lion´s share of 
Table 3. Influence of regenerated cellulose membrane cut-off on absolute recovery of a 147 kDa 
immunoglobulin, n = 5, Srel for all data <0.95, experiment time 15 min, focusing step was 
abandoned. 
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protein loss is recorded during the initial stages of focusing (0-100 s). BSA (66.4 kDa), 
erythropoietin (EPO, 38 kDa) and γ-immunoglobulin (IgG, 147 kDa) are shown to yield the 
highest recovery rates. Given the background that those globular proteins are empirically 
characterized as very hydrophilic proteins, this appears rational. E.g., the adsorption of EPO on 
membranes made of regenerated cellulose was shown to be very low (Opatrny et al., 1998). 
Moreover, in contrast to granulocyte colony stimulating factor (G-CSF), EPO is a glycoprotein 
with an average carbohydrate content of ~40%, thus revealing increased hydrophilicity (Narhi et 
al., 1991). In case of the less hydrophilic G-CSF (19.6 kDA), the increased sample loss may be 
ascribed to protein passage through the membrane, as the molar mass of G-CSF exceeds the 
membrane cut-off only 4-fold. However, facing a ~40% sample loss of interferon α-2a – IFN-2a, 
revealing a 19.4 kDa molar mass – after 300 s focusing, at least in terms of IFN α-2a adsorption 
appears to contribute more to sample loss than potential membrane permeation phenomena.  
These experimental data is circumstantiated by former studies, showing interferon to 
adsorb readily not only to hydrophobic and hydrophilic surfaces but also to hydrophobic 
nanoparticles or proteins and other macromolecules (Nagaki et al., 2003; Lecomte et al., 2002; 
Ruzgas et al., 1992). Additionally, it is known that proteins of the IFN α-subtype generally inhere 
a flexible nature (Alkan and Braun, 1986). This (conformational) flexibility may facilitate – 
besides unfolding and aggregation – adsorption tendencies of IFN α-2a.  
It is to be summarized that for all investigated proteins – except IFN α-2a – a 100 s 
focusing step results in acceptable recovery rates of ~90%. However, in order to gain an increase 
in IFN α-2a recovery, the optimization of carrier liquid – e.g., by solvent effects - seems 
inevitable. The importance of solvent effects in protein analytics becomes evident, as proteins 
can be switched form positively to negatively charged polyelectrolytes by pH variation. Generally, 
the carrier pH should be chosen outside the range of the isoelectric point (IEP) to avoid 
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Fig. 33. Recovery rates of proteins depending on focusing time: BSA (66.4 kDa), granulocyte 
colony stimulating factor (G-CSF, 19.4 kDa), erythropoietin (EPO, 38 kDa), γ-immunoglobulin 
(IgG1, 147 kDa), interferon α-2a (IFN-2a, 19.4 kDa); AF4 parameters: focusing flow 0.8 
mL/min, 15 min elution without cross flow, membrane cut-off 5 kDa , detection via 
MALS/UV280, sample load 25 µg each, n= 5, Srel for IFN-2a data >1.7, for all other data <0.83. 
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adsorption problems (Coelfen and Antonietti, 2000). Given a carrier pH of 7.4 and IEP values of 
the five proteins of 4.0-5.5, adsorption due to inadequate pH may not be an issue. 
On the other hand, the use of nonionic surfactants in order to eclipse protein adsorption 
phenoma is state-of-the-art (Wang et al., 1995). In HPLC, nonionic surfactants are known to 
hydrophobically adsorb onto column surfaces to create a hydrophilic layer that will exclude 
proteins from the surface (Desilets et al., 1991). In this realm, Tween 20 was used in the 
fractionation of wheat proteins by Flow-FFF (Stevenson and Preston, 1997). Morever, Tween 20 
was demonstrated to displace adsorbed interferon specimen completely from both hydrophilic 
and hydrophobic surfaces (Ruzgas et al., 2003). As a consequence, in order to reduce IFN α-2a 
adsorption upon the ultrafiltration membrane, 0.01% (w/w) Tween 20 was added (Fig. 34). 
The addition of Tween 20 definitely increased the recovery of BSA, G-CSF and IFN α-
2a. Compared to the humble gain in BSA and G-CSF recovery (~6%), the influence of Tween 20 
on IFN α-2a recovery is notably. Whereas the impact of Tween 20 at conditions without focusing 
stays scarce (~3%), Tween 20 gives the IFN α-2a recovery a significant edge when the protein is 
subjected to 200 s focusing. Carrying the cross flow duration to the extremes (300 s), the 
recovery gain adds to ~30%, demonstrating the importance of proper carrier choice in AF4 
protein analytics. One explanation of the data may be that nonionic surfactants adsorb to both 
charged and neutral surfaces (Barman and Moon, 2000). Thus, when Tween 20 molecules adsorb 
on both protein and membrane surfaces and extend into the aqueous phase, they generate a steric 
barrier, inhibiting the close approach of protein molecules and membrane. It was shown via FT-
IR assessments that Tween 20 binding does not induce any structural change upon binding to 
proteins. Moreover, the hypothesis for the inhibition of protein aggregation being due to steric 
effects caused by Tween binding on hydrophobic sites on protein surfaces was repeatedly 
published (Bam et al., 1998). 
Fig. 34. Recovery rates of proteins depending on focusing time/carrier composition: BSA, G-
CSF, IFNα-2a (carrier containing 0.01% Tween20), IFNα-2a (carrier without Tween20); AF4 
parameters: focusing flow 0.8 mL/min, 15 min elution without cross flow, membrane cut-off 5 
kDa, detection via MALS/UV280, sample load 25 µg each, n= 5, Srel for IFN data >1.7, for all 
other data <1.02. 
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It is to be outlined that the presented data do not justify to ennoble the addition of 
surfactants to carrier liquids as general procedure. E.g., minimal concentrations of surfactant 
(<0.001M SDS) were proven to cause protein precipitation during FFF separations (Stevenson 
and Preston, 1997). In order to retain the biological activity of the separated protein analytes, 
aqueous solutions based on phosphate buffered saline (PBS), Tris buffer or acetate buffer with 
ionic strengths in the range of 10-200 mM are typically used. For a detailed list of aqueous carrier 
liquids utilized in FFF analytics, it is referred to the literature (Li and Hansen, 2000).  
 
6.3.2 Elution order 
 
It seems likely that the IFN α-2a protein-membrane interplay initiated by the focusing 
step described in the previous chapter will influence the elution profile of the protein towards 
increased retainment. “Retention” in FFF refers to the fact that a zone of analyte is retained by 
its confinement to flow laminae revealing velocities lower than the average velocity of all flow 
laminae present in the channel (Schure et al., 2000). Thereby, the elution profile – i.e., analyte 
transport coefficients and analyte retention time - can be related to physicochemical parameters 
of the analytes. E.g., provided that parameters such as t0, Vc, V0 and w are known (refer to 
Section 2.3.2), via determination of the retention time tR the assessment of diffusion coefficients 
and hydrodynamic diameters is rendered possible (Eq. 16/17). Moreover, diffusion coefficients 
can directly be related to molar masses (M). Thus, in case of idealized spherical sample 
components – such as globular proteins –, a plot of log tR versus log M was calculated to produce 
a straight line with a slope of 0.33 (Li and Hansen, 2000). Referring to this, a linear relationship 
between log tR and log  protein M was published, substantiating this theoretical assumption (Liu 
et al., 1993). Consequently, that relationship may be applied as calibration curve to calculate the 
molecular weight of proteins, similarly to procedures in SE-HPLC technique (Harris, 1992).  
However, this matter is based on the assumption that a monodisperse sample – such as a 
monomeric protein – reveals only one single set of transport coefficients, and therefore inheres 
only one characteristic retention time. Yet the elution profile of a monodisperse sample is not a 
delta function but rather Gaussian-shaped, spread over a range of retention times. Thereby, the 
dispersion in that profile is due to the slight diversity of each individual sample molecule 
concerning its position in axial flow laminae. Thus, there is a random variation in the velocities of 
the molecules around the average value, resulting in axial dimensioned zone spreading (Schimpf, 
2000c). In the literature this phenomenon is referred to as random dispersion, column dispersion 
or band broadening (Weber and Carr, 1989).  
Besides interaction with the cross flow – via the instrument diffusion coefficient -, the 
analytes´ retention times may decisively be influenced by sample-membrane interactions, as 
illustrated in Fig. 35. By subjecting IFN α-2a to 300 s focusing and a 80% cross flow, the protein 
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is immobilized upon the membrane, as no UV280 signal can be seized for 30 min elution with 
PBS. On the contrary, monomeric G-CSF – exhibiting similar molecular weight and diffusion 
coefficient – would elute at identical separation conditions within 6 min (data not shown). As 
outlined before, the addition of 0.01% Tween 20 dramatically decreases IFN α-2a adsorption 
intensity upon the membrane. Utilizing a carrier liquid enriched by Tween 20, in case of 70% 
cross flow IFN α-2a leaves the channel sluggishly, thereby inducing a broad, low-rising UV280 
signal. It may be concluded that the IFN α-2a diffusion coefficient now exceeds the opposing 
parameters of cross flow and cohesive adsorption, thus unslaving the protein from 
immobilization. Minimizing the cross flow intensity rapidly from 70% to zero after 16 min 
experiment time enables an unimpeded protein elution of IFN α-2a, visualized by a sharp raise of 
the UV280 signal, pretending a symmetrical analyte peak. However, this UV signal unifies the 
complete set of protein specimen still present in the channel – monomers, dimers, oligomers and 
hmw aggregates. 
As shown in Fig. 35, sample-membrane interactions – i.e., cohesive forces of membrane 
adsorption – can influence analytes´ retention time. Although Tween 20 notably reduced the 
affinity of IFN α-2a to cellulose membrane material, adsorption was not annihilated totally, 
reflected by data from G-CSF separations. Furthermore, IFN α-2a experiments inhered low 
reproducibility. Referring to this, it is known that the evidence of adsorption typically comes in 
the form of irregularly shaped peaks and irreproducible elution profiles (Schure et al., 2000).  
In order to eclipse IFN α-2a membrane adsorption onward, it was found in the literature 
that the amount of sample load may be harmlessly enlarged when the ionic strength of the carrier 
is concomitantly increased (Moon and Myers, 2000). This statement is substantiated by early 
observations revealing that the enhancement of channel overloading by the introduction of 
charge into analyte polymers may be most distinct at low ionic strengths (Giddings et al., 1978c). 
Additionally, in case of water-soluble polymers the double-layer thickness – commonly referred 
to as Debye length – decreases at high ionic strengths (Benincasa and Giddings, 1992). Hence, by 
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Fig. 35. Elution profile of IFN α-2a dependent on AF4 separation parameters; sample load 50 µg, 
forward flow 0.6 mL/min, UV280 detection, PBS carrier, constant 80% cross flow and complete 
sample immobilization (left). PBS carrier plus 0.01% Tween 20, 70% cross flow, at t = 16 min 
minimized to 0% value. Retained elution is superseded by unrestricted protein wash-out (right). 
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lessening the effective volume of a polymer molecule its diffusion coefficient increases – a factor 
generally considered to oppose the extent of adsorption. Finally, the potential energy of 
interaction between the channel surface and polydispersed colloidal analytes and thus adsorption 
was successfully minimized by changing the ionic strength of the FFF carrier solution 
(Karaiskakis et al., 2002).  
The information clearly amounts to the utilization of a carrier with high ionic strength in 
order to approach reduced IFN α-2a membrane adsorption. Popular ionic strengths of carriers in 
both FFF and SE-HPLC technique range between 10-4 and 10-3 mM salt concentration. Facing 
notable IFN α-2a adsorption despite the presence of Tween 20, the NaCl concentration of the 
carrier was decided to be 20 mM NaCl.  
Applying the revised carrier formidably ameliorates the IFN α-2a characterization via 
AF4/MALS (Fig. 36). Besides an enhanced recovery (>90%), the benefit of increased experiment 
reproducibility and peak symmetry are to be recorded. 
Interestingly, the increased ionic strength appears to unveil one characteristic feature of 
IFN α-2a: at cross flow rates beyond 30% the protein still inheres significant adsorption 
tendency, resulting in sample retainment and recovery loss. On the other hand, when subjected 
to field strengths below 30% IFN α-2a complies with the theoretical principles of FFF separation 
– i.e., IFN α-2a elution profiles resemble those of the equally-sized G-CSF. The high diffusion 
coefficient of IFN α-2a exceeds the retainment of 30% cross flow conditions, and the protein 
elutes apace. 
However, this bivalent feature of IFN α-2a when being subjected to the cusp of the 30% cross 
flow threshold may prompt the AF4 operator to press home a significant advance: may both the 
characteristics of IFN α-2a and AF4 separation conditions facilitate the fractionation of proteins  
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Fig. 36. Separation of IFN α-2a; the initial 65% cross floss was programmed to decrease linearly 
to 0% within 13 min, passing the 30% threshold after 7 min. MALS determined a 20.2 kDa molar 
mass of IFN α-2a. Due to the carrier composition (0.01% Tween 20, 20 mM NaCl), protein-
membrane interactions were eclipsed and IFN α-2a eluted within a 3 min interval. 
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with identical size? Up to now, no such successful FFF separation is described, reflecting the 
complicacy of such a task. 
The topic is examined by analyzing a sample containing IFN α-2a and a protein with 
similar diffusion coefficient such as G-CSF. Considering the proteins´ minimal 200 Da difference 
in molar mass, the relationship M ~ 1/D guarantees both G-CSF and IFN α-2a D values to be 
similarly ~12*10-7 cm²/s20°C,w (Saltzman et al., 1994).  
Initially, the proteins´ principal alikeness in M and D values was verified by SE-HPLC, as 
separation in SE-HPLC is solely driven by discrepancies in analyte size. Optimal conditions 
ensured, G-CSF (19.6 kDa) should elute only marginally prior to IFN α-2a (19.4 kDa), if at all. As 
illustrated in Fig. 37, the proteins reveal similar retention times, indicating comparable D values. 
 
The successful separation of G-CSF and IFN α-2a by means of AF4/MALS is depicted 
in Fig. 38. Since G-CSF exhibits no membrane adsorption tendency, it´s retainment is merely 
directed by the cross flow, which is linearly decreased within 13 min from 70% to 0%. Since G-
CSF experiences higher cross flow rates, the protein reveals a broader UV280 peak, compared to 
IFN α-2a. As the cross flow intensity passes the 30% threshold, IFN α-2a becomes exonerated 
from cohesive membrane adsorption and elutes readily within 2.5 min. Data interpretation was 
supported by MALS, assigning G-CSF a 21.8 kDa molar mass and IFN α-2a 20.2 kDa, 
respectively. 
To carry the matter to the extremes, it can be investigated whether sample-membrane 
interactions may have an impact on AF4 elution order in normal mode separations. I.e., the 
cohesive and retaining forces of IFN α-2a adsorption may be deemed that effectual to invert the 
elution order imposed by the FFF theory. Thus, the underlying principles may apparently be 
infringed. However, this experiment approach is not heretical, as the standard FFF theory, 
developed for point masses at infinite dilution, in principle rules out a priori any effect on 
Fig. 37. SE-HPLC separation of G-CSF and IFN α-2a, with G-CSF 
eluting first. The low resolution reflects the similar hydrodynamic 
diameters of both proteins, indicating even D values. Experiment 
parameters: TSKgel G3000SWXL column (Tosoh Biosep GmbH, 
Stuttgart, Germany); detection via UV280, mobile phase PBS pH 7.4, 
flow 0.5 mL/min. 
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retention behavior due to the amount of sample load or sample-wall and sample-sample 
interactions (Benincasa and Giddings, 1992). 
Referring to this, the fractogram of EPO (38 kDa) and IFN α-2a is shown in Fig. 39. 
 
As long as the cross flow intensities exceed 30%, IFN α-2a is forced towards the 
ultrafiltration membrane and becomes in effect immobilized. Contrarily, EPO – assigned 42.6 
kDa molecular weight by MALS – elutes earlier, obviously revealing no adsorption tendency. The 
data is consistent with the findings of investigations on EPO recovery rate, proving EPO to 
reveal hydrophilicity comparable to that of albumin and γ-immunoglobulins (refer to Fig. 33). 
Hitherto, inversions of analytes´ elution order were only monitored when the FFF 
conditions changed from normal mode to steric mode (Giddings, 1993). E.g., κ-carrageenan was 
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Fig. 38. AF4 separation of G-CSF and IFN α-2a. Injected protein load 50 µg each, experiment 
conditions identical as described in Fig. 36. Due to IFN α-2a adsorption phenomena, which 
increases the protein´s effective diffusion coefficient, both proteins are fractionated base-line, 
although inhering similar molar masses and diffusion coefficients. 
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Fig. 39. Inversion of theretical FFF normal mode elution order. Fractionation of EPO (38 kDa) 
and IFN α-2a. Injected protein load 25 µg each, experiment conditions identical as described in 
Fig. 36. Although EPO doubles the molar mass of IFN α-2a, it elutes prior. 
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shown to alter the elution profile of lmw specimen from normal mode to steric/hyperlayer mode 
after severe aggregation (Wittgren et al., 1998).  
Facing an increasing share of analyte specimen with low hydrophilicity – e.g., protein 
complexes and lipoproteins – the problem of sample-membran interactions will likely be on the 
rise in future pharmaceutical AF4 analytics (Li and Hansen, 2000). Yet, by proper choice of 
carrier liquid and taking advantage of analyte features which are at first glance obstructing, even 
challenging protein separation tasks may be successfully approached.  
 
6.4 Fractionation of protein specimen 
 
6.4.1 Monomers, oligomers, soluble aggregates 
 
The acid test for any separation technique is providing greatest resolution within shortest 
time, thereby avoiding the generation of artifacts. Due to its equipment with field strength 
programming, FFF inheres the capability to considerably meet this standard. E.g., a six 
component latex mixture, ranging from 20 to 426 nm in size, was fractionated in normal mode 
Flow-FFF within 10 min (Botana et al., 1995). In terms of protein analytics, the size distribution 
of wheat proteins was investigated by separation of monomeric and polymeric specimen via 
Flow-FFF/MALS (Southan and MacRitchie, 1999).  
Even multi-protein analysis was approached by AF4, managing the separation of four 
proteins within 20 min. Thereby, the scope of molar masses covered the range from 29 kDa 
(carbonic anhydrase) up to 669 kDa (thyroglobulin) (Moon and Hwang, 2001). However, the 
separation of samples containing two or more different proteins inheres one major pitfall: as 
proteins tend to take a variegated shape – comprising fragmented and oligomeric as well as 
unfolded forms – there may arise difficulties in assigning one single peak one separated 
component exclusively. E.g., G-CSF dimer (~39 kDa) may unify with the detection signal of 
EPO (38 kDa), as both specimen reveal identical molar masses, thus exacerbating correct data 
interpretation. The matter is exemplified by the fractionation of albumin solution containing a 
147 kDa immunoglobulin (Fig. 40).  
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Fig. 40. Separation of HSA solution containing 
immunoglubulin. Due to the ~10% difference in 
molar mass between HSA dimer (133 kDa) and 
the antibody (147 kDa), a base-line separation is 
impeded, despite high-resolution conditions 
(75% cross flow). Thus, the overlap of UV280
signals hampers data interpretation.  
HSA 
monomer 
HSA 
dimer 
IgG 
Chapter 6. AF4 as analytical tool in protein aggregation analytics 
 72
In order to demonstrate AF4 applicability in monitoring protein stability, G-CSF was 
exposed to short-time temperature stress (1 mg/mL in PBS pH 7.4, 1.0 mL in 1-mL poly-
propylene tubes, tubes were heated in borings of a 60 °C metal block and subsequently stored in 
0 °C ice-water). Heat-induced aggregation of G-CSF was monitored via AF4/MALS (Table 4): 
 
storage time (min) 0 2 4 6 8 10 
monomer (%) 90.2 90.1 85.5 82.7 63.8 41.5 
≥dimer 2.8 2.9 7.4 9.5 13.0 25.8 
aggregates (%) 7.0 7.0 7.1 7.8 23.2 32.7 
 
 
 
 
As outlined in Table 4, subjecting the protein solution to heat induces notable 
aggregation, especially after ≥6 min storage, where the samples revealed a very slight turbidity. 
Besides, AF4 proves to be capable of detecting even a minor degree of protein instability, as 
demonstrated by a marginal increase of aggregate content in the primary stage of the stress test. 
To avert the simultaneous elution of G-CSF monomer and contigently generated fragment 
specimen, the AF4 separation was started with initial high field-strengths (80%). Thus, protein 
monomer elution was delayed for ~5 min (Fig. 41).  
Because of higher diffusion coefficients – compared to the monomers - protein 
fragments are expected to elute prior to intact G-CSF. Though, no fragments were detected, 
giving rise to the question whether fragments may have avoided detection by passing the 
ultrafiltration membrane, which revealed a 5 kDa cut-off. Since absolute recovery rates of all 
samples remained equal, fragment loss due to potential membrane passage could be excluded. 
Besides, the major denaturation pathway of proteins exposed to elevated temperatures is 
considered to be aggregation rather than fragmentation (Cleland et al., 1993).  
As illustrated in Fig. 41a, a 80% cross flow rate was maintained for 10 min and then 
linearly lowered to 0% (t= 17 min). Due to that, G-CSF monomers and dimers could be seized as 
separated fractions. Additionally, an individual fraction of aggregates eluted when no cross flow 
was effective (Fig. 41b). According to the data, the unstressed G-CSF solution exhibits only little 
dimer and no multimers, but a considerable amount of hmw aggregates. This is consistent with 
results published in the course of an analytical case study of G-CSF/Neupogen®, where also no 
fragments and no intermediate multimers have been observed, but only monomers and a notable 
aggregate fraction (Herman et al., 1996).  
However, eposure to harsh thermal stress induces the formation of multimers – though 
outnumbered by the generation of a large fraction of soluble hmw aggregates. As illustrated in 
Table 4. Monitoring of temperature-induced aggregation of G-CSF via AF4/UV280 (storage at 60 
°C , conc. 1 mg/mL), n=3, Srel for aggregate data <1.25, for all other data <0.7. % monomer 
relates the monomer AUC280 to the AUC280 of total protein; the term “aggregates” denotes protein 
hmw aggregates which are yielded as distinct fraction applying 0% cross flow. 
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Fig. 41, the tool of cross flow programming contributes substantially to the efficacious 
performance of AF4 in the fractionation of protein specimen. Thus, membrane 
adsorption/immobilization of larger aggregates can be circumvented.  
Compared to SE-HPLC, adsorption phenomena in FFF may generally act a minor part, 
considering FFF channel surface areas of usually 30 cm² and SE-HPLC package material surface 
areas of ≥30,000 cm² (Klein and Huerzeler, 1999). However, the cross flow induced analyte-
membrane contact may somewhat annihilate this AF4 feature. In both techniques, the application 
of carrier liquids containing surfactants such as SDS or Tweens in order to reduce potential 
adsorption phenomena is popular (Barth et al., 1994).  
As long as the concentration of carrier surfactants is assessed below their critical micelle 
concentration (CMC), this procedure can be deemed lege artis. On the other hand, surfactant 
concentrations beyond the CMC incolves problems, since proteins will not enter the micelles, but 
may anyway be enriched in the micelle phase (Sivars et al., 1996). Consequently, protein specimen 
can avoid detection. According to the literature, the CMC of Tweens in water at room 
temperature is ~11 mM (Hillgren et al., 2002). Other investigations determined CMC weight 
percentage values of 0.006 for Tween 20 and 0.01 Tween 80 (Hoepfner et al, 2002).  
In contrast to SE-HPLC, the use of surfactants in concentrations >CMC is delicate, and 
concurrently the pro´s of field programming turn into con´s: micelles derived from 
polyoxyethylene-based surfactants like Tweens increase their size with concentration, 
temperature and decreased polyoxyethylene chain length, but their size distributions stay rather 
Fig. 41. Monitoring G-CSF instability due to storage at elevated temperature (60 °C) via 
AF4/UV280. Minimizing the 80% cross flow linearly to 0% at t = 17 min enables to seize an 
individual fraction of aggregates (a). To scrutinize a potential impact of concentration, AF4 
sample loads were varied (25 µg in (a), 50 µg each in (b) and (c), respectively). 
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narrow and constant at fixed conditions (Joensson et al., 1998). I.e., Tween micelles have to be 
considered as sample components in AF4 experiments, as the micelles are sensitive for cross 
flow. Thus, the micelle concentration in flow laminae in immediate proximity to the membrane 
will exceed the micelle concentration of more elevated laminae. Anyhow, as long as flow 
intensities remain unchanged, the micelle concentration of carrier leaving the channel and passing 
the detector cells will stay constant. Contrarily, a rapid decrease of the cross flow strength will 
force micelles hitherto accumulating at the membrane surface to elute, thereby inducing 
considerable detector response (Fig. 42). 
Phenomena related to this context – where these surfactants were referred to as “stealth 
analytes” - have been reported before (Fraunhofer, 2002b). It is important to note, that stealth 
analytes are not to be subsumed to the experimental artifact of “ghost peaks” – here, a part of the 
sample analyte does not reach its steady-state concentration distribution and is thus transported 
with different velocity in the flow field, which can occur when high flow rates are exerted 
(Granger et al., 1986).  
If solely the injected samples contain amounts of surfactants beyond the CMC, these 
phenomena are usually not observed, as the sample is diluted with carrier liquid during the 
injection/focusing process. However, micelles derived from samples with ultra-high 
concentrations of Tween 20 may ride out this dilution process, especially if the carrier liquid 
contains surfactants, too. Surfactants such as Tweens are traditionally used for protein extraction 
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from lipophilic matrices or from apoprotein/lipoprotein complexes (Ikai, 1980). For instance, 
0.9% Tween 20 was used to extract G-CSF from lipid implants based on tristearin matrices. 
Accordingly, sample analysis via AF4/UV220 revealed two peaks, due to the presence of G-CSF 
protein and micelles of Tween 20 (Fig. 43). 
 
6.4.2 High-molecular weight aggregates / precipitates  
 
The absence of package material within the AF4 separation channel enables the 
characterization of insoluble analytes aside soluble specimen. Hence, AF4 may be predestined to 
the analysis of protein formulations containing soluble, insoluble or precipitated hmw aggregates. 
The general potential of AF4 for the separation of hmw aggregates and protein precipitates was 
demonstrated before (Litzén et al., 1993). Referring to this, wheat flour protein was characterized 
by means of Flow-FFF subsequent to various extraction methods only recently, where it was 
shown that the detected amount of polymeric and hmw protein depended on the extraction 
method used (Ueno et al., 2002).  
In order to enable the FFF provision of protein sample solutions with predefined 
composition, G-CSF protein was heat-stressed until precipitation occurred (50 °C, 30 min, conc. 
1 mg/mL in PBS pH 7.4). The precipiates were isolated via centrifugation (2500 rounds/min, 5 
min, rotation radius 13 cm) and resuspended in PBS pH 7.4 via vortexing (120 rounds/min, 1 
min, rotation radius 2 cm). A definite suspension volume was added to unstressed G-CSF 
solution and subjected to AF4 analysis (Fig. 44). 
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Fig. 44. Fractionation of G-CSF solution containing visible protein precipitates. Due to their size, 
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Because of their size, precipitated specimen are fractionated in accordance with the 
principles of the steric mode, thus eluting earlier than G-CSF monomers. The known absence of 
fragments enables the elution of the monomer fraction immediately afterwards, what is 
performed via moderate initial cross flow rates (50%). Thus, the individual separation of the 
protein specimen is rendered possible within relatively short time (10 min). 
Whereas the assessment of molar masses for monomer (20 kDa) and hmw aggregates is 
trustworthy, MALS analysis of precipitated protein may be deemed unaccurate: the protein 
concentration is determined via UV280-spectrophotometry, i.e., photodiodes gauge the difference 
of radiated and detected intensity of a monochromatic light beam – the difference is per 
definitionem ascribed to absorbing amino acids of the protein. However, when insoluble 
precipitates pass the detector cell, obscuration phenomena may account for a potential difference 
rather than absorption, thus pretending higher concentrations of protein than essentially present. 
Given the background of both MALS theory and MW calculation via Zimm plot (Eq. 
26/27), with the amount of scattered light R(θ) ~ c * MW, the consequence becomes evident: the 
calculated mass of analytes will be too low, in case of incorrect high concentration values 
assessed. As visualized in Fig. 44, the precipitates´ MW is determined to be approximately 106 
Da, well below the MW of soluble/insoluble hmw aggregates separated in normal mode. 
Though, the applicability of AF4 to separate even insoluble hmw aggregate specimen and 
precipitates is substantiated. In order to comprehensively evaluate AF4 efficiency and reliability, 
the results are to be compared to data derived by techniques established in particulate matter 
analytics due to protein instability. In this realm, the utilization of light obscuration is state-of-
the-art. Additionally, the assessment of protein aggregation may be performed via Coulter 
technique. E.g., Coulter counters were repeatedly used in stability monitoring of pharmaceutical 
immunoglobulin solutions (Mueck, 2002; Antonsen et al., 1994).  
 
Consequently, light obscuration, Coulter technique and AF4 were employed in stability 
monitoring of two pharmaceutical immunoglobulines (SVSS-C40, PAMAS GmbH, Rutesheim, 
Germany; MultisizerTM3, Beckman Coulter GmbH, Krefeld, Germany). Antibody solutions were 
subjected to elevated temperatures in order to induce protein aggregation (5 mL solution in 10R 
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glass vials, 2.5 mg/mL in PBS pH 6.8, solutions were heated in metal block borings and cooled in 
ice water). As illustrated in Fig. 45, the instability of afelimomab (40 °C storage, immunoglobulin 
fragment, ~100 kDa) is reflected by a notable rise in particulate matter contamination. Both 
methods assess the generation of particles ≥4.1 µm to commence not later than ~90 min 
experiment time. 
Simultaneously, the afelimomab solution was characterized by AF4. As outlined in Fig 46, 
data correlation of AF4 and light obscuration technique excels. Similarly to light obscuration, 
AF4 assessed a remarkable increase of hmw aggregates at t=90 min. “% aggregates” denotes 
hmw aggregates which are yielded as individual fraction in AF4 separation when the cross flow is 
reduced to 0%. 
 
The correlation of AF4 and established particle counting techniques concerning the 
characterization of hmw aggregates and precipitates was circumstantiated by data derived from 
adalimumab experiments (immunoglobulin subclass G1, 147 kDa). Experiment design was 
identical to that of afelimomab, except for the storage temperature (60°C). 
As outlined in Fig. 47, both particle counting techniques mark the onset of protein 
aggregation - reflected by a notable increase in particulate matter contamination - unambiguously 
at identical time. These results – backed by AF4 data shown in Fig. 48 – are consistent with the 
findings of afelimomab investigations.  
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Basically, the time at which an increase in particulate matter contamination due to protein 
aggregation can first be assessed does not depend on the specification of the detection limit of 
particle counters. It was demonstrated in a comprehensive study that the commencement of 
protein aggregation – if monitored by light obscuration and Coulter counter – is to be assessed at 
identical time, regardless if the minimal detection limit is 0.7 µm or 10 µm (Mueck, 2002). Thus, 
the formation of insoluble protein aggregates was hypothesized to occur commensurately at 
various dimension levels, provided that the aggregation process proceeded beyond the cusp of 
insoluble – though subvisible – aggregate formation. Bearing in mind the capability of AF4 to 
quantify both soluble and insoluble aggregates, the data above is absolutely consistent with this 
theory. Otherwise, AF4 were to detect the formation of hmw aggregates at more primary stages 
of the aggregation process than light obscuration and Coulter counter, respectively. A caveat not 
to generally ascribe techniques like AF4 or SE-HPLC an inherent superiority in protein instability 
monitoring is to be noted. Due to the variety of aggregation pathways at hand, each protein may 
form aggregates in unique ways, thereby skipping the formation of hmw aggregates or totally 
eliding the genesis of multimers, as shown in the following chapter.  
 
6.5 Characterization of protein solutions by AF4 and SE-HPLC: a comparative study 
 
Even the most sophisticated techniques in protein analytics remain unconvincing and 
smack of inefficacy as long as they are not compared to general accepted state-of-the-art 
methods. Referring to quantification of protein aggregation, SE-HPLC certainly represents the 
gold standard in both industry and science.  
Up to now, only two relevant comparative studies between FFF techniques and SE-
HPLC have been performed. However, one study addressed the characterization of polystyrene 
standards in organic solvents by means of Th-FFF and was mainly aimed at compiling the 
particular theoretical principles of each method (Gunderson and Giddings, 1986). The other 
study correlated the results of both AF4 and SE-HPLC in terms of antibody analytics – solutions 
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of several immunoglobulins were stressed via rapid pH change and characterized subsequently. It 
was found that AF4 can give higher selectivity and greater resolution which is maintained over a 
wider molecular weight range than in SE-HPLC. Unfortunately, antibody samples were prepared 
individually for AF4 and SE-HPLC analysis, thus hampering accurate data correlation. 
Furthermore, different elution media for both techniques were chosen, and the study lacks 
recovery rate data (Litzén et al., 1993). Though, this study revealed the principal feasibility of AF4 
in analysis of unprepared samples, allocating AF4 a greater application range and maybe more 
informational power. 
Referring to the latter, this has to be affirmed, as demonstrated in the following case 
study of Neupogen® (a formulation of G-CSF protein). It was known to the formulation 
scientists that Neupogen® characteristically inheres a very small amount of hmw aggregate 
(<0.2%), while dimers solely occasionally can be detected. The hmw fraction was assigned a 
molecular weight of ~ 500 kDa by laser light scattering (Herman et al., 1996). The question, 
whether the hmw fraction is to be considered a native, stable component or if it is potentially 
prone to further accretion was of crucial interest. According to SE-HPLC data, the hmw fraction 
indeed constitutes a stable component, as no intermediate multimers have been observed 
between dimers and larger aggregates. It was hypothesized that those multimers are either bond 
irreversibly to the SE-HPLC column or that they are dissociated to monomer by the harsh 
conditions, thus avoiding detection. 
 
Whereas the first speculation may be verified by monitoring of recovery and be 
approached by eluting the column with buffer medium containing SDS, eluate sampling and 
subsequent analysis via PAGE, the second assumption is Gordian. As illustrated in Fig. 49, the 
findings of Herman et al. are corroborated. Despite the G-CSF formulation was proved to have 
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undergone aggregation subsequent to 50 °C storage for 20 min – indicated by a notable increase 
in subvisible particulate matter – no multimers and only a sparse quantity of aggregates can be 
detected via SE-HPLC, substantiating the suspect of agglomerate/aggregate shear degradation. 
On the other hand, the detection of oligomers and a large hmw fraction is amenable via 
AF4, assessing the content of hmw aggregates to be ~33%, compared to ~3% SE-HPLC data. 
Due to the absence of both sample preparation by centrifugation and shear effects in the AF4 
channel, hmw aggregates can be seized. Equally to the light scattering results of Herman, a 
consistent fraction of hmw aggregates with ~550 kDa molar mass was analyzed; and this fraction 
appears to represent the low-limit barrier of the hmw aggregate fraction, which extends to over 
107 Da. 
It may be concluded that the primary driving forces of (thermally induced) G-CSF 
aggregation are mainly due to noncovalent hydrophobic interaction rather than decreased 
conformational and translational parameters because of the following arguments: (a) hmw 
aggregates are susceptible to abrasion and shear degradation, as outlined by SE-HPLC and AF4; 
therefore, aggregation is to be deemed a parameter of quaternary protein structure, which is 
consequently to be related with hydrophobic self-association (Kunitani et al., 1997). (b) lower-
order specimen like multimers are also prone to shear degradation, thus thus objecting covalent 
oligomerization; (c) deamidation phenomena, a main factor facilitating subsequent covalent-based 
aggregation, have only been observed in G-CSF samples stored for extended periods at elevated 
temperatures, not during short-term stress; (d) G-CSF characteristically inheres a minimal 
amount of hmw aggregates (<0.2%, Herman et al., 1996). This meta-stable hmw aggregate cluster 
with ~550 kDa molecular weight can be observed in SE-HPLC, but mainly in AF4 analytics and 
is relatively sensitive to shear degradation. It may be assumed therefore, that once the protein 
aggregates have transcended this clustered state, a potential process of (physical) regression is 
contained at this definite cluster-state level. As a consequence, as soon as established, this G-CSF 
cluster may be reflected by a permanent difference in native monomer content assessed via 
abrasive techniques such as SE-HPLC and moderate methods like AF4. The difference is to be 
ascribed to abraded G-CSF cluster – what repeatedly was circumstantiated (Fig. 50).  
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Thus, the delicate balance between native and aggregated state is interfered by a stable 
denatured form of quaternary structure, which is supportive of further destabilizing hydrophobic 
interaction rather than by the aggregation pathway of covalent dimerization – oligomerization – 
hmw aggregates. Even at extreme conditions, the dimer ratios of G-CSF solutions were 
comparable to the ratio of moderately stressed solutions. (refer to Fig. 41). This corroborates 
latest findings, which elucidate the dimeric G-CSF not to participate in the irreversible 
aggregation process (Sampathkumar, 2002). 
Though, formulation scientists investigate heterogeneity, structural integrity and stability 
of protein drugs routinely. Hence, for evaluation of the benefits of analytical techniques they turn 
their attention to parameters such as efficiency, recovery rates, resolution power, and 
reproducibility. In order to compare AF4 and SE-HPLC characteristics in this realm, three 
protein model formulations were analyzed with both methods in the course of a benchmark 
study. 
(Formulation parameters: a BSA stock solution was formulated by dissolving BSA in 
solution medium (conc. 10 mg/mL, BSA A-3059, lot 108H0881, Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany; solution medium was throughout 20 mM PBS, pH 6.8, containing 27 
mM K2SO4). The stock solution was further diluted with solution medium to yield three 
formulations with concentrations of 0.125, 0.25 and 0.5 mg/mL, approximately, and subjected to 
sterile filtration (Minisart®, 0.2 µm, cellulose acetate, Sartorius GmbH, Goettingen, Germany). 2R 
glass vials were filled with 1.0 ml solution, plugged with teflon-coated bromobutyl closures, 
crimped, and stored for 12 hrs at 5 °C prior to analysis.  
Chromatograms which are representative for the SE-HPLC separations of BSA are 
illustrated in Fig. 51. 
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Fig. 51. SE-HPLC analysis of BSA, applying different columns. BSA formulation, conc. 0.25 
mg/mL, separation with column I (left), separation with column II (right). Though a sufficient 
separation of BSA monomer and dimer is performed, the resolution power of column I 
exceeds that of column II slightly. Facing noisy MALS signals, molar mass calculation revealed 
values of ~68 kDa for BSA monomer and ~136 kDa for dimer and did generally not exceed 
103 kDa. 
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Basically, the performance of the columns was identical, as both manage the fractionation 
of monomers and dimers with sufficient resolution. The base-line separation of dimers and 
higher-order oligmers was not possible, even if the flow rates were reduced to 0.3 mL/min. A 
comparison with corresponding AF4 data (Fig. 52) makes the consequences of the fundamental 
differences between both methods evident. According to the theoretical prinicples, AF4 is 
assigned a higher peak capacity and a greater selectivity (Jiang et al., 2000). Referring to 
theoretical AF4 selectivity values of 0.5-0.7 – versus 0.2 for SE-HPLC –, AF4 is considered to 
provide a much higher resolution, especially for samples with molar masses >100 kDa (Coelfen 
and Antonietti, 2000). Whereas SE-HPLC failed to resolve higher-order oligomers, AF4 rendered 
the fractionation of trimers and even tetramers possible, thereby guaranteeing high selectivity. 
E.g., the determination of the tetramers´ molar mass via MALS assessed a value of ~268 kDa, 
exhibiting an <1% aberration from the theoretical value. Thus, the BSA components accounting 
for the tetramer UV280 peak have to be almost exclusively tetramer specimen, reflecting the 
pronounced AF4 resolution power in concern of hmw analytes. 
Both separation methods exhibit similar experiment time – though, in contrast to SE-
HPLC, the 100 s-focusing step adds to the time required for the AF4 separation process per se. 
On the other hand, both methods differ considerably in characterizing hmw aggregate fractions. 
By means of AF4, an indiviual fraction of hmw specimen can be separated, spanning a molar 
mass range from 500 kDa to over 104 kDa, thus indicating the presence of agglomerated 
components. Contrarily, the BSA analysis via column II lacks the detection of protein larger than 
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Fig. 52. AF4 fractionation of a BSA formulation, conc. 0.25 mg/mL. Exertion of 80% cross flow 
renders the separation of oligomer specimen possible, reflected by distinct UV280 peaks. Additionally 
to monomer (1), dimer (2), trimer (3) and tetramer (4) as well as higher-order oligomers (≥5) can be 
separated. Ultra-hmw aggregates (a) elute >23 min, when no cross flow is applied. Due to the high 
sensitivity of MALS on hmw analytes, molar masses can be calculated up to values of >107 Da 
reliably, even if the analogical UV-signal reveals low concentrations (<0.1µg/mL). 
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103 kDa. Although the analysis with column I was not combined with MALS detection, a likewise 
situation is to be assumed: according to the column specifications, column I reveals a denser 
packing of the silica based packing material than column II – what is reflected by a ~16 bar 
difference in bed pressure during operation. Thus, BSA samples separated via column I may be 
exposed to even harsher conditions than exerted via column II. However, in both columns the 
hmw components are subjected to potential abrasion due to shear forces. Given the background 
that the BSA samples were not prepared – e.g., by filtration or centrifugation -, shear forces 
represent the only parameter accounting for the differences in aggregates´ molecular weight, 
depending on the separation technique applied.  
As far as data of sample consistency is concerned, both columns yielded similar results, 
though varying substantially from AF4 data (Table 5). 
 
separation method % monomer % dimer % ≥trimer % recovery 
column I 77.30.07 16.40.08 6.40.07 - 
column II 77.00.05 16.50.08 6.50.08 97.82.07 
AF4 69.30.65 16.50.76 16.20.57 88.53.65 
Commensurate with the illustration via fractograms, the main difference in SE-HPLC and 
AF4 appears to be in quantification of hmw analytes. The aggregate values detected by AF4 – 
wherein trimers and higher-order protein specimen are to be subsumed – exceed the 
corresponding SE-HPLC data by nearly 10%. Due to column package, the protein (hmw-) 
aggregates undergo abrasion, thereby contributing to the yields of monomer and dimer. It is 
known that BSA is prone to the formation of non-covalent bonded aggregates, which may 
further interact hydrophobically and generate higher-order agglomerates (Zhu and 
Schwendeman, 1998; Nishimura and Goto, 1997). Thus - backed by the data of G-CSF analytics 
(Fig. 49) – the results can be explained reasonably.  
Compared to SE-HPLC, the absolute recovery rates of AF4 are notably lower (~9%). 
This may be due to two parameters: the first addresses the void peak. Whereas considerable 
analyte losses due to pronounced void peak phenomena were reported, this study proved a 100 s 
focusing step to be sufficient to minimize AUCUV280 void peak values to <0.5% of AUCtotal 
(Schimpf et al., 2000c). Generally, protein eluting in the void peak is not to be added on the mass 
of separated protein, if separation is based on normal mode. Additionally, the exerted high cross 
flow facilitates a close contact of BSA and membrane material –  and immobilization of sample 
Table 5. Characterization of BSA formulation, conc. 0.5 mg/mL, via AF4 and SE-HPLC (two 
different columns); % content values indicate ratio of total detected AUCUV280; the numbers in 
subcript refer to standard deviation values; % recovery refers to absolute recovery values. As 
column I was not combined with MALS detection, protein mass values could not be calculated, 
thus lacking recovery data. 
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material because of adhesive membrane effects may be the outcome. Facing no notable 
differences of standard deviation values of the individual fractions of monomer, dimer and 
higher-order specimen, a proneness of aggregates to particularly interact with the cellulose 
membrane can be excluded. Anyway, the low sample recoveries in AF4 analytics are reflected by 
higher standard deviation values, compared to SE-HPLC data. Referring to the SE-HPLC 
recovery being also notably below the optimum value, the ambitious effort to pit the determined 
recovery rates against the absolute recovery has to be outlined: protein masses, determined via 
UV280/MALS analytics are related to the protein mass that is theoretically injected into the 
separation system, i.e., the theoretical volume of a sample loop assesses the maximum value. 
However, as inherent apparatus parameters as injection system or sample loop fidelity/specificity 
should be included into the evaluation of a technique designated for routine analysis, the absolute 
recovery rate was set the maximum standard. (To comprehesively attend that matter: relative 
recovery rates may be determined via conducting the sample loop content direct into the 
detection units, thus bypassing the separating units such as column or channel. In this case, for 
both SE-HPLC and AF4 recovery rates of >99.8% were assessed.) 
The results are circumstantiated by the analysis data of 0.25 mg/mL formulation and 
0.125 mg/mL, respectively (Tables 6 and 7). 
 
separation method % monomer % dimer % ≥trimer % recovery 
column I 79.00.05 16.10.11 4.90.08 - 
column II 78.90.09 16.20.07 4.90.12 97.03.76 
AF4 69.30.83 16.50.81 16.20.75 88.36.78 
 
separation method % monomer % dimer % ≥trimer % recovery 
column I 81.20.09 14.90.10 3.90.05 - 
column II 81.10.07 14.90.06 4.00.08 97.11.87 
AF4 72.10.57 14.50.85 13.40.64 88.25.27 
It is to be noted that in both SE-HPLC and AF4 analytics the relative monomer contents 
of the samples increase with decreasing protein concentrations of the formulations. 
Consequently, the conclusion may be derived that the protein has undergone aggregation during 
Table 6. Characterization of BSA formulation, conc. 0.25 mg/mL, via AF4 and SE-HPLC (two 
different columns); captions and procedure are identical to Table 5. 
Table 7. Characterization of BSA formulation, conc. 0.125 mg/mL, via AF4 and SE-HPLC (two 
different columns); captions and procedure are identical to Table 5. 
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~12 hrs storage prior to analysis. Furthermore, the dependence of protein concentration on 
aggregation impetus is prevalent opinion (Wang, 1999). 
As neither SE-HPLC – though revealing higher recovery rates – nor AF4 - exhibiting 
notably greater resolution – emerges from this comparative study unambigiuously victorious, it is 
to be summarized that AF4 has the potential to be more than a promising alternative to SE-
HPLC in the characterization of protein solutions.  
Especially for laboratories which analyze a broad range of biopolymers on a routine basis, 
it is important to hold a technique that can be tuned to maximize the efficiency of each particular 
analysis. Whereas in AF4 the field strength is variable, in HPLC the column has to be changed. 
Although several SE-HPLC columns can be purchased for the price of one single FFF channel, 
the columns are to be replaced periodically as a result of degradation of the packing material.  
In order to amplify the scope of SE-HPLC application to a range as broad as five orders 
of magnitude in weight and maintain accuracy, that, however, requires the connection of several 
columns in series, which significantly increases both run time and operating pressure, thereby 
facilitating artifacts (Coelfen and Antonietti, 2000).   
Addressing the realm of an overall assessment, the possibility of AF4 to characterize 
unprepared samples gives AF4 a significant edge. E.g., for the purpose of quality control in 
pharmaceutical manufacturing this AF4 feature permits the native sample to be analyzed, without 
ignorantly removing the information sought (Litzén et al., 1993). In combination with sensitive 
techniques such as MALS even trace amounts of insoluble analytes can be quantified. 
 
6.6 Summary 
 
In this chapter, the general applicability of asymmetrical flow field-flow fractionation (AF4) in 
protein characterization was comprehensively evaluated. Furthermore, the impact of proper 
conduction of operational procedures such as focusing on subsequent fractionation efficiency has 
been demonstrated. 
The unique AF4 feature to universally modulate the resolution power between two 
individual runs or even during one run was exemplified by the analysis of HSA: a progression of 
cross-flow intensity was directly correlated with a gain in resolution. Optimal system parameters 
provided, the fractionation of HSA into protein specimen such as monomer, dimer, trimer and 
tetramer can be considered state-of-the-art and was thereby implemented as control-parameter in 
the course of routine system check-ups during this study. Moreover, AF4 was proved to reveal 
reliable data when confronted with the task to analyze samples with varying concentrations – 
spanning a range of more than two orders of magnitude. Due to this robustness AF4 in this 
realm may be deemed superior to other analytical methods such as HPLC, where the risk of 
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potential column overloading effects demands the injection of appropriate sample amounts 
(Barth et al., 1994).  
In general, parameters of fractionation like sample recovery and elution order was payed 
major attention. Hitherto, the exerted cross flow intensity was considered to account for the 
lion´s share of contingent sample loss during an AF4 experiment because of protein adsorption 
phenomena upon the ultrafiltration membrane (Schimpf et al., 2000). However, it was 
demonstrated via analysis of several proteins with different hydrophilicity that focusing rather 
than the subsequent fractionation step may contribute considerably to sample loss. Additionally, 
the influence of adequate choice of membrane material and carrier liquid was exemplified by 
analysis of interferon (IFN α-2a), where the addition of surfactants to the carrier liquid was 
shown to notably enhance the recovery rates. Referring to this, potential pitfalls such as the 
detection of “stealth” effects as the basis of surfactant micell elution were elucidated. 
Sample-membrane interactions, prevalently deemed to negatively influence AF4 
efficiency, were thorougly investigated. Adjustment of carrier additives, e.g., salts or surfactants, 
enabled not only to overcome this problem but were implemented to successfully approach 
analytical problems considered up to now impractical. Given the background that size differences 
of proteins – which account for differences in diffusion coefficients – are the driving force of an 
effective AF4 separation, it was shown that the retaining impact of membrane adhesion is to be 
deemed to practically add to size differences. As a consequence, proteins differing merely ~1% in 
molecular weight – e.g., G-CSF and IFN α-2a – could be fractionated. 
In this concern, the possibility to invert the elution order in normal mode conditions was 
demonstrated. As the underlying normal mode theory categorically postulates the elution of 
smaller samples prior to larger samples, the accomplishment to elute 40 kDa analytes prior to 20 
kDa analytes is to be considered new. 
The possibility to subject nonprepared samples to AF4 analysis is a prerequisite for the 
quantification of high molecular weight aggregates, which is dealt with in a feasibility study. 
Because the channel lacks package material, hmw aggregates, which inhere a major sensitivity on 
abrasive shear forces, can be separated as individual fraction. Besides, (sub-)visible particulate 
matter such as protein precipitates is amenable to quantification. Due to this non-destructive 
character AF4 was proven to provide information on protein instability and to elucidate protein 
aggregation pathways. For instance, by means of AF4 G-CSF dimer was satisfactorily shown to 
be not involved in thermally induced irreversible aggregation, thus circumstantiating latest 
research in this field (Krishnan et al., 2002).  
Chapter 6 is concluded with a comparative study of AF4 and SE-HPLC in routine 
analysis of protein solutions. Whereas SE-HPLC revealed higher recovery rates, AF4 substantially 
exhibited greater resolution, hence permitting a deeper insight into the effective situation. Data 
reproducibility was similar between both techniques, at high levels. Though, the combination 
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with advanced detection systems like multi-angle light scattering revealed SE-HPLC to induce 
artifacts in terms of hmw aggregate quantification. Hence, AF4 turned out to be more than a 
promising alternative to SE-HPLC in the routine analysis of protein pharmaceuticals. 
This work provides a valuable code of practice for even advanced AF4 operators and 
demonstrates the usefulness of AF4 in protein analytics. Certain separation problems were 
successfully solved for the first time. 
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7 Analytics of pharmaceutical antibody solutions in siliconized syringes 
 
7.1 Introduction 
 
Traditional non-invasive delivery systems – administering drugs mainly via the oral route 
– are prevalently considered to be impractical for protein drugs. Enzymatic cleavage by 
proteolytic enzymes and denaturation due to HCl secretion by parietal cells would irreversibly 
damage the protein after drug release in the stomach or intestine (Patton, 1997). Hence, proteins 
are usually applied parenterally by injection. Although injections are a relatively recent form of 
therapy, the first recorded attempt to inject medication intentionally was in 1665 by Sir C. Wren. 
Unfortunately, the crude nature of the apparatus and the absence of pure, sterile drugs caused the 
practice to fall into disrepute. Later on, the work of Pasteur and Lister pointed out the need for 
the development of aseptic techniques – and things came into move rapidly: Simousin developed 
the first ampoule in the 1890s, and the “Luer-Syringe” was invented in 1896 by H. Walfing Luer, 
presenting a major step towards the disposable syringes used today. In 1923 it was demonstrated 
that the pyrogenic inducing bodies came from the water used to prepare the solutions, and care 
in using a pyrogen-free water eliminated the fever problem. This lead to the official acceptance of 
injectable solutions by the American Formulary in 1926, which is the true beginning of universal 
parenteral therapy (Frampton and Dean, 2000).  
Today, disposable prefilled syringes for the parenteral application of drugs enjoy a great 
popularity among both patients and physicians, as they combine the function of a primary 
container with that of a conventional syringe, thus inhering several advantages: they enable the 
immediate administration of a gauged accurate dose from one item and offer reduced risks of 
errors in medication and contamination. Moreover, prefilled syringes can be used everywhere and 
provide easy handling, hence making patient´s drug self-application possible, e.g., with insulin in 
diabetes care or heparines in thrombosis prophylaxis (Kock et al., 1995). Additionally, such 
syringes provide convenient multi-dosing, enabling for instance the dispensing of epoetin-α at 
definite intervals to coincide with peritoneal dialysis (Naughton et al., 2003). In the course of an 
independent market research, physicians and nurses exhibited a 85% preference for prefilled 
syringes over vials/ampoules (Becton-Dickinson, 1998). 
Prefilled syringes comprise several main components. The barrel consists primarily of 
glass or a sterilizable grade of polypropylene and the administration end is fitted with a standard 
medical luer tip or a needle. A plunger rod enables to move the piston up and down the barrel. In 
order to guarantee leak-proof syringes, a seal is made via circumferential ribs assembled on the 
plunger rod, which exert radial interference and thus affect the seal (Frampton and Dean, 2000).  
In general, the special features of syringes are conferred by siliconization. Hereby, thin 
films of silicone oil – i.e., trimethylsiloxy endcapped polydimethylsiloxane, PDMS – are spread 
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from diluted aqueous silicone oil emulsions on the inner barrel surface and successively heat 
treated above 300 °C for ~30 min. As a consequence, lubricant films are generated which render 
a smooth gliding of the piston down the barrel possible. Furthermore, siliconization is required 
to reduce the adsorption of hydrophilic drug compounds via deactivation of glass walls and to 
increase the hydrolytic stability of the glass surface (Mundry, 1999).  
However – as many pros often imply some cons -, even after heat curing besides an 
immobilized bound component a soluble silicone oil fraction is present. This soluble silicone oil 
is amenable to detachment, may permeate into the syringe volume and thereby result in (sub)-
visible particulate matter via coalescence processes - thus potentially contravening regulatory 
standards. Dramatic increases in particle contamination of disposable siliconized syringes due to 
silicone oil detachment and potential interactions of drugs with silicone oil syringe coatings have 
repeatedly been reported (Jeandidier et al., 2002; Sendo et al.; 1995; Kobo, 1990; Bernstein, 
1987).  
Given that background, this chapter attends to an analytical case study of siliconized 
prefilled syringes. The solution of a pharmaceutical immunoglobulin (adalimumab, 147 kDa, 50 
mg/mL) was formulated into siliconized disposable syringes. Subsequent to filling, the syringe 
production lots conformed to particulate matter regulations, i.e., the syringes were free of visible 
particulate matter and plainly met the subvisible particle limitations of maximal 6000 particles 
≥10 µm/mL and maximal 600 particles ≥25 µm/mL (U.S. Pharmacopeia XXIII). During 5 °C 
storage the syringes sporadically developed visible particulates which can be characterized as 
whitish-gray fluff/droplets, revealing dimensions of 50-500 µm. Morever, transparent, spheroidal, 
diminutive vesicles adhered to the barrel inner surface. 
The question of the particulate matter origin was of crucial importance – and two main 
possibilities were considered. First, the particles may be attributed to denatured and aggregated 
protein drug, indicating insufficient protein stability. On the other hand, silicone oil may have 
detached off the barrel surface, this leading to particle formation due to coalescence. Bearing in 
mind the way of siliconization the syringes were subjected to, the latter hypothesis appeared 
rather causative: the syringe needles were fixed to the barrels (BD HypakTM 1 mL) with a thermo-
labile glue, thus ruling out heat curing subsequent to barrel treatment with silicone oil emulsions. 
Instead, siliconization was performed by a so-called strip-off procedure, whereby a definite 
volume of silicone oil emulsion is atomized via nozzles into the syringe barrel and peeled off after 
a definite time interval. It is generally accepted that silicone oil films maintain a considerable level 
of mobility when heat curing is avoided (Mundry, 1999). Thus, the migration of a mobile silicone 
oil fraction into the aqueous syringe volume may be facilitated and the detached fractions may 
merge to (sub-)visible particulate matter and clouding phenomena.  
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7.2 Analysis of syringe volumes by light obscuration 
 
The assessment of particulate matter intensity in parenterals via light obscuration is state-
of-the-art (Boom et al., 2000; Barber et al., 1992). Furthermore, subjective notions of human 
visible inspections can be transformed into objective values (Borchert et al., 1986). Hence, 
syringe volumes of the production lot revealing occasionally visible particulate matter are 
analyzed via light obscuration (SVSS-C40, PAMAS GmbH, Rutesheim, Germany). More 
importantly, the mobility of silicone films on the surface of syringe barrels can be demonstrated 
by emptying the syringes in two different ways. A gentle – though alternative - manner to provide 
syringe volumes for light obscuration analysis is to remove the plunger backwards and draining 
the syringe content via the barrel aperture. The negative pressure arising thereby within the 
syringe is counterbalanced by air streaming through the needle into the container. Thus, artifacts 
associated with the movement of the piston down the barrel – commonly referred to as stiction – 
can be avoided (Capes et al., 1996). On the other hand, the traditional way of emptying 
siliconized syringes through a needle or LuerTM via piston movement involves (intense) reaming 
of the plunger exterior along the siliconized barrel surface. As a consequence, the silicone film 
can be abraded and be brushed along the barrel in a bow wave manner ahead of the plunger. 
Finally, droplets of abraded silicone oil may elute through the needle and may analytically be 
seized as particulate matter, visualized in Fig. 53 in case of siliconized syringe placebos. 
Due to the generation of silicone oil droplets, the particle content of normally drained 
syringes exceeds the particle content of alternatively drained syringes by factor 4. Since the 
syringe containers and the filling process of placebo syringes were identically to the filling of 
adalimumab verum syringes – i.e., SCFTM filling: sterile, clean, ready to fill -, light obscuration data 
of verum were expected to corroborate the results of placebos. As illustrated in Fig. 54, the way 
of syringe draining also in case of verum had a decisive impact on the assessed degree of 
particulate matter contamination: draining the protein solution via the needle route led to a ~6-
fold increase in particle content compared to draining via the opened barrel aperture. Hence, it 
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Fig. 53. Light obscuration data of four 
siliconized placebo syringe volumes, 
dependent on the way of syringe draining: 
removing the plunger backwards and 
draining the syringe content through the 
barrel aperture (alt.) vs. normal draining 
through the needle via plunger motion 
(normal), leading to partial abrasion of the 
silicone film and particulate matter (n=3, 
Srel for all data <7.4). 
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may be concluded that the layer of silicone oil on the syringe barrels is not irreversibly fixed, but 
exhibits a notable mobility: mechanical stress of plunger motion is sufficient to compel silicone 
oil to detach from its barrel locations. 
These data are consistent with latest findings, which prove the heat curing process in 
siliconization of pharmaceutical glass containers to yield two qualities of silicone oil films: an 
irreversibly fixed silicone oil layer inhering covalent bonds between siloxane of the glass matrix 
and the organosilicon backbone of PDMS. This thin layer of covalent bound PDMS is overlayed 
by a thicker film of mobile silicone oil that adheres solely by hydrophobic interaction and can 
easily be removed by mechanical forces or suitable solvents (Mundry et al., 2000). Referring to 
that, the (partial) displacement of silicone oil films off glass surfaces by permanent sprinkling 
with water was demonstrated earlier (Steinbach and Sucker, 1975).  
It is important to note that light obscuration analysis merely provides quantitative 
information on particulate matter and that a discrimination between particles originating by 
silicone oil detachment and particles due to adalimumab aggregation is not possible. This caveat 
can not be overemphasized. E.g., light obscuration analysis of a heat-stressed protein solution 
and a protein solution enriched by a small volume of aqueous silicone oil emulsion reveals similar 
data on particulate matter contamination, although the particle source is totally different (Table 
8).  
 
particles/mL analyzed sample ≥ 2 µm ≥ 10 µm ≥ 25 µm 
solution A: 5 mg/mL adalimumab in PBS pH 6.8, 
filtrated through 0.2 µm filter (PVDF) 62 0 0 
solution A: 43 °C storage for 7 d 7 648 590 43 
1.0 mL solution A: + 0.2 mL silicone oil emulsion 8694 275 63 
 
Table 8. Analysis of particulate matter via light obscuration.  
 
On that account, the provenience of (sub-)visible particles in individual adalimumab syringes can 
not automatically be ascribed to silicone oil detachment. Assumed that the visible particles are 
due to protein precipitation, adalimumab solution is deemed to exhibit substantial 
microheterogeneity, i.e., to reveal higher-order protein components such as oligomers and hmw 
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Fig. 54. Light obscuration data 
of verum syringe contents 
dependent on the way of syringe 
depletion: draining via opened 
barrel apertures (alt.) vs. draining 
through needles (normal), which 
adds abraded silicone oil 
droplets to particulate matter 
data (n=3, Srel for all data <8.6).
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aggregates. The presence of protein precipitates as a consequence of protein denaturation is 
considered to be mandatorily associated with the presence of lower-order components aside 
monomers, which establish a thermodynamic and kinetic basis for (continuous) protein 
aggregation phenomena (Constantino et al., 1994b).  
In order to elucidate that matter, adalimumab solution of turbid syringe volumes was 
subjected to state-of-the-art analysis targeted on characterization of protein oligomers and soluble 
aggregates. 
 
7.3 Detection of soluble aggregates 
 
Volumes of clear and turbid syringes were analyzed via SDS-PAGE (Laemmli method; 
NU-PAGE 10% Bis-Tris-gel, staining with colloidal blue, Invitrogen GmbH, Karlsruhe, 
Germany) (Fig. 55). SDS-PAGE is commonly used to characterize molecular weight and purity 
of pharmaceutical proteins as well as to evaluate protein stability over time during formulation 
and storage. Furthermore, the formation of covalent aggregates, e.g., through intermolecular 
disulphide bridges, can effectively be detected by performing the experiments under both 
reducing and non-reducing conditions (Nguyen and Ward, 1993).  
 
Fig. 55. SDS-PAGE analysis (reducing conditions) of syringe volumes. Application of molecular 
weight marker (M), adalimumab standard (std), volume of clear syringe (cl), volume of turbid 
syringe (tur). Distinct visible protein bands are marked by blue auxiliary lines. 
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As illustrated in Fig. 55, no difference is detectable between adalimumab solution derived from 
clear and turbid syringes, respectively. Concomitant investigations with protein bulk solution 
disclosed fragmentation as a major pathway of adalimumab degradation – reflected in PAGE 
analysis by three fragment fractions, which are detectable in all syringe volumes and reveal molar 
masses of some 70, 50 and 25 kDa, respectively. According to the marker proteins, adalimumab 
monomer with an assigned molecular weight of ~150 kDa represents the largest protein 
specimen within the syringe volumes. Although inconspicuous bands in the range of ~300 kDa 
suggest the possibility of present dimer, the intensity of dimer bands increased considerably in 
case of non-reducing conditions, disclosing dimerization via disulfide linkage to be a potential 
aggregation pathway. Again, no discrepancies between the syringe samples were to be monitored.  
This is consistent with published data, revealing that antibody domains generally carry a 
highly conserved internal disulfide bond, connecting both β-sheets of the β-sandwich structure 
(Ramm et al., 1999). Immunoglobulines of subclass G like adalimumab were shown to dimerize 
via inter-heavy chain disulfide bridges at the N-terminal region, what substantiates the results of 
PAGE analysis (Krapp et al., 2003). 
It may be hypothesized that detachment of silicone oil notably increases water-oil 
interfaces, thus fostering protein denaturation. E.g., fibrinogen was shown to rapidly denature 
and aggregate due to irreversibly interaction with silicon surfaces (Ortega-Vinuesa et al., 1998). 
As a consequence, provided the visible particulate matter in syringes to be due to silicone oil, the 
hydrophobic surface is deemed to pedal adalimumab protein towards aggregation. Nevertheless, 
PAGE analysis proved volumes of syringes to be free of noteworthy aggregate amount – 
corroborated by SE-HPLC analysis (Fig. 56). Storage at 5 °C for 12 m does not affect 
adalimumab stability, as there is merely a slight increase in aggregate content, resulting in <1% of 
total protein after 12 m; and no visible particulate matter was evident. 
The situation in terms of aggregate content in syringe volumes exhibiting severe 
particulate contamination is on the same lines: low (<0.3%) amount of aggregate, outnumbered 
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Fig. 56. Stability of adalimumab 
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even by adalimumab fragments (Fig. 57). According to MALS, the fragment fraction exhibits a 
micro-homogeneity, i.e., the fragments were shown to inhere no multimodal mass distribution 
but may consist of two subfractions, each revealing molar mass uniformity. This is supported by 
PAGE, which confirmed adalimumab fragmentation to obey a certain regularity, as distinct 
fragment bands were to be observed. The staining would result in smearing bands, given the lack 
of a fragmentation pattern. Whereas the calculation of adalimumab monomer molar masses 
yields veritable data of ~148 kDa – with <1% difference from the theoretical value -, in case of 
fragment analysis MALS faces a worst case scenario: low concentrations and low molar masses, 
and both parameters are known to detract from MALS accuracy (Eq. 27).  
 
 
Obviously, PAGE and SE-HPLC ascribe adalimumab solutions identical stability, 
regardless of the presence/absence of visible particulate matter. Although it is prevalent opinion 
that even smallest amounts of (insoluble) aggregates – i.e., in the range of nanograms - may be 
causative for protein solution turbidity with subsequent particulate matter, protein aggregation 
per se had to be deleted from the register of suspects being accused of particle formation within 
the syringe volumes (Hoffmann, 2000): the potential corpus delicti – i.e., protein aggregates – was 
not to be tracked down. However, those facts have been reported before: silicone oil was added 
to protein solutions and turbidity was induced by mechanical stress. Furthermore, the silicone 
lubricant in syringes was dispersed in droplets forming a turbid emulsion via vigorous movement 
of the plunger. In both cases no reduced protein potency, e.g., by denaturation or aggregation, 
has been monitored (Collier and Dawson, 1985). Pertaining to that, silicone-protein interactions 
can be exploited in order to stabilize the protein against denaturation at interfaces (Brook and 
Zelisko, 2001).  
Principally, in trying to identify the origin of visible particulate matter with analytical 
methods not capable of undissolved analyte characterization, the application of SE-HPLC and 
PAGE may be considered a bad choice. On the contrary, AF4 was shown to separate dissolved 
and undissolved sample components successfully. Hence, the task to separate particulate matter 
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Fig. 57. SE-HPLC analysis of 
turbid syringe volume. UV280-
spectrophotometry (black line) 
reveals the monomer content 
to exceed 99.7%. Molar mass 
calculation of monomer was 
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of syringe volumes from adalimumab protein and to identify both components by advanced 
detection methods such as MALS appeared tailor-made. However, AF4 applicability in that very 
analytical task was first to be screened by means of silicone oil emulsions. 
 
7.4 Development of AF4 application: aqueous silicone oil emulsions 
 
Hitherto, AF4 analysis of silicone oil droplets in µm range has not been performed. In 
contrast, the chromatographic characterization of silicone oils in organic media is well 
established. Molecular weight distribution analysis of siliones was performed as well as the 
specification and quantification of organosilicone compounds at sub-ppm level (Muller and 
Opila, 1988; Dorn et al., 1994). Conversely, running HPLC with aqueous media normally leads to 
irreversible deposition of siloxane polymer on the columns (Sible, 1996). 
Bearing in mind the low inner surface area of an AF4 channel – usually <30 cm² and 
therefore reducing potential adsorption incidents - and the successful separation of 
supermicrometer polystyrene latex particles by AF4 recently, the development of an AF4 
application targeting the characterization of silicone oil droplets/emulsions should have promise 
(Wahlund and Zattoni, 2002).  
Since silicone oil DC 360 is used as syringe lubricant, that grade was used to produce 
aqueous emulsions (DC 360, 12,500 cSt, Dow Chemicals, Midland, MI, USA). Facing a 
maximum degree of 0.38% syringe siliconization - i.e., ~3.4 mg silicone oil per syringe –, 0.5% 
w/w emulsions were generated in 50 mL Falcon-tubes using PBS pH 7.2 medium at ambient 
temperatures. The addition of surfactants such as SDS in incipient experiments in order to 
enhance emulsion stability due to reduction of silicone oil coalescence subsequent to dispersion 
proved to render no significant gain in stability of µm sized droplets. Moreover, surfactants may 
impair detector signal-noise ratios, facilitate base-line artifacts and generally change the 
adsorption behavior of samples (Schimpf et al., 2000). Hence, SDS was omitted. 
As illustrated in Fig. 58, exerting shear stress by an ultra-turrax (T25 basic, IKA-Werke 
GmbH, Staufen, Germany) lead to emulsions featuring a criterion generally considered to be 
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Fig. 58. Size-distribution of 
silicone oil droplets in a 0.5% 
w/w aqueous emulsion 
depending on storage time 
(cumulative view). Due to 
coalescence events, the number 
of silicone oil droplets 
decreased over the whole size 
range. Coevally, small visible 
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typically for stable emulsions, equivalent conditions provided: the lower the droplet size, the 
larger the droplet number (van Aken and Zoet, 2000). Because of the lower detection limit of the 
applied light obscuration technique, droplets <1 µm could not be detected. In contrast to the 
number of droplets, which rose with increasing of both time of shear and shear intensity, those 
parameters did not influence the size distribution profile (time intervals 3-6 min, shear intensity 
11,000-24,000 r/min). However, subsequent to storage for 6-12 hrs, the number of droplets 
lessened, regardless of the size. Concomitantly, small transparent vesicles emerged at the surface 
of the Falcon-tubes, thus uncovering the progression of droplet coalescence. This phenomenon 
may be explained by monitoring the size distribution in differential way during storage (Fig. 59).  
Since the decrease in droplet number affects principally the complete spectrum, silicone 
oil must be deprived of the dispersed component – via adherence upon the tube surface prior to 
visible vesicle formation. Thus, the findings merge into a coherent picture.  
 
 
It is important to emphasize the intention of droplet formation being targeted on (short-
time stable) µm sized droplets to mimic (sub-)visible particulate matter in syringes rather than on 
long-time stable droplets in nm range. The presence of droplets well in the µm range can be 
visualized by light microscopy (Fig. 60). Due to the waiving of surfactant use – which would 
Fig. 60. Silionce oil emulsion characterized by light microscopy; storage time 6 hrs at 25 °C; 
scale-bar represents 100 µm. 
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negatively influence parameters such as stealth signals and signal-noise ratio – the size of the 
generated droplets increases. Moreover, their size distribution reveals a bivalent profile. This is 
consistent with latest findings, where the absence of stabilizing surfactants – e.g., proteins – was 
shown to facilitate the formation of larger µm range droplets in o/w emulsions within 2 hrs 
storage (van Aken and Zoet, 2000). Furthermore, a bivalent size distribution was assessed 
dependent on surfactant concentration.  
The merger of droplets in the nm range may explain the slight increase of the absolute 
number of droplets ≥1 µm after 2 hrs storage (Figs. 58 and 59). However, the emulsions – 
concerning µm sized droplets – exhibited a stability for at least 6 hrs. Subsequently, silicone oil 
vesicles emerged upon the tube surface, resembling the situation within turbid siliconized 
syringes. As practical consequence a maximum 6 hrs time slot was used for AF4 analysis.  
UV-spectrophotometry – though a traditional detection method for HPLC or AF4 – is 
not typically used for silicone characterization due to a lack of absorption in the UV region of the 
spectrum (Sible, 1996). Nevertheless, the droplets induced a notable UV280 respondence when 
subjected to AF4/UV analysis (Fig 61). So, how is that? 
One the one hand, the inherent turbidity of the emulsion fraction implies a reduced 
transmission of light within the UV detector flow cell. More importantly, a notable amount of 
light will be scattered by the oil droplets, provoking the detector photodiodes to monitor a 
decreased light intensity. Thus, reduced transmission and scattering phenomena supersede 
absorption, and the quantification of silicone oil is rendered possible.  
The dimension of the droplets implies several consequences: as demonstrated in Fig. 61, 
the droplets elute according to a steric mode profile. I.e., despite the exerted 65% cross flow – 
adalimumab monomer would be retained for ~15 min – the droplets are detected without 
notable retention, exhibiting a characteristic elution profile. Furthermore, the intense MALS 
signal gives evidence of the high sensitivity of MALS detection on large analytes, straightening 
out UV data, which attribute the droplets to finish elution within the first 2 min of fractionation. 
Contrarily, MALS demonstrates droplet elution to maintain twice as long. If the injected 100 µL 
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droplet amount is reduced by factor 10, the UV signal is no longer overexcited and the matter 
becomes more straightforward (Fig. 62). 
Considering steric mode conditions and a small amount of injected sample, one may 
ratiocinate the silicone oil droplets to reveal membrane adsorption tendencies: though the 
droplets commence elution with the void peak, the elution process is maintained for a relatively 
long time. Anyhow, as the droplets scatter light in anisotropic way, MALS responsivity is on the 
rise towards smaller angles, exposing droplet elution to continue for ~6 min (Fig. 63).  
 
 
Additionally, droplet adherence and immobilization upon the membrane is reflected by a 
thin, greasy layer of oil covering the membrane surface and being palpable at membrane removal. 
Hence, the separation power of the system bates, as the area of open membrane pores is 
downsized by adhering silicone. Unfortunately, this limited membrane reuse for a total of 
approximately ten AF4 experiments. Since the extent of adsorption remained constant, however, 
when the membrane was sufficiently “coated”, this drawback was of low effect (Fig. 64). 
Compared to UV detection – which is here solely based on obscuration and scattering 
incidents, applying RI detection for data acquisition renders greater sensitivity, especially at low 
analyte concentrations, and is therefore frequently used in PDMS analysis (Schunk and Long, 
1995). Yet, the responsiveness of RI can not compete with that of MALS. Besides, RI baseline 
stability was found to be prone to disturbance when subjected to pressure fluctuations induced 
Fig. 63. Monitoring AF4 droplet 
elution via MALS. The higher 
responsivity of lower angles (45°, 
upper profile) demonstrates the 
droplets to elute within ~6 min, 
indicating adsorption phenomena 
to interfere with elution. Medium 
angles (90°, lower profile) 
pretend the silione to have left 
the AF4 channel within ~4 min. 
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Fig. 62. Fractionation of 
silicone oil emulsion. Due to 
the small amount of injected 
emulsion (10 µL) the UV signal 
(black line) is dwarfed by the 
still overexcited MALS signal 
(grey line). Note the high signal 
intensity of MALS compared 
to UV. 
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by cross flow modulations. Nevertheless, RI detector passage of the droplets is reflected by an 
distinct inverse-shaped peak (Fig. 65).  
Theoretically, a calibration curve will result by plotting various masses of injected silicone 
oil versus pertaining AUCRI values, thereby providing a convenient method for the quantification 
of detached/dispersed silicone oil. A conditioned membrane assumed, injecting 10 µL of a 0.5% 
PDMS emulsion – i.e., 50 ng PDMS – made up the lower AF4 analytical limit which provided 
data with acceptable accuracy (Srel<20), thus representing an alternative method of silicone 
quantification. Furthermore, the principal applicability of AF4 in the separation of silicone oil 
droplets in steric mode has been effectually verified. In order to preclude misconceiving: because 
of its minimal degree, the extent of silicone migration into parenteral formulations is generally 
unknown. However, conventional silicone determination methods such as IR or atomic 
absorption spectrometry (AAS) are capable of detecting trace amounts in the ppm and ppb 
range, and advanced methods like graphite furnace AAS inhere potential for even higher 
sensitivity (Mundry et al., 2001). 
 
7.5 Analysis of syringe volumes 
 
The attempt to artificially induce silicone oil detachment off syringe surfaces is propelled 
by one main argument:  if the detachment of silicone oil can not be enforced by exerting harsh  
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(1) (2) (3) Fig. 64. Successive injection of 
oil droplets into the AF4 
channel. Notwithstanding 
adsorption events occurred, the 
detected AUCUV280 perpetuated 
continuity once the membrane 
was lined with a silicone film: 
0.435 (1), 0.426 (2), 0.428 (3). 
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Fig. 65. Detection of silicone 
oil droplets via RI (black line) 
and MALS (grey line). 
Whereas MALS reveals a 
substantially greater sensiti-
vity, RI signal intensity is 
proportional to sample 
concentration. 
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stress conditions, a spontaneous detachment in syringes at moderate conditions such as shock-
less storage at 5 °C seems unlikely. In that case, the syringe particulate matter is not to be 
ascribed to detachment events. 
The removal of oil from solid surfaces in the presence of aqueous solutions was 
performed earlier by Rowe using a benchtop ultrasonic bath (Rowe et al., 2002). In the style of 
Row, siliconized placebo syringes were subjected to ultrasound for 30 min (Sonorex RK 510, 
Bandelin electronic, frequency 35 kHz, Berlin, Germany). The effect of temperature (25 – 50 °C) 
was found to have no impact on the findings. Within several minutes, a slight turbidity appeared, 
which intensified and resulted in the formation of whitish, fluffy entities of ~500 µm in size. 
Subsequent storage at 5 °C did not lead to the coalescence of transparent vesicels at the inner 
glass surface. However, ultrasound-stressed placebo syringes were consistently attributed a 
greater turbidity than verum syringes,  which developed particulate matter during storage. AF4 
analysis of the stressed syringe volumes disclosed the turbidity to be due to seizable particulate 
matter (Fig. 66). 
   
 
The elution profile resembles that of silicone oil emulsions. Consequently, the 
fractionated sample can present forced-detached silicone. It may be hypothesized that due to the 
(mechanic) energy supply of ultrasound silicone oil was removed from the glass surface, either by 
mechnisms of emulsification and solubilization or roll-up, which is responded to later on (Miller 
and Raney, 1993). The final identification was performed by subjecting a highly concentrated 
sample of the eluting fraction – i.e., ~1 min after experiment start – to light microscopy (Fig. 67). 
In order to prove the principal possibility of oil detachment in verum syringes, 
adalimumab solution in syringes was replaced by PBS pH 6.8 prior to ultrasound stressing. 
Otherwise, adalimumab protein may aggregate, resulting in particle formation – thus potentially 
intervening with the AF4 characterization of detached oil.  
The fractogram of PBS volume stored in verum syringe glass containers during 
ultrasound stress is illustrated in Fig. 68. Subsequent identification of the fractionated component 
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Fig. 66. Characterization of 
placebo syringe content 
subsequent to 30 min 
ultrasound stress. Due to the 
steric mode elution profile 
(65% cross flow), the detected 
specimen are assigned 
dimensions >1 µm; detection 
with UV280 (black line) and 
MALS (grey line).  
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Fig. 69. Light microscopy picture of a fraction 
collected during AF4 analysis of buffer-filled verum 
syringe volume (refer to Fig. 68). 
via light microscopy unveiled silicone oil droplets to cause the turbidity/ particulate matter after 
30 min exposure to ultrasound (Fig. 69). 
Interestingly, the question whether syringe plungers may contribute to particulate matter 
is rarely addressed in the literature. Conversely, it has been repeatedly published that siliconized 
rubber stoppers can be the source of undesired negative features in the parenteral product, 
mainly particle formation (Li et al., 1993). Actually, siliconized stoppers do not mandatorily have 
to come into contact with the product to facilitate particle generation, e.g., in case of the 
manufacturing of freeze-dried products (Gebhardt et al., 1996).  
 
 
 
 
 
 
 
 
As the plungers of all syringes are coated with silicone oil, however, this topic was 
evaluated by placing the plungers of 10 placebo syringes in 20 mL PBS, pH 6.8. The batch was 
exposed to ultrasound for 15 min and analyzed via light microscopy – and no particles could be 
detected (limit of resolution ~1.8 µm). On the other hand, placing the remaining barrels into 30 
mL buffer medium, the same proceeding yielded silicone oil droplets comparable to those 
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Fig. 68. Buffer-filled verum syringes 
stressed via ultrasound prior to AF4 
analysis. Parameters: 65% cross flow, 
detection with UV280 (black line) and 
MALS (grey line). Box represents the 
volume that was sampled and analyzed 
by light microscopy (Fig. 69). 
Fig. 67. Light microscopy analysis of 
components inducing turbidity in 
placebo syringes after ultrasound 
stress. Comparing this picture to the 
image of droplets in silicone oil 
emulsions verifies the siliconic nature 
of the particulate matter in placebo 
syringes; scale bar represents 100 µm. 
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illustrated in Fig. 69. Obviously, the siliconized inner barrel surface exhibits a greater potential to 
contingent particle formation than the siliconized plunger surface. 
The developed AF4 application is only of value if the separation of silicone oil aside 
adalimumab protein can satisfactorily be shown. This feat can be jeopardized by the 
inconsistency of AF4 separation parameters required for the fractionation of droplets, 
adalimumab monomers and higher-order protein specimen, respectively. Moreover, adalimumab 
may exhibit an affinity to silicone oil adhering upon the membrane, thus abetting the incident of 
artifacts. Considering that, to simulate the situation within turbid syringe volumes by adding 
silicone oil emulsions to adalimumab solutions and to analyze those model samples via AF4 
seems reasonable. As the steric mode elution of the droplets proceeds for over 4 min, the in 
effect optimal separation conditions for adalimumab have to be adapted (Fig. 70): reducing a 
30% cross flow level after 2 min in a non-linear way to a 0% level at t=6 min enables the 
separation of adalimumab monomer and higher-order components within 9 min. MW calculation 
with MALS reflects the elution of an inhomogeneous aggregate fraction at ~6.5 min by 
displaying the molecular weights around 107 Da. The void peak – representing non-focused 
material regardless of the MW – is assigned ~106 Da, what is to be considered as MW average of 
monomers and aggregates. Bearing in mind a >4 min interval of droplet elution, the 2 min delay 
of adalimumab monomer elution start is not eligible for analysis of samples containing both oil 
droplets and protein monomers. 
 
 
Via reduction of both focus time and intensity and slight changes in the cross flow 
profile, eluting adalimumab monomer can be reflected by an UV280 peak with ideal symmetry 
(Fig. 71). Additionally, the superiority of MALS in detection of hmw specimen (3) is impressively 
demonstrated: confronted with the task to detect an aggregate fraction which accounts for <0.1% 
of total protein – the appendant UV peak can be visualized solely in magnified view – MALS 
responds to the marginal aggregate portion with an AUCLS90° exceeding that of the monomer.  
In order to generate a model of turbid syringe volumes, the 800 µL content of clear 
syringes were diluted with AF4 elution medium to provide adalimumab sample loads of 100-800 
Fig. 70. Optimal AF4 
separation of adalimumab 
monomer (2), keeping 
distance to void peak (1) 
and aggregate fraction (3), 
the latter representing 
<0.1% of total protein 
mass (black curve: UV280
signal; grey dots: molar 
masses, derived via MALS).1,E+04
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µg. That high sample loads may be associated with low qualities of resolution power is a well-
known fact (Schimpf et al., 2000). Subsequently, 200 µL of silicone oil emulsion (0.5%) were 
added to 800 µL syringe volume and homogenized via vortexing (10 s, 120 rpm, rotation radius 2 
cm). Thereby, the resulting 1 mg/mL content of silicone oil aligns with the scope of syringe 
siliconization degree of ~3.4 mg/syringe. Compared to turbid verum syringes, the model 
volumes exhibited a greater turbidity and were prone to creaming phenomena: after storage for 
24 hrs at 5 °C and 25 °C a thin, coherent film of silicone oil was buoying at the surface. Thus, the 
model volumes were analyzed via AF4 within 6 hrs after creation.  
Pertaining to Fig. 72, droplets and protein monomer can be separated, whereby the 
droplet fraction is represented by a characteristic acuminate peak. In order to provide a sufficient 
lag between (post-)eluting oil droplets and the onset of protein elution, the cross flow level was 
risen to 65% - thus retaining adalimumab for ~4 min. However, as UV detection provides a 
rather ambiguous picture of the droplet elution profile, an alignment of both UV and MALS 
signal is conducive to clarification of facts (Fig. 73). Furthermore, if the MALS signal of the 
droplets were to intervene with that of the protein, the adalimumab MW calculation – at present 
conditions yielding ~150 kDa - would be erroneous. 
 
 
 
 
 
 
 
 
 
Unfortunately, protein adsorption occurs, reflected by fronting and tailing of the 
monomer peak (Fig. 73). Referring to this, the affinity of immunoglobulins G with silicone 
Fig. 71. Sample load identical 
to the experiment illustrated 
in Fig. 71. Humble variations 
of AF4 separation parameters 
ameliorate peak symmetry, 
but prolong experiment time. 
Note the intense respond of 
MALS (grey line) on 
aggregates, in contrast to the 
minimal UV respond (black 
line). -0,1
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Fig. 72. AF4 separation of 
adalimumab solution enriched 
by silicone oil emulsion. The 
fronting/tailing of the protein 
UV280 peak (black line) is 
attributed to protein affinity to 
the silicone oil film covering the 
membrane surface. 
aggregates 
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surfaces was evaluated earlier, demonstrating the antibody adsorbing to silicone surfaces more 
strongly than proteins that are considered to inhere equal hydrophilicity such as albumine 
(Ortega-Vinuesa et al., 1998). Thereby, protein adsorption is suggested to be an irreversible 
process (Wigren et al., 1991). But as the extent of this irreversibility depends on the contact time 
– and the AF4 experiment being performed apace -, the small time of adalimumab exposure 
applies the brakes on irreversible protein adsorption (Lundstrom and Elwing, 1990). 
The separation of silicone oil droplets and protein specimen via AF4 was successfully 
demonstrated – what hitherto has never been published - and this application can be employed to 
elucidate the origin of particulate matter in siliconized verum syringes.  
 
The situation in syringes which appear clear during visual inspection is unambiguous (Fig. 
74). Because of the separation conditions (65% cross flow, programmed to reach a 0% level in 
non-linear manner at t= 13 min) the first evidence of adalimumab elution can be monitored not 
until 5 min. Furthermore, the presence of a small aggregate fraction is disclosed, accounting for 
<2% of total protein and spanning the gamut from 500,000 Da to almost 108 kDa. (It will be 
explained later on why the latter information has to be scrutinized and doubted.) 
 
 
Focusing step and high initial cross flow rates allow for reducing the void peak to 
minimal levels. Thus, it can be further embarked on the strategy that visible particulate matter, if 
present in syringe samples, is assumed to elute in steric mode and to induce detector signals in 
the first stages of the AF4 experiment.  
Fig. 74. AF4 analysis of 
the content of clear 
verum syringes. Besides 
monomer, a small 
aggregate fraction can be 
detected, visualized by 
the UV signal (black line) 
in magnified view and by 
(arguable) MW data (grey 
dots) (refer to text). 
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Fig. 73. Fractionation of 
droplets and protein monomer. 
Both UV (black line) and 
MALS90° (grey line) prove 
system parameters to provide 
sufficient resolution of droplet 
fraction and monomers. 
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Even if the visible component inheres no UV activity and is present in minimal 
concentrations, the sensitivity of MALS on large analytes guarantees to scent out that very visible 
entity. In case Milli-QTM-water is subjected to AF4 separation conditions identical to those 
applied in Fig. 74, according to UV280 data no analytical entity is to be detected (Fig. 75). 
However, Homer sometimes nods, and MALS unequivocally verifies the detector passage of one 
fraction immediately after start of the separation step, whereas a second fraction is identified 
when the exerted cross flow is zero (t=13 min).  
Prior to the experiment, a silicone oil emulsion was characterized. A humble fraction of 
oil adheres upon the membrane and may leave the channel during the successive experiment, 
thereby inducing artifact peaks. During the focus step, the membran is flushed by two opposing 
flow profiles, and a minute fraction of silicone oil may become dispersed into the channel volume 
– thus partially being positioned at elevated channel positions and leaving the channel embedded 
in fast flow laminae. That lowest gravitational or hydrodynamic forces may be sufficient to 
actuate spontaneous oil detachment off surfaces has been repeatedly described (Thompson, 
1994). Conversely, at no cross flow forces effective after 13 min, the mere streaming of elution 
medium ushers in similar detachment phenomena. As a consequence, it has to be carefully 
deliberated about the trustability of these data. In worst case, the MALS signal may be 
misconceived as sluggishly eluting hmw protein aggregates or can superimpose the signals of 
sample components, then potentially adulterating the values of calculated molar masses (refer to 
Fig. 74). 
The situation within turbid syringes is presented in Fig. 76. 
The eye-catching peak at t=0.5 min bears a substantial resemblance to signals of silicone oil 
emulsions and of syringe volumes with artificially induced detachment incidents. Adalimumab 
protein is unified by a UV280 signal exhibiting considerable tailing – that may be ascribed to 
system parameters, protein adsorption events and concentration effects of the component eluting 
before. Assumed that this component represents silicone oil droplets, tiny droplets in nm range 
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Fig. 75. UV (black line) and 
MALS90° signal (grey line) of 
Milli-QTM-water characteriza-
tion subsequent to a run 
analyzing silicone oil 
emulsion. Due to experiment 
conditions, silicone oil 
adhering upon the membrane 
is unhitched  and detected 
solely by MALS (refer to 
text). 
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may elute within the protein fraction – or oil drops resolve sporadically from the contaminated 
membrane and pass the detectors concomitantly with adalimumab. MALS misattributes the 
scattering of silicone to protein, thus overcalculating molar masses and rendering broad mass 
distributions. According to Fig. 76, adalimumab is assigned ~180 kDa at the UV280 maximum 
(+20% aberration), and at minor protein concentrations the MW data is fringed because of an 
unfavorable signal (adalimumab) – noise (single particulate specimen) ratio.  
  
 
Hence, the component eluting in steric mode may indeed be oil droplets. Due to the 
affinity of silicone oil to the membrane, the droplet fraction – if really consisting of silicone oil – 
should reveal a kind of delay in its elution profile, regardless of the theoretical constraints. 
Anyway, that is easily to be verified by confronting UV and MALS signals (Fig. 77).  
 
 
 
Two causalities can be mentioned in terms of MALS overexcitement in the initial 
experiment stage: high analyte concentration and ultra-large analyte dimension. Considering the 
intensity of MALS substantially outnumbering the analogical UV signal in case of the steric mode 
sector, the latter appears to apply. However, once the challenge of particulate matter separation is 
performed, the walk through the task of identification is straightforward: one possibility is to 
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Fig. 76. Analysis of the 
volume of turbid 
syringes. The main 
difference to fractograms 
of clear syringes is an 
intense UV peak (black 
line) preceeding the 
adalimumab monomers 
(refer to text). 
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Fig. 77. UV (black line) and 
MALS90° signal (grey line) of 
turbid verum syringe content. 
MALS demonstrates the first 
fraction - being separated in 
steric mode - a delayed elution 
profile, thus indicating analyte 
adhesion events upon the 
membrane. 
Chapter 7. Analytics of pharmaceutical antibody solutions in siliconized syringes 
 107
combine AF4 with electrospray mass spectrometry as on-line detector for analyte identification 
(Hasselloev et al., 1997). Alternatively, the sampled fraction can be subjected to proton nuclear 
magnetic resonance spectroscopy (1H-NMR) or AAS, which have both been repeatedly applied in 
the identification of silicon compounds (Lykissa et al., 1997; Leung and Edmond, 1997). 
Otherwise, the particles´ origin can easily be elucidated by comparing the steric mode fraction to 
silicone oil emulsions in light microscopy analysis – and detached silicone oil emerges to be the 
cause of syringe turbidity (Fig. 78). That the sampled AF4 fraction inheres less droplets than a 
0.5% silicone oil emulsion is thereby comprehensible.  
The degree of silicone oil detachment in syringes poses the question of the impact on 
adalimumab stability. The tendency of especially hydrophobic surfaces to denature proteins is 
deemed a top issue in the literature (Ostuni et al., 2003). Hence, assuming the inner barrel surface 
area of 690 mm² to be multiplied by the droplet formation due to detachment/coalescence, the 
threat to protein stability is a serious one. The more, as established methods like light obscuration 
were shown to fail in differentiation between oil droplets and protein precipitates (refer to Table 
8). However, according to Fig. 76, no distinct aggregate fraction is detected.  
 
Fig. 78. Light microscopy analysis of a collected AF4 fraction of turbid syringe volume (left 
image) versus silicone oil emulsion (0.5%, right image); scale-bar represents 100 µm. 
Fig. 79. Subjecting syringes 
which already experienced 
detachment to thermal stress 
(45 °C, 10 d) renders three 
components amenable to AF4 
separation: silicone oil droplets 
(1), adalimumab monomer (2) 
and hmw aggregates (3).  
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In order to go further into this issue, adalimumab denaturation was compelled within 
turbid syringes – i.e., detachment has occurred - via 10 d storage at 45 °C. Subjected to stress, 
adalimumab obviously has undergone denaturation, and the appendant aggregate fraction can be 
separated as individual fraction via AF4 (Fig. 79).  
In conclusion, via AF4 the visible particulate matter in siliconized adalimumab 
disposable syringes has convincingly been demonstrated to be due to detachment of silicone oil 
during storage. Besides, protein aggregates could not be detected. This topic was further 
elucidated applying analytical techniques like PCS and SEM, thereby corroborating the data 
presented above (Fraunhofer et al., 2002c). 
 
7.6 The effect of silicone oil detachment on syringe frictional drags 
 
Commercial disposable syringe barrels – regardless if made by polypropylene or glass – 
are lubricated with silicone oil to reduce the coefficient of friction during plunger motion. 
Thereby, the plunger movement is determined principally by the interference or squeeze between 
piston and barrel and the amount of compression set (deformation) a constrained piston takes 
during sterilization and subsequent storage, but mainly by the type and amount of lubricant 
(PDA, 1981). In this regard, especially if the siliconization process is not accompanied with a final 
heat curing process, simple water washes have been shown to flush a proportion of the silicone 
lubricant from syringes, what leads to increased frictional drags during plunger motion, referred 
to as syringe stiction (Capes et al., 1996). In general, the matter of potential lubricant detachment 
has enormous impact on the safety and quality of the emptying process, because due to the then 
increased frictional drags the drug application is impeded. If syringe pumps are applied, the 
effects may be dramatic: more than one million Becton Dickinson brand syringes were recalled, 
because their high breakloose force was causing false alarms with syringe pumps 
(communication, 1991). 
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Fig. 80. Monitoring frictional 
drags during depletion of clear 
siliconized adalimumab syringes: 
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Bearing in mind lubrication being the main function of barrel siliconization, adalimumab 
syringes which have undergone silicone oil detachment – i.e., a loss of lubrication – should reveal 
different frictional drags during depletion compared to syringes with intact siliconization. The 
force required to initiate and maintain syringe plunger motion can be gauged with methods 
specified by regulatory authorities or professional associations (Fig. 80). 
Thereby, the syringes were mounted vertically in the holding system with the needle tip 
downwards and the plungers were moved automatically at a nominal speed of 70 mm/min 
(friction transducer WN805687, Boehringer Ingelheim GmbH, Biberach, Germany). The plunger 
was straightened in the barrel so that the major axes of the plunger, barrel and the force gauge 
were parallel to prevent lateral forces or rocking of the piston during operation. Initially, the 
breakloose force – defined as the force required to commence plunger movement against the 
static frictional drag - has to be overcome (PDA, 1988). For that almost ~4 N were required. 
Subsequently, only the sliding frictional drags have to be opposed. A force of ~2 N is sufficient 
to maintain the average extrusion force. Generally, the upper limit of the force sensor was 8.5 N.  
As outlined in Figs. 81 and 82, the extrusion force profile changes dramatically when the 
barrel lubrication of placebo and verum syringes decreases because of induced silicone oil 
detachment. 
In the course of sample preparation/providing for characterization of syringe volumes, 
clear and turbid adalimumab syringes were emptied by moving the plunger with a backup piston. 
As subjective the personal impression may be: the notion that the required forces for manual 
depletion of turbid syringes exceeded the force necessary for clear syringe depletion by a multiple 
was corroborated by automatic force monitoring (Fig. 83). 
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Fig. 81. Frictional drags during depletion of siliconized placebo syringes, prior to (left) and 
subsequent to (right) induced silicone oil detachment by ultrasound stress. After stressing, the 
syringe volumes were turbid because of oil detachment and droplet formation. As the lubricating 
effect is decreased, the average extrusion force for plunger movement steadily increases, 
indicating non-uniform detachment. 
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According to Fig. 83, the migration of silicone oil off the barrel surface into the syringe 
volume spirits away the lubricating effects. The signals due to primary static friction and 
subsequent sliding friction merge, and a constant force of at least 6 N is needed to empty the 
syringes. In conclusion, the data of AF4 analysis countenance the findings illustrated above, 
ascribing the particulate matter development during syring storage to oil detachment.     
  
Generally, there a few requirements limiting the amount of silione oil – i.e., PDMS – in 
siliconized containers or medical devices. The European Pharmacopeia postulates a siliconization 
degree of <0.25 mg/cm² for disposable syringes (2002 Edition, Monograph 3.2.8: Sterile single-
use plastic syringes). Neither the USP24/NF19 nor the Japanese Pharmacopeia XIII state any 
requirements for the degree of siliconization of glass and plastic containers or rubber closures. 
However, one actual limitation for lubricants in food and drugs of 1 ppm is stipulated by the U.S. 
Food and Drug Administration (FDA) for the use of silicone oils – i.e., dimethylpolysiloxane, 
viscosity >300 cSt - in 21 CFR § 178.3570, (1998) “Lubricants with incidental food contact” 
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Fig. 83. Depletion of two 
adalimumab syringes which 
experienced silicone oil 
detachment and turbidity during 
storage. Right from the 
beginning, forces of >6 N are 
required for plunger motion (red 
line), whereas in a second syringe 
the frictional drags after 7 mm of 
plunger motion exceeded the 
upper record limit of the 
apparatus (8.5 N, green line). 
0 10 20 30
0
2
4
6
8
10
Prüfzeit in s
Ko
lb
en
re
ib
kr
af
t i
n 
N
0 10 20 30 40 50
0
2
4
6
8
10
Prüfzeit in s
Ko
lb
en
re
ib
kr
af
t i
n 
N
fr
ic
tio
na
l d
ra
g 
fo
rc
e 
(N
) 
fr
ic
tio
na
l d
ra
g 
fo
rc
e 
(N
) 
time (s) time (s) 
Fig. 82. Frictional drags during depletion of clear siliconized adalimumab verum syringes, prior 
to (left) and subsequent to (right) induced silicone oil detachment by ultrasound stress. Again, 
silicone oil detachment impedes plunger movement, demonstrated by rising average extrusion 
forces up to 8 N. 
Chapter 7. Analytics of pharmaceutical antibody solutions in siliconized syringes 
 111
(Mundry et al., 2001). Still far away from propelling a laissez-faire policy, the FDA nevertheless 
has eclipsed the mischiefs associated with silicones by the recent general approval for silicone oil 
(1000 cSt) for intraocular injection (Benedetto and Lewis, 2003). 
Conversely, product purity and stability are generally arresting more attention, as those 
parameters are deemed to directly influence general drug safety. Even for the professional it may 
be astonishing how closely package siliconization is connected to the issue of general drug safety: 
 
7.7 Can protein drugs vanish within a syringe? 
 
By means of AF4 the turbidity of adalimumab syringe volumes was demonstrated beyond 
doubt to be caused by silicone oil detachment and not by precipitated protein. Unfortunately, by 
screening the AF4 data not only qualitatively but also quantitatively, the matter gains intricacy 
(Table 9).   
According to Table 9, there seems to be an indirect correlation between syringe volume 
turbidity – i.e., silicone oil detachment – and sample recovery. Obviously, clear syringes 
outnumber turbid syringes in protein content by ~15%. Can the detachment of silicone oil really 
influence the amount of detectable protein? Two reasons jump the queue – and both are 
associated with incidents based on oil droplet formation. Here, the protein is confronted with an 
immensely increased hydrophobic surface, and why should the protein not take the bait and 
adsorb thereon? In most qualitative pictures of adsorption, processes involving the interaction of 
a hydrophobic patch on the protein surface and a hydrophobic surface region such as oil droplets 
are followed by conformational changes in the protein that (partially) exposes its hydrophobic 
core. Dehydration of hydrophobic sites provides an entropic impetus for adsorption (Ostuni et 
al., 2003). As denaturation often comes along with fragmentation, adalimumab may have 
fragmented and the fragments pass the AF4 ultrafiltration membrane, thus avoiding detection. 
On the other hand, proteins do not mandatorily have to change their conformation when 
they adsorb on surfaces (Norde, 1998). However, since the droplet fraction induces UV response 
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Table 9. Comparison 
of sample recovery in 
terms of UV280 data: 
turbid versus clear 
syringes (sample load 
of samples 1-3: 2 mg; 
sample 4: ~0.7 mg). 
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subsequent to AF4 fractionation merely by reduced transmission and scattering phenomena, the 
UV signal of proteins potentially adhering upon the droplet surface is superseded and eclipsed. 
As a consequence, in that case protein is underquantified by UV280 detection, if ever. 
Pertaining to the fragmentation hypothesis, the matter can easily be elucidated by 
filtration of clear and turbid syringe volumes, revealing the ~15% loss of protein to be ascribed 
to the removal of oil droplets rather than to fragmentation (0.2 µm, PVDF).  
 
 
batch syringe volume UV280 absorbance 
turbid 1.033 50 µl filtrated syringe content 
+ 3000 µl Milli-QTM water clear 1.182 
 
 
The findings above are substantiated by the evaluation of SE-HPLC data. Originally, SE-
HPLC analysis was applied in order to investigate whether turbid syringe volumes differ from 
clear syringe volumes in qualitative terms, i.e., in aggregate content. Via quantitative interpretation 
of the data, a correlation of turbidity and protein disappearance (~14%) becomes manifest (Table 
11).  
 
 
syringe sample preparation sample AUC UV280 AUCUV280 average
1 8.37 
2 8.52 clear volume filtration (0.1 µm, PVDF) 3 8.51 
8.47 
1 8.55 
2 8.47 clear volume none 
3 8.65 
8.56 
1 7.25 
2 7.25 
turbid volume 
-  
oil detachment 
ultracentrifugation, 
5500 g, 
3 min 3 7.28 
7.26 
1 7.50 
2 7.66 
turbid volume 
-  
oil detachment 
filtration 
(0.1 µm, PVDF) 3 7.73 
7.63 
1 7.28 turbid volume 
-  
oil detachment 
filtration, twice 
(0.1 µm, PVDF) 2 7.41 7.35 
 
 
 
The possibility of adalimumab adhering irreversibly upon the siliconized barrel surface is 
to be ruled out – in that case, the assessed protein content should differ from 40 mg, as declared. 
As a matter of fact, assessed and declared content matched. 
To elucidate the adsorption problem, it may be helpful to leave the mere pharmaceutical 
ken towards other fields of research. In the laundry business, the cleaning of solid surfaces is of 
considerable interest, as oily contaminants that could otherwise be deleterious to subsequent 
process steps or for quality purposes have to be removed (Rowe et al., 2002). Thereby, the strong 
Table 10. UV280 absorbance of  adalimumab syringe volumes after 0.2 µm filtration (n=3). 
Table 11. Detected AUC UV280 of adalimumab during SE-HPLC analysis dependent on syringe 
volume conditions: turbid due to silicone oil detachment versus clear. Sample preparation did 
virtually not influence sample recovery, as illustrated.
Chapter 7. Analytics of pharmaceutical antibody solutions in siliconized syringes 
 113
adhesion of surfactant molecules upon the oil contaminants is considered to be a crucial step. In 
Food Industries, protein emulsifiers protect finely dispersed droplets against immediate 
recoalescence and, during storage, provide long-term stability towards creaming and flocculation 
– by rapid adsorption at the oil-water interface (Dalgleish, 1997). In all those fields, proteins 
adhere to considerable extent at interfaces in oil-water emulsions. Returning to the syringes: given 
a siliconization degree of >3mg PDMS per syringe, with a notable amount therefrom undergoing 
detachment, coalescence and droplet formation during storage, turbid syringe volumes may be 
considered as PDMS-water emulsions. As a consequence, abundant protein emulsifiers – i.e., 
adalimumab - will adhere at interfaces, thus potentially avoiding detection in AF4 experiments. 
This hypothesis is fueled by the fact that especially globular β-lactoglobulins are known to adsorb 
substantially on oil-water interfaces – hence, the risk for globular immunoglobulin to meet a 
similar fate seems genuine (Dickinson, 1998).  
In order to assess the amount of protein adsorbed on the droplet surfaces, if ever, the 
AF4 droplet fractions leaving the channel within the first 2 min of separations were collected and 
the quantity of adalimumab incorporated therein was quantified via a protein-specific bio-assay 
(Dc protein assay, Bio-Rad Laboratories, Hercules, CA, USA). Due to the assay specificity 
towards protein and the dilution of the collected steric-mode fraction (~1.5 mL), artifacts in 
UV595 detection which are based on scattering, refraction and reflectance of light are virtually 
forestalled. The principal applicability of the assay was scrutinized by generation of a standard 
calibration row (Fig. 84).  
 
In theory, the AF4 droplet fraction of turbid syringe volumes – note that only turbid 
volumes contain silicone oil droplets – should reveal a protein content commensurate with the 
difference in protein content of clear and turbid syringes. In this realm, the observed ~15% 
difference in drug load correspond to 6 mg protein.  
There is, of course, a substantial flaw in the methodology: the underlying principles of 
AF4 imply the void peak to comprise sample specimen which circumvented focusing. Although 
the applied AF4 separation conditions guarantee the adalimumab void fraction to be <0.2% of 
the injected sample mass, protein of the void fraction eluting concomitantly with the droplet 
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Fig 84. Response of protein-
specific Lowry-assay on 
various adalimumab loads (50-
1000 µg/mL); R 0.994;  
x=2000(y-0.01), detection via 
UV595 spectrophotometry. 
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fraction will inevitably be recorded subsequently by the assay. Hence, clear syringe volumes – i.e., 
no oil droplets being present – and placebo syringe volumes were also analyzed in terms of 
reconciliation (Table 12).  
Pursuant to Table 12, via combination of AF4 and bio-assay quantification the amount of 
adalimumab adsorbing on silicone oil droplets in turbid syringe volumes averages ~6% of total 
syringe content. Thus, it can be concluded that silicone oil – once migrated into the syringe 
volume and causing droplet formation – exhibits a great tendency for protein adsorption and 
subsequent immobilization.  
 
analyzed sample experiment protein mass contained in void/ droplet fraction (µg) 
protein mass of void/droplet 
fraction in relation to total 
syringe load (%) 
1 2784 6.96 
2 2344 5.86 turbid syringe volume 3 2680 6.70 
1 344 0.86 clear syringe 
volume 2 312 0.78 
1 8 0.02 placebo syringe 
volume 2 8 0.02 
 
 
 
 
Since previous experiments with filtration, SE-HPLC and AF4 assessed the difference in 
detectable protein between celar and turbid syringe volumes to be ~15%, the question of the 
protein whereabouts can not be answered completely. Possible explanations therefore are: 
subsequent to interface adsorption and denaturation, the proteins may fully migrate into the 
interior of the silicone oil droplets. Complete unfolding provided, the attractive van der Waal 
contribution would have to be added to the entropic impetus of dehydration of the hydrophobic 
protein surface, which could be attained thereby (Ostuni et al., 2003). Moreover, the features of 
the inner barrel surface will alter due to silicone oil detachment. As a consequence, adalimumab 
may develop a greater tendency towards immobilization upon glass surfaces which lack the shield 
of covering silicone oil.  
The final argument addresses the silicone oil layer adhering the AF4 ultrafiltration 
membrane – what renders one artifact to become conceivable: because of the cross flow induced 
close proximity between sample components and the ultrafiltration membrane, an intense 
interplay between (still) eluting and (already) adsorbed silicone oil specimen appears likely – 
needless to state that the same applies to eluting protein, too. Hence, a transfer of silicone oil 
between the eluting fraction and the membrane-covering fraction will occur. Additionally, it was 
found that emulsion droplets exchange a notable quantity of oil molecules even if immediate 
vicinity is not provided through the continuous phase, i.e., the elution medium. Processes similar 
Table 12. Protein masses eluting within the void/droplet fraction of AF4 runs. Samples drawn 
from turbid syringe volumes exceed notably samples of clear and placebo volumes in protein 
content – proving the silicone oil droplets to capture a notable amount of protein drug. 
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to Ostwald ripening were demonstrated to foster those events (Taisne et al., 1996). Anyhow, 
protein-rich droplets of lower stream laminae may swap places with protein-poor silicone oil 
covering the membrane. In summary, any of the processes outlined will result in an AF4 under-
quantification of protein. On this account, the data merge into a coherent picture. 
Generally, silicone oil droplets within the syringe volumes are no static entities but 
amenable to processes of permanent coalescence, re-emulsification incidents and re-migration of 
droplet appendant silicone oil (Dickinson, 1998) (Fig. 85). 
 
 
 
In this realm, also protein adsorption may be deemed a steady process and proteins 
adhering on the droplet surface may displace and migrate back into the aqueous medium (Bos et 
al., 1997). Provided that adalimumab maintains the native conformational state, there is no reason 
to worry. The matter is further complicated since adsorption of proteins is highly competitive 
with surfactants – mainly proceeding via solubilization in case of ionic surfactants, whereas non-
ionic surfactants such as Tweens involve a replacement mechanism (Heertje et al., 1996). As the 
protein was formulated into the syringes using Tween 80, formulation components – including 
protein monomers and aggregates - may adsorb and detach even alternately. Therefore, a final 
statement whether the protein adsorbs onto the dispersed silicone oil droplets exclusively in 
monomeric form is not possible.  
Silicone oil detachment may facilitate protein aggregation and aggregates in general may 
abscond from detection via immobilization on oil droplets – against the background of the 
potential of aggregates to trigger adverse immune responses and immunogenicity, respectively, 
syringes revealing silionce oil detachment are assessed to inhere risks in terms of general drug 
safety. In a case study proteins were demonstrated to primarily build up a monomeric formation 
on silicone surfaces, but with increasing adsorption time a rising amount of aggregates was 
detected (Alemeida et al., 2002). Advanced analytical techniques like front-face fluorescence 
spectroscopy or atomic force microscopy may provide information about the interfacial 
composition, but neither technique is capable of general, apodictic statements (Rampon et al., 
Fig 85. Characterization of a silicone oil droplet of 
turbid syringe volumes subsequent to separation via 
AF4 by scanning electron microscopy (XL40ESEM, 
Phillips GmbH, Germany). Note the agile droplet 
character reflected by surface bubbling, surface 
protuberances and vesicle coalescence. 
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2003). Facing a variety of unanswered questions, this field with utmost probability will be the 
topic of intensive future research. 
 
7.8 Summary 
 
Today, disposable prefilled siliconized syringes for the parenteral application of drugs 
enjoy a great popularity among both patients and physicians. However, the process of 
siliconization – if of insufficient quality - is known to potentially give rise to particulate matter 
contamination. This chapter attends to an analytical case study of protein drug containing 
siliconized syringes, which sporadically developed visible particulate matter and a slight turbidity 
during 5 °C storage. Subvisible particulate matter analysis showed those syringes to be 
substantially contaminated with particles ≥1 µm (>150.000 per mL). In this regard, the answer of 
questions aiming at particle source and protein stability was urgently required. 
Originally, the embarked strategy appeared straightforward: (a) find an increased ratio of 
soluble aggregates in the turbid syringe volumes, (b) separate the visible particulate specimen, (c) 
identify that specimen to reveal a proteinic nature and (d) finally subsume the matter to decreased 
protein stability due to insufficient formulation composition. 
Analysis via SDS-PAGE and SE-HPLC, however, provided no hints towards a satisfying 
answer – in terms of protein stability, clear and turbid syringe volumes were of equal quality. As a 
consequence, the protein drug instabilities were not to account for particle origin. 
On the other hand, it was found that the manner of syringe depletion was decisive for the 
number of subvisible particles assessed in the syringe volumes. Traditional emptying via plunger 
movement through the needles resulted in substantially higher particle numbers than providing 
the syringe volume via the barrel aperture subsequent to backward plunger removal. Given the 
background of barrel siliconization without a final heat curing – which is known to increase 
adhesive strength and inertness of the silicone oil layer -, the observed difference in particle 
contamination was possibly due to silicone oil, abraded via plunger movement.  
In order to translate this hypothesis into syringes – i.e., to verify the processes oil 
detachment, coalescence and droplet formation -, an AF4 application was developed, targeting at 
the separation of µm sized silicone oil droplets. Hitherto, no successful characterization of oil 
droplets via AF4 has been published. The task was approached by the analysis of aqueous 
silicone oil emulsions, followed by the fractionation of ultrasound-stressed syringe volumes 
containing detached and coalesced silicone oil after stress exposure. Thereby, a possible scenario 
of the conditions within turbid syringes was simulated. Finally, a notable fraction of silicone oil 
could be identified in the volumes of turbid syringes, whereas clear syringe volumes lacked a 
droplet fraction. These data were corroborated by light microscopy and matched the findings of 
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syringe frictional drag analysis – which ascribed syringes to exhibit increased frictional drags 
during depletion when the lubricating effect is diminished because of silicone oil detachment. 
Unfortunately, this turned out to be only half of the truth. Because the droplet formation 
increased the hydrophobic surface based on silicone, adsorption incidents were revealed, leading 
to a substantial reduction of the detectable protein content in syringes. AF4 provided the 
analytical fundament for the isolation and semi-quantification of that surface, i.e., the silicone oil 
droplets. Via protein-specific bioassay the isolated droplets were demonstrated to branch off a 
considerable fraction (>6%) from the declared protein drug load within the syringes. Thereby, a 
thorough approach to the question whether protein aggregates contingently adhere – and maybe 
detach - would be beyond the scope of this chapter. The more, as it was repeatedly shown that 
due to its complexicity the question if proteins adhere upon surfaces exclusively in monomeric or 
aggregated form can definitively not be answered. 
Earmarked to elucidate the visible particulate matter origin in the course of an analytical 
case study of siliconized syringes, the application of AF4 thereby turned out to provide much 
more information on a variety of parameters than usually intended. Hence, AF4 proved to be a 
valuable tool for answering challenging questions, which otherwise would have necessited to 
apply a multiplex daedalian array of expensive analytical methods. 
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8 Characterization of gelatin nanoparticles by AF4 
 
8.1 Introduction 
 
The highly interdisciplinary field of nanoparticles encompasses chemistry, materials 
research, molecular biotechnology, immunology, medicinal and engineering sciences (Niemeyer, 
2001). In the pharmaceutical industry, nanoparticles prepared from a variety of natural or 
synthetic polymers attracted much attention because of the target-oriented advanced drug 
delivery features of these systems (Farrugia and Groves, 1999). The research field of 
nanoparticles is expected to rapidly evolve and gain increasing importance for medicine and 
pharmaceutics in the next years (Langer, 1998).  
Especially in applications like gene therapy, the design of ideal polymeric carriers, those 
being able to target specific cell types, is highly desired  the more, as DNA delivery with non-
viral vectors is deemed the most important delivery challenge of the new millenium (Kaul and 
Amiji, 2002). In this regard, via nanoparticles, the sustained parenteral delivery of DNA and oral 
gene delivery were successfully approached as well as the transfection of stem cells only a few 
months ago (Roy et al., 1999; Cohen et al., 2000; Corsi et al., 2003). Although the majority of 
nanoparticles described in the literature is formulated with poly(D,L)-lactide-co-glycolide 
(PLGA), the use of PLGA in DNA delivery bears one grave drawback: being a hydrophobic slow 
degrading polymer that results in highly acidic local microenvironment, PLGA is not a very 
effective polymer matrix for DNA encapsulation (Kaul and Amiji, 2002).  
Pertaining to that, nanoparticles based on the natural biopolymer gelatin are very 
promising, as they enable high transfection rates (Truong-Le et al., 1999). Moreover, gelatin has a 
long history of safe use with low antigenicity in a wide range of medical and and pharmaceutical 
applications, cosmetics, as well as in food products (Ward and Courts, 1977). The parenteral use 
of gelatine derivatives over many years provides a sound safety basis for future applications, and 
there are numerous ways for nanoparticle implementation. Fundamental knowledge of 
nanoparticle dimensions is of utmost importance as the influence of size on nanoparticle efficacy 
is still intensively discussed. For instance, 100 nm-sized nanoparticles exceeded 1000 nm-sized 
nanoparticles considerably in membrane permeability and thus uptake efficiency (Desai et al., 
1996). Consequently, the application of new analytical methods in nanoparticle characterization 
struggles to keep pace. 
For nanoparticle size determination, two main techniques are established: Electron 
Microscopy and Photon Correlation Spectroscopy (PCS), often referred to as Dynamic Light 
Scattering (DLS) or Quasi-elastic Light Scattering (QELS).  
The intensive utilization of Scanning Electron Microscopy (SEM) may be ascribed to 
both high resolution and ease of sample preparation. The accessible physicochemical parameters 
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include particle size, porosity and morphology (Li et al., 1999). However, the conditions 
precedent to SEM analysis are sample conductivity and tolerance of vacuum ambience. 
Sometimes the presence of surfactants in the preparation may inhibit nanoparticle 
characterization via SEM due to the formation of a smooth, camouflaging coating on 
nanoparticle surfaces (Kreuter, 1983). The second microscopic method implemented for 
nanoparticle characterization is Transmission Electron Microscopy (TEM). The exceeding 
magnifications of TEM enable accurate particle surface and morphology analysis (Chui and 
Mumper, 2002). Inherent drawbacks of both methods are random sampling - instead of an 
overall sample analysis - and time consuming sample preparation and measurement procedures.  
In reviewing the literature dealing with nanoparticle characterization, one will come 
across PCS as the dominating sizing technique. Because of its non-invasive and non-destructive 
performance, PCS evades artifacts. Dissolved and undissolved matter can be sized within minutes 
in a reproducible way. The major obstacle in order to achieve veritable results is due to the 
underlying principles: since PCS measures the effective z average of the diffusion coefficient 
proportional to the reciprocal particle radius for spherical shapes, the sizes derived are influenced 
by the presence of dust or agglomerated fractions present in the sample (Wyatt, 1998). 
Furthermore, a number of assumptions inherent in data analysis also affect particle distributions. 
However, PCS has become the preferred choice of technique for nanoparticle sizing, provided 
that size distributions are narrow. 
Other sizing techniques play a minor role in nanoparticle characterization. Considering 
the prevalent dimensions of polymeric nanoparticles used in medicinal and pharmaceutical 
sciences ranging from 50 to 400 nm, light obscuration and Coulter technique are deemed a poor 
choice in nanoparticle analysis, due to their low resolution in nm scale. Conversely, the upcoming 
technique of Scanning Force Microscopy (SCM), also known as Atomic Force Microscopy 
(AFM), was successfully used in visualizing nanoparticles (Jungmann et al., 2002). Yet, the main 
area of application lies in the investigation of surface morphologies.  
However, without exception the analytical methods outlined above are batch techniques, 
i.e., the constraints of enlarging the size application range to a maximum due to the presence of 
inhomogeneous samples - with small components present aside large components  call for a 
significant loss in resolving power. In this realm, optimal conditions provided, AF4 was shown 
recently to be capable of analyzing a cellulose derivative over a wide range of molar mass, 
including hmw components (Andersson et al., 2001). The question arises, whether such an AF4 
application can be transferred to the issue of gelatin nanoparticle characterization: (a) starting 
with the important characterization of basic gelatin raw material, as it was demonstrated that the 
presence of notable lmw gelatin fractions in the preparation batch detracts from nanoparticle 
stability (Coester et al., 2000); (b) gelatin nanoparticle characterization per se  since the 
resolution of FFF/MALS was demonstrated to exceed that of (T)EM measurements for many 
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classes of particles (Wyatt, 1998); (c) monitoring drug loading efficacy. Herewith, the separation 
of DNA loaded nanoparticles from unloaded DNA would provide a fast, convenient and 
accurate possibility of drug loading assessment. Up to now, a successful realization of such an 
analytical approach has not been published. 
 
8.2 Materials and methods 
 
Gelatin type A from porcine skin (175 Bloom), glutaraldehyde (25%), EDC (N-[3-
dimethylaminopropyl]-N´-ethylcarbodiimide hydrochloride) and cholaminchloride hydrochloride 
([2-aminoehtyl]-trimethylammonium chloride hydrochloride) were purchased from Sigma-Aldrich 
(Taufkirchen, Germany). Gelatin nanoparticles were prepared via a two-step desolvation method 
(Coester et al., 2000). Initially, 1.25 g of gelatin was dissolved in water under gentle heating (5% 
w/w). The first desolvation step was initiated by adding 25 ml acetone. After sedimentation of 
precipitated gelatin fractions over 60 s, the supernatant was discarded and the sediment was 
redissolved in water under constant heating and magnetic stirring at 500 rpm (MR 3001K, 
Heidolph GmbH, Germany). Subsequently, the pH was adjusted to 3.0 using 1 M HCl. By drop-
wise addition of acetone the gelatin was desolvated again and stirred for 10 min. Finally, 200 µl 
glutaraldehyde (25%) were added in order to stabilize the gelatin nanoparticles by intra-particular 
crosslinking of gelatin amino groups. Surface Modification: 50 mg EDC and 50 mg 
cholaminchloride hydrochloride were added and the batch was incubated for 14 hrs. The 
resulting nanoparticles were purified by triple centrifugation (16,000 g for 20 min) and 
redispersed in Milli-Q-water (conductivity < 0.04 mS/cm). 
DNA plasmid loading: 20 µg of DNA plasmid, containing the Photinus pyralis luciferase gene 
(under control of the cytomegalovirus enhancer/promoter) were incubated with surface modified 
gelatin nanoparticles in water (1.0 mg/ml). After incubation at 37 °C (using a Thermomixer 
comfort, Eppendorf AG, Hamburg, Germany) the samples were centrifugated (~8,000 g, 20 
min) and unbound plasmid was determined by UV260 spectrophotometry in the supernatant.  
Analytical instrumentation: nanoparticles were characterized using a Zetamaster (Malvern 
Instruments, Worcestershire, UK); the assigned size, polydispersity index and zetapotential values 
based on ten individual measurements. Additionally to the on-line detection methods outlined in 
Chapter 6  i.e., RI and UV spectrophotometry coupled with MALS via a miniDAWNTM - AF4 
was combined with a DAWN EOSTM (MALS, Wyatt Technology Corp., Santa Barbara, USA). 
Via that apparatus, scattered light is detected by an array of 15 photodiodes arranged at various 
angles relative to the incoming laser beam. According to light scattering theory, nanoparticles 
scatter light in anisotropic way (i.e., in a more forward direction). Consequently, the photodiodes 
placed at lower angles will detect more scattered light than photodiodes placed at higher angles. 
To enable accurate size determination of the nanoparticles, the sensitivity of eight photodiodes 
Chapter 8. Characterization of gelatin nanoparticles by AF4 
 121
was dimmed by a factor of 100 (photodiode angles: 14°; 26°; 35°; 43°; 90°; 121°; 142°; 163°). 
Thus, overexcitement of the photodiodes by huge intensities of light scattered by nanoparticles 
was avoided. Considering that small analytes (e.g., <10 nm) such as oligonucleotides or proteins 
with molar masses below 500 kDa scatter light scarcely, the sensitivity of the seven remaining 
photodiodes was retained unchanged at highest level (appendant angles: 52°; 60°; 69°; 80°; 100°; 
132°; 153°). This arrangement measured scattered light intensity concomitantly with dimmed and 
unattenuated photodiodes and enabled the simultaneous size determination of large analytes like 
nanoparticles aside small analytes such as proteins or oligonucleotides. For nanoparticle size 
determination, a detector fit/plotting method according to Debye theory was implemented. For 
molar mass determination of gelatin and other proteins, the refractive index increment dn/dc was 
set to 0.174 mL/g and the second virial coefficient was set at 0. SE-HPLC experiments were 
performed with a TSKgel G 3000 SW column (7.5 mm x 30 cm; Tosoh Biosep GmbH, Stuttgart, 
Germany). The SE-HPLC system comprised a LKB 2248 pump (Pharmacia Corp., Germany), an 
autosampling device (Spectra Series AS 100) and a vacuum in-line degaser (both from Thermo 
Separation Products, Germany). The AF4 and SE-HPLC separation experiments were performed 
at 24 °C, using a buffer with pH 7.4 (5 mM Na2HPO4*2H2O and 14 mM NaCl) for nanoparticle 
characterization, whereas gelatin characterization was performed in a buffer at pH 6.0 (2 mM 
Na2HPO4*2H2O and 14 mM NaCl). 
 
8.3 Analytics of gelatin raw material 
 
The most widely applied method for the analysis of gelatin molecular weight distributions 
within the pharmaceutical and clinical field is SE-HPLC (Barth et al., 1998). In this realm, the 
characterization of lmw gelatin specimen is most important. For instance, the mean weight 
average of succinylated gelatin - an extensively utilized gelatin-based plasma substitute  was 
found to be 43 kDa (Kaur et al., 2002). As SE-HPLC lacks absoluteness, size calibration 
standards are necessary for size determination. In case of gelatine, the use of polystyrene 
sulfonates, denatured globular proteins, standard gelatins and dextrans have been reported for 
this purpose (Pernigo et al., 1994; PAGI, 1997). Yet, considering the proneness of that procedure 
when hmw samples are to be analyzed, the use of MALS for absolute size determination of 
gelatin fractions has demonstrated to render data with higher veracity (Kaur et al., 2002). A 
typical size distribution profile of gelatin bulk solution is visualized in Fig. 86. 
According to the chromatogram, the bulk solution exhibits two fractions of gelatin 
specimen, which can be defined as hmw and lmw fractions. The borderline between "high 
molecular weight" and "low molecular weight" was assessed at 100 kDa because of two reasons: 
(a) hmw gelatin specimen are represented by a sharp, pronounced UV signal peak, enabling the 
convenient quantification of evidently two different fractions. The end of the peak descent 
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corresponds to a molar mass of 100 kDa, verified by MALS calculation. Concerning to that, the 
characterization of a 100 kDa globular protein (monoclonal antibody; F(ab´)2 fragment of 
isotype G3Κ) substantiated the accuracy of the SE-HPLC/MALS method. (b) It has repeatedly 
been reported that the molecular weight of the gelatin α-fraction matches ~100 kD (Steckert et 
al., 1992). Gelatin α-chains are the result of hydrogen-bond breaking and disruption of the triple-
helix structure of soluble tropocollagen, and they define the borderline between a sub-α fraction 
(primarily hydrolysis fragments) and β-, γ- and δ-fractions, with the latter ones being composed 
of aggregates of the main α-chain fraction (Farrugia and Groves, 1999).  
It is noteworthy to accent the criterion which assesses the suitability of gelatin batches in 
terms of nanoparticle preparation  i.e., the more hmw components present, the higher the nano-
particle stability (Coester, 2000). The established 100 kDa benchmark renders the evaluation of 
gelatin batches straightforward and the efficacy of the desolvation step can be scrutinized. 
As outlined in Fig. 87, the desolvation by acetone has a great bearing on the elution 
profile of the various gelatin batches: hmw specimen  i.e., γ- and δ-fractions  account for 58% 
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Fig. 87. SE-HPLC analysis of various
gelatin fractions associated with the
desolvation step process. According to
the UV280 elution profile, the ratios of
hmw specimen >100 kDa were 29% in
supernatant, 38% in bulk and 58% in
sediment (flow 0.7 mL/min). 
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of total gelatin mass in the sediment. Conversely, the original 38% ratio decreases within the 
supernatant by approximately 10%. Apparently, the quantification of hmw components  
running the gamut from 100 kDa up to ~500 kDa  via SE-HPLC seems to be faultless. 
Since the molecular weight composition of the precipitated gelatin is influenced by 
several parameters (i.e., organic solvent proportion, pH of the solution, temperature, time 
available for precipitation/sedimentation), the generation of precipitated gelatin batches with 
identical molecular weight properties in a reproducible way is difficult (Farrugia and Groves, 
1999). Needless to note that different gelatin raw materials will render nanoparticles which vary 
in size and stability. Therefore, reliable characterization of the molecular weight profile of the 
desolved gelatin is indispensable. It is well-known that biopolymeric hmw components may be 
artifact prone, when analyzed by SE-HPLC (due to shear degradation and upper exclusion 
limitations of the columns). Consequently, variations of separation parameters can have a deep 
impact on data reproducibility. As illustrated in Fig. 88, decreasing the elution flow volume from 
0.7 mL/min to 0.3 mL/min  changing thereby invariably other separation parameters such as 
sample residence time and system pressure  results in noticeable data change.  
Maintaining the evaluation criteria applied hitherto  i.e., assigning the first UV280 peak to 
hmw components  leads to a significant reduction of hmw components in all batches, though 
the order of hmw content remains constant: sediment (24%) > bulk (15%) > supernatant (13%). 
As the suggested bivalent MW distributions of the batches were verified by analyzing a 100 kDa 
protein which elutes concomitantly with visualized UV280 signal minima at t=18 min, the question 
of the hmw components´ whereabouts arises. 
Hence, SE-HPLC fractionation conditions have to be selected carefully and should be 
retained unchanged in order to enable proper comparison of data from experiments performed at 
different time (Barth et al., 1994). Contrarily, the overall molar mass range of gelatin specimen 
analyzed by AF4/MALS ranged from about 20 kDa to over 10,000 kDa, outranging maximal 
molar mass values yielded with SE-HPLC/MALS experiments by more than one order of 
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magnitude (Fig. 89). Because of low field strengths exerted (5%), the elution profile of the gelatin 
specimen corresponds to a characteristic molecular weight order without separating individual 
fractions. Yet, the molecular weight heterogeneity of gelatin is confirmed. 
It is to be assumed that the differences in the values of the maximal molar masses are due 
to minimized sample stress because of the moderate conditions of AF4 experiments  i.e., 
package material free separation and a 6 bar maximum of hydrostatic pressure within the AF4 
systems compared to >20 bar column pressure during SE-HPLC runs. Pertaining to that, it is 
known that especially hmw polymers in SE-HPLC experiments tend to degradation- advanced by 
abrasive shear forces exerted by column package material - what may lead to data 
misinterpretation (Barth et al., 1994). Conversely, because of greatly reduced shear forces, even 
very shear sensitive proteins can be fractionated via AF4 without running the risk of structural 
alterations (Li et al., 1997). The results shown above are in good agreement with former studies 
on molar mass distributions of natural rubbers in microgels, wherein the largest molecules 
detected via FFF were found to be more than three orders of magnitude greater than indicated 
by SE-HPLC (White, 1997).  
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Fig. 89. Analysis of gelatin bulk
solution via AF4. Due to a 5% cross
flow the gelatin specimen exhibit a
characteristic elution profile, with
smaller components eluting prior to
larger ones. Because of the absence
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detected. 
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Principally, AF4 corroborates the findings of SE-HPLC, as the share of hmw 
components accumulates in the order gelatin in supernatant < gelatin in bulk < gelatin in 
sediment. Due to the dimensions of hmw gelatin specimen, the exertion of only 10% cross flow 
is sufficient to at least double their elution time (Fig. 90). Despite the fact that those components 
are not separated as individual peaks, the elution profile changes notably, foreshadowing the 
presence of a substantial hmw fraction mainly in the sediment batch. 
The difference of the gelatin batches in their hmw content becomes evident when the 
samples are exposed to higher cross flow rates (Fig. 91). In case of sediment, 40% initial cross 
flow is sufficient to separate a hmw fraction revealing minimal molar masses of ~450 kDa, 
accounting for ~27% of total protein. In contrast, supernatant and bulk exhibit lower hmw ratios 
of 10% and 17%, respectively, thereby backing the purpose of the desolvation step. 
Referring to this, increasing the initial cross flow rates to 55% influenced data solely in 
absolute way  i.e., the proportions of hmw content of the batches relative to each other 
remained constant, ascribing the sediment fraction a greater hmw ratio (32%) than bulk (23%) 
and supernatant (18%). In all AF4 experiments the assessed maximal molar masses of gelatin 
analytes exceeded those determined via SE-HPLC/MALS, hence indicating the absence of shear 
forces and reflecting AF4 data veracity. In summary, both SE-HPLC and AF4 proved to be 
capable of evaluating the efficacy of the acetone desolvation step. Yet, as AF4 separated ultra-
hmw gelatin components without running the risk of fostering polymer degradation, AF4 inheres 
a significant asset compared to SE-HPLC. 
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Fig. 91. Separation of hmw fractions of gelatin batches with 40% (left) and 55% cross flow (right).
Increasing the AF4 resolution by changing the cross flow intensities did influence data concerning
absolute hmw contents. However, the relative proportion of hmw fraction content of the different
batches remained constant, affirming the hmw content to increase in the order supernatant < bulk
< sediment.  
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8.4 Size determination of unloaded/loaded nanoparticles 
 
Data on nanoparticle size characterization by PCS and zeta-potential measurements are 
summarized in Table 13. The zeta-potential values of both loaded and unloaded particles indicate 
the presence of interparticular forces, by this opposing agglomeration tendencies. Emanating 
from dimensions of ~256 nm, the size increase due to plasmid loading is almost negligible. 
Thereby, the plasmid strands enjoy a great steric freedom, propelling a tight packing of the 
twisted strands on the particle surface. Furthermore, the remarkably positive zeta potential of 
unloaded nanoparticles is attracting a diffuse layer of surrounding medium, thus increasing the 
hydrodynamic layer encasing the particles. Conversely, if the positive surface charge is 
countervailed by negatively charged oligonucleotides, both zeta-potential and thickness of the 
surrounding diffuse medium layer are decreased, resulting in reduced hydrodynamic diameters 
determined by PCS (Mueller, 1996).  
 
nanoparticles unloaded loaded 
size (nm; via PCS) 256 ± 1.80 269 ± 7.37 
PI (polydispersity index) 0.028 ± 0.012 0.062 ±0.038 
zeta-potential (mV) + 42 + 29 
size (nm, estimated via SEM) 150 - 300 150-300 
Rrms (nm, via MALS) 60 - 98 68 - 105 
size (nm, calc. from Rrms) 155 - 253 175 - 271 
 
 
 
SEM images of loaded nanoparticles substantiate this theory, unveiling the surface of the 
spherical nanoparticles to be smooth and unruffled (Fig. 92).  
 
 
 
 
 
 
 
 
 
In contrast to the unimodal size distributions suggested by PCS, SEM analysis  
demonstrating smaller and larger nanoparticles to be present at random - provides reason to 
Table 13. Nanoparticle characterization by PCS, SEM and MALS. Note that data derived by PCS
is prima facie inconsistent with SEM and MALS data, respectively.  
 Fig. 92. SEM picture of plasmid loaded
nanoparticles, revealing a broad nanoparticle
size distribution, as smaller (~150 nm) and
larger (~300 nm) particles are detectable in
random quantities. 
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critically reconsider PCS data: whereas SEM reveals particle dimensions to encompass 150  300 
nm, PCS assigns nanoparticle sizes of ~256 nm (unloaded) and 269 nm (loaded), respectively.  
Of course, one explanation for the differences can be ascribed to the underlying 
principles of both methods, exemplified earlier with synthetic polymer-based nanoparticles 
(Hoffmann et al., 1997; Finsy et al., 1992): the contrast of SEM pictures allows only the 
visualization of the nanoparticle core  conversely, PCS assesses the hydrodynamic radius of 
analytes. Anyway, due to the data inconsistency of SEM with PCS, a demand for accessorial 
sizing techniques appears on the analytical agenda.  
Generally, if AF4 experiments aim at providing great resolution, to apply high cross flow 
intensities is considered to be state-of-the-art (Coelfen and Antonietti, 2000). But great cross flow 
rates may cause the sample concentration at the ultrafiltration membrane to increase and thereby 
the risk of inducing artifacts via sample-sample and sample-membrane interactions is growing. 
Hence, to approach optimal separation conditions by primarily low retention levels and to 
increase the resolution subsequently run-by-run can be an appropriate procedure in the 
characterization of ultra-hmw components (Wittgren and Wahlund, 1997) (Fig. 93).  
As a consequence, cross flow intensities were increased run by run in 5% intervals, and 
conditions of initial 20% cross flow rates  which were maintained for 10 min prior to 
programmed decrease  revealed both the drawback of notable void peaks and the assett of 
sufficient nanoparticle resolution. Pertaining to that, size distributions of unloaded nanoparticles 
were determined to span a 155-253 nm hydrodynamic diameter range. In this regard, dimensions 
yielded by MALS are first to be expressed as root mean square (rms) radii, often referred to as 
radii of gyration (RG). However, RG values can easily be transferred to values expressed as 
hydrodynamic diameters  e.g., assessed by PCS  via extracting the root of 20/3 (RG)². 
Fortunately, raising the injected sample mass by a factor of 1.8 (from 0.5 mg/mL to 0.9 mg/mL) 
resulted in a commensurate increase in AUCUV280 values (from 1.56 to 2.80), did not affect size 
distribution data and had no effect on the resolution power, hence fostering MALS data veracity. 
This is the more important, as the polydispersity of hmw specimen such as ethylhydroxyethyl 
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Fig. 93. AF4/MALS analysis of unloaded 
gelatin nanoparticles. A difference in 
sample loads - 0.5 mg/mL (grey line) and 
0.9 mg/mL (black line), respectively  did 
not influence the determined sizes, 
demonstrated by absolute identical size 
distribution profiles. Substantial void 
peaks are due to low initial cross flow 
rates of 20%. 
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cellulose was shown to be constantly underestimated, if the resolution of the AF4 system is 
insufficient (Andersson et al., 2001). The dependency of nanoparticle elution profiles on even 
slight cross flow modifications is illustrated in Fig. 94. 
Obviously, the exertion of 5% cross flow intensities is insufficient for the accurate 
measurement of nanoparticle size distributions, as the sample components elute not in total 
accordance with their size: nanoparticles inhering smallest dimensions elute contemporarily with 
larger nanoparticles right at the beginning of the elution process. Consequently, the MALS signal 
of the smallest nanoparticles is superimposed by the signal of larger nanoparticles and, 
sequentially, MALS averages the dimensions of both eluting fractions to a mean radius of 80 nm. 
Due to the insufficient resolution at 5% cross flow conditions, nanoparticle aggregation 
phenomena can not be circumvented. If 10% cross flow rates are applied, the resolution is 
sufficient to achieve an elution order in strict accordance with particle sizes. Now the MALS 
signal of the smallest nanoparticles is not superimposed, and the radii of the nanoparticles which 
elute first are calculated to be 68 nm. 
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Fig. 94. Characterization of plasmid 
loaded nanoparticles using 5% cross 
flow (black line) and 10% cross flow 
(grey line). Differences in resolution 
power induced MALS to yield 
variations in determined sizes, despite 
samples are identical (highlighted by 
circle).  
Fig. 95. Characterization of plasmid
loaded nanoparticles using 10% cross
flow (grey line) and 15% cross flow
(black line). Due to sufficient
resolution, increasing field strengths do
not facilitate MALS to yield different
data on size distributions (highlighted
by circle). 
10
100
1000
0 10 20 30 40 50
time (min)
rm
s 
ra
di
us
 (n
m
)
0,00
0,05
0,10
0,15
U
V signal (V)
Chapter 8. Characterization of gelatin nanoparticles by AF4 
 129
In order to control, if 10% cross flow rates really provide sufficient resolution, the field 
strength was increased to a 15% level, what led to a further delay of the nanoparticle elution 
profile (Fig. 95). However, as far as the calculated nanoparticle size distributions are concerned, 
there is no data difference, regardless if 10% or 15% field strength is applied. In both cases, the 
distribution of the nanoparticle radii is calculated to span 68  105 nm. Hence, any possibility of 
latent data ambiguity is eliminated and the separation conditions are considered to be proper, 
because otherwise, cross flow modulations should influence the calculated size distributions.  
In summary, MALS clearly substantiates SEM data: from both analytical techniques, a 
broad particle size distribution within a diameter range of 150  300 nm can be concluded. Thus, 
PCS data  suggesting unimodal size distributions and being prima facie inconsistent with SEM 
data  is to be scrutinized when used in nanoparticle characterization.  
 
8.5 Determination of nanoparticle loading efficacy via AF4 
 
Hitherto, assessing drug loading efficacy of colloidal drug carriers like gelatin 
nanoparticles is a time consuming and somewhat tedious procedure. After incubation of drug 
carrier and designated payload the samples are subjected to several washing and centrifugation 
steps. Subsequently, the unbound payload share  e.g., plasmid or a designed oligonucleotide  is 
determined UV spectrophotometrically in the supernatants (Prbha et al., 2002). However, this 
modus operandi is delicate. If the force of gravity exerted upon the sample is too intense, the 
nanoparticles may be destructed or aggregate, thus opposing proper redispersing. On the other 
hand, a too gentle centrifugation would inevitably give rise to the possibility of not removing the 
nanoparticles from the supernatant quantitatively. Generally, the risk of DNA degradation is to 
be avoided, as fragmentation of DNA is deemed to affect the transfectivity of loaded 
nanoparticles (Walter et al., 1999).  
In this concern, the wide applicability of AF4 provides the prospect of an alternative way 
to assess loading efficacy. Being capable of separating entities like plasmids, DNA or dissolved 
drugs from undissolved drug carriers, AF4 may allow almost real-time analysis of sample 
concentrations in the incubation container. Ideally, after incubation the AUCUV decrease of the 
DNA fraction designated for loading should comply with the AUCUV increase of the (then 
loaded) nanoparticles. Consequently, the difference in signal intensities of unloaded and loaded 
nanoparticles is considered to be due to drug payload. Whereas AF4 was shown to be able to 
characterize nanoparticles qualitatively  i.e., to assess size and size distributions - the 
quantification of nanoparticle concentration in reproducible way is a precedent condition for the 
monitoring of the nanoparticle loading step.  
As outlined in Fig. 96, the correlation of nanoparticle concentration with assessed AUCUV 
values can be performed with AF4 in a reproducible way  i.e., the quantification of 
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nanocolloidal drug carriers is manageable. This is not to be taken for granted, considering a 
variety of pitfalls described in the literature associated with the AF4 analysis of samples inhering 
dimensions of ~100 nm.  
E.g., the characterization of polyorganosiloxane nanoparticles in aqueous dispersion by 
AF4 was shown to involve void peaks accounting for >50% of total UV detector signals 
(Jungmann et al., 2001). Similarly, the AF4 analysis of Janus micelles  which exhibited 
dimensions of 40  250 nm  was coming along with comparable problems: probably due to a 
notable sample loss obligatory with both challenging application and arranged separation 
parameters, the sample recovery was assumed to be 100% - but was not verified - to enable 
weight-average molar mass determination via MALS (Erhardt et al., 2003). In the course of 
monitoring nanoparticle loading efficacy, conditions such those prevailing in both examples 
outlined above would prohibit accurate analyte quantification. 
The task of separating nanoparticles from unbound DNA drug load was approached by 
surrogate experiments, e.g., the fractionation of nanoparticle-protein mixtures. Therefore, G-CSF 
as a model compound (~20 kDa) was added to nanoparticle batches and the influence of cross 
flow variations on the nanoparticle elution pattern was investigated (Fig. 97).  
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Fig. 97. Separation of G-
CSF (~20 kDa) from
nanoparticles applying a
decay of initial 20% cross
flow to 1% after 13 min
(pale line), 16.3 min (grey
line) and 19.7 min (black
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Fig. 96. Quantification of
nanoparticle concentration via
AF4/UV280 (experiments
performed in triplicate). The
assessed AUCUV values were in
sound agreement with the
individual sample concentrations:
476 ng/mL  AUC 1.966 
238 ng/mL  AUC 0.901 
119 ng/mL  AUC 0.459 
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According to the underlying principles of AF4, G-CSF elutes prior to the nanoparticles. 
Furthermore, the protein is separated from the drug carrier in base-line quality. Of course, 
variations in field strength also render a modified elution profile of protein possible, giving 
analytical leeway if a change in sample elution pattern were desired (Fig. 98).  
This flexibility of AF4 separation parameters is an essential prerequesite for both accurate 
sample quantification and size determination because superimposing of UV or MALS detector 
signals would inevitably lead to assessing incorrect concentrations or size distributions.  
In case of the fractionation of an oligonucleotide (5.4 kDa) from nanoparticles, the 
attention is directed towards a sufficient separation of void peak and oligonucleotide (Fig. 99).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Principally, small analytes tend to elute out of the channel early, adjacent to the void peak. 
The base-line separation of void peak and lmw samples by exerting intense field strengths is 
common practice. However, the committment to eliminate the void peak usually demands AF4 
operation conditions which assist potential (irreversible) adhesion phenomena, such as intense 
focusing or high initial cross flow modes. Hence, providing data on void peak intensity is a must 
Fig. 98. The possibility to
program cross flow intensities
in desired way provides a great
flexibility in assessing sample
elution profiles: initial 30%
cross flow conditions (black
line) force G-CSF to elute
earlier than 50% field strengths
(grey line). 
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Fig. 99. Fractionation of a
sample containing oligo-
nucleotide (ODN, 5.4 kDa)
and nanoparticles. The
swapping of the depicted three
individual fractograms indicates
a reproducible manner of
quantification (Srel <0.3). 
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and considered a cachet, if sample quantification is intended  in contrast to situations where 
nanoparticle characterization is a priori reduced to qualitative terms (Lao et al., 2002).  
At optimal conditions, even demanding separation tasks can be successfully approached, 
thereby maintaining due distances between each component peak (Fig. 100). 
 
 
 
 
 
 
 
 
 
 
 
 Providing sufficient resolution in order to reproducibly separate oligonucleotides, 
immunoglobulins and nanoparticles within one single run, AF4 system parameters may be 
considered to guarantee an accurate monitoring of nanoparticle loading with plasmid DNA. 
Prior to the incubation step, the amount of DNA designated for nanoparticle payload 
was assessed via AF4. Likewise, unloaded  but surface modified  gelatin nanoparticles were 
quantified and both components were subjected to incubation. Subsequently, the incubation 
batch was analyzed using conditions equally to those yielding elution profiles as illustrated in Fig. 
99. The fractograms of the particular AF4 separations are visualized in Fig. 101. 
 
According to Fig. 101, the extensive signal of the DNA plasmid yielded prior to the 
incubation is downsized  because of binding on nanoparticles - to a humble fraction of 
 
Fig. 100. Exemplifying the
broad AF4 application range in
the field of nanoparticles by a
challenging separation task:
oligonucleotides (ODN; 5.4
kDa), immunoglobuline (IgG,
150 kDa) and nanoparticles are
fractionated within 50 min. 
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Fig. 101. Fractograms illustrating
nanoparticle loading with DNA
specimen (pale line). Subsequent to
incubation, the AUCUV of the DNA
component decreases due to
adsorption upon the nanoparticle
surface. Hence, the AUCUV of
unloaded nanoparticles (black line)
experiences a gain after the
incubation step due to DNA
binding (grey line). 
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remaining unbound plasmid. Conversely, the nanoparticle UV signal intensity is increased 
commensurately. Since the AUC values can be transferred to masses of nanoparticles and 
plasmid, respectively, the loading efficacy can conveniently be determined (Table 14).  
 
prior to incubation/loading process after incubation/loading process  
DNA nanoparticles total unbound DNA 
nanoparticles 
+ DNA 
DNA load 
therof total
AUCUV 1.536 0.981 2.517 0.797 1.691 0.739 2.488
mass (µg) 20 1000 1020 10.38 1009.62 9.62 1020
AUCUV 1.602 0.996 2.598 0.850 1.807 0.752 2.657
mass (µg) 20 1000 1020 10.61 1009.39 9.39 1020
Table 14. Monitoring of two nanoparticle DNA loading processes with AF4/UV.  
 
The efficacy of two nanoparticle loading processes was assessed by AF4 to be ~50%, as 
9.62 µg and 9.39 µg, respectively, out of 20 µg DNA available were bound. Given the possibility 
of characterizing and quantifying DNA and nanoparticles in one single run, two further 
reasonable applications arise: monitoring of nanoparticle stability and durability of drug load. 
During long-term storage, size and size distribution of nanoparticles may alter, and both 
parameteres can conveniently by evaluated by AF4/MALS. On the other hand, bound DNA may 
detach from the nanoparticle surface during storage, thereby reducing the amount of drug load. 
In this case, unbound DNA will be accessible to AF4 quantification via inducing a individual 
peak in the fractogram. Conversely, the nanoparticle UV signal intensity is to be decreased by a 
commensurate degree. 
 
8.6 Summary  
 
The persisting impediments in efficient delivery of DNA with non-viral vectors can be 
attributed to three factors: (1) poor in vitro/in vivo correlation, (2) non-decomplexation of 
(plasmid) DNA from the carrier, (3) and the lack of physico-chemical characterization of 
formulations (Hussain et al., 2003). If the issue of DNA loaded nanoparticles is indeed relapsing 
due to the first factor may be deemed a matter of opinion. How to overcome the second is topic 
of extensive research and approached via adsorption and encapsulation of DNA upon/within 
nanoparticles (Singh et al., 2000). Contrarily, research on nanoparticle characterization was forced 
to take a back seat, since methods such as PCS and electron microscopy are considered to be well 
established  although data are often contradictory.  
In this concern, the aim of this chapter was to demonstrate the ability of AF4 to provide 
an overall characterization of gelatin nanoparticles, from gelatin bulk material analysis to 
monitoring of nanoparticle drug loading processes.  
Chapter 8. Characterization of gelatin nanoparticles by AF4 
 134
It was shown that gelatin bulk material can be analyzed by AF4/MALS without inducing 
artifacts. Bearing in mind the contribution of hmw components to gelatin nanoparticle stability, 
the feature of AF4 to analyze hmw gelatin without inducing shear degradation is deemed a crucial 
parameter in evaluating bulk preparation efficacy by desolvation steps. Pertaining to that, SE-
HPLC was demonstrated to yield similar results as far as the order of hmw ratios in different 
gelatin batches is concerned. However, MALS proved the hmw gelatin specimen to be abraded 
during SE-HPLC analysis. As this phenomenon detracts from data veracity  and thus from 
accurate bulk evaluation  AF4 is considered to be more suitable in gelatin bulk material 
assessment. Against the background of (hmw) polymer-based drug delivery systems, the AF4 
application performed is of great value to upgrade the spectrum of analytical tools in 
pharmaceutics (Langer, 1998). 
For the first time, the determination of size and size distribution of gelatin nanoparticles 
by means of AF4/MALS was performed. Loaded and unloaded nanoparticles were characterized 
and the data was put into correlation with PCS and SEM results. Because MALS is able to size 
nanoparticles subsequent to AF4 separation, data accuracy is superior to PCS measurements, 
where the underlying principles force the samples to be characterized in the whole batch (Wyatt, 
1998). On the other hand, SEM is reliant on sample preparation. In conclusion, AF4 was shown 
to assess nanoparticle size with high confidence. Thus, data derived from other techniques and 
being prima facie inconsistent with each other  e.g., PCS versus SEM - merge into a coherent 
picture. 
This AF4 application was developed further to render a new way of monitoring the drug 
loading process of nanoparticles possible. AF4 separation parameters were established which 
enable the separation of colloidal drug carriers and the designated drug load simultaneously in 
one single run. Moreover, the reproducibility of AF4 in nanoparticle quantification was 
satisfactorily shown. Based thereon, the amount of DNA binding on the colloidal carrier was 
quantified aside unbound DNA remaining in the incubation container. It is to be outlined that 
AF4 is capable to determine the efficacy of nanoparticle drug loading without precedent sample 
preparation essential in prevalently applied methods (e.g., centrifugation and redispersing). 
The suitability of AF4 to conveniently monitor stability of colloidal drug carriers and 
decomplexation of DNA during storage is additionally valorizing the developed application.  
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9 Particulate matter in parenterals: a case study 
 
9.1 Introduction 
 
The control of key features of a product and the respective manufacturing processes are 
essential to quality assurance. With parenteral formulations, important variables influencing 
product quality are often discussed in absolute terms. While dealing in absolute yes/no 
statements may be philosophically satisfying, this practice can not accommodate all real world 
scientific problems – among those are problems of sterility and particle contamination associated 
with the mass production of parenterals (Knapp, J. Z., 1998). Referring to the latter, particulate 
matter may be described as insoluble material inevitably present in injectable solutions (Groves, 
1991). It is prevalently known that any recipient of parenteral medication such as infusion will 
receive a significant particle load encountered therein. In the case of infusions, this load was 
estimated to potentially encompass many thousand individual particles in µm range (Puntis et al., 
1992). 
In case the particle load contains visible specimen the formulation is to be rejected, since 
it is not acceptable to hazard the consequences of vascular occlusions subsequent to intravenous 
application. Pertaining to subvisible particulate matter, there is little evidence of clinically 
deleterious effects. Nevertheless, studies have identified the presence of particles originating from 
parenterals in lung tissue, lymph nodes and liver, causing granulomas and inflammatory 
responses. Additionally, investigations in neonates also have unveiled potentially serious effects 
linked to particles originating from infusions (Allwood, 2000).  
Whereas the absence of visible particulate matter in parenterals is generally considered as 
a must, the presence of subvisible particulate matter is permitted within narrow margins. Yet, the 
stated upper limitations in particle size and numbers as well as designated analytical methods for 
particle characterization vary within the national pharmacopeias (e.g., USP, Ph. Eur., Japanese 
Pharmacopeia). One reason therefore may be the lack of global harmonization of the results of 
particle analysis. E.g., there is no commonly accepted framework for the definition or analysis of 
the outcome of a manual inspection for visible particles (Knapp, 1998).  
In this realm, the control of particle contamination in injectable products is a two-fold 
problem for the pharmaceutical industry, and both issues appear to necessarily conflict with each 
other: (a) the provision of a contamination-free product at (b) economic costs acceptable to the 
user. Nowadays, processing conditions for parenteral solutions are designed to substantially 
minimize the absolute dimensions of particulate components present in the formulation down to 
~0.1 µm. Generally, there are strong recommendations that terminal in-line filtration is deemed 
best practice, especially for large volume parenterals (Allwood, 1998).  
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Basically, the source of particulate matter is manifold: packaging material, manufacturing 
variables such as filters, air flow, equipment and housekeeping procedures as well as the active 
drug and excipients pose possible sources of particle contamination (Borchert et al., 1986). 
However, a constant threat to particle-freedom is in conjunction with the main dogma 
guaranteeing general safety of parenterals: product sterility achieved via sterilization. 
Unfortunately, the effects of sterilization are two-edged: although glass and metal can withstand 
the temperatures exerted during heat sterilization (~170 °C in case of dry heat and ~120 °C with 
moist heat), there are relatively few “engineering” type plastics and a limited numer of rubbers 
which retain satisfactorily physical properties and, hence, do not facilitate particle contamination 
(Frampton and Dean, 2000). Additionally, the parenteral product per se may experience a 
deleterious effect due to sterilization. E.g., bottled dextran solutions for clinical use were reported 
to be prone to severe insoluble particle formation during sterilization (Veljkovic et al., 1989). 
Contrarily, protein formulations in primary containers are generally not amenable to sterilization 
due to their proneness to thermally induced denaturation. As a consequence, package material is 
to be sterilized prior to filling the sterile filtrated product into the prime container. 
In terms of visible particles, quantification is commonly performed via human visual 
inspection, though mechanic inspection systems - basing on the autoscanning and evaluation of 
video/camera images – are available (Knapp, 1986). Subvisible particle quantification is 
approached via microscopic methods, light scattering, Coulter technique, light obscuration and 
holographic techniques. Similarly, a broad variety of methods is implemented for particulate 
matter identification, ranging from standard techniques like chromatography, atomic 
spectroscopy and molecular spectroscopy (e.g., Raman spectroscopy, mass spectrometry) to 
advanced techniques such as x-ray energy dispersive spectroscopy (Allwood et al., 1998).  
In summary, it is noteworthy that despite the variegated spectrum of analytial techniques 
applied, the final parenteral product quality depends on product quality prior to inspection and 
the parameters of the inspection process, respectively (Knapp, 1998).  
 
9.2 Background  
 
A pharmaceutical G1 antibody was formulated in phosphate buffered medium at pH 5.2 
(50 mg/mL, 0.8 mL, 2R glass vials). At that time, the protein solution was proved to be free of 
visible and subvisible particulate matter and conformed to appendant specifications of protein 
stability, the latter assessed by protein activity assay, SE-HPLC and ion exchange 
chromatography (IEX). During long-time storage over 12 months at 5 °C within one production 
lot – encompassing several thousand vials – a visible component emerged in some vials at 
random after arbitrary storage time. Due to the peculiar feature of that particulate specimen to 
ostensibly vanish/dissolve during moderate vial shaking, the problem of how to seize the 
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particles analytically emerged. In this regard, the question of particle origin is of crucial 
importance. Given the background that – in accordance with empirical knowledge of many 
pharmaceutical formulators - the development of particulate matter during storage in protein 
parenterals in many cases is to be ascribed to insufficient protein drug stability, the analytical 
investigation primarily focused on parameters concerning immunoglobulin stability (Wang, 1999). 
The more, as the shelf life generally required for economic viability of a typical protein 
pharmaceutical product is considered to be 18-24 months (Cleland et al., 1993).  
It is the aim of this chapter to present a case study of a parenteral product, wherein 
analytical challenges – though of daunting nature – were approached, combining state-of-the-art 
methods like light obscuration, SE-HPLC and PAGE with (relatively) new methods such as AF4, 
MALS and ultra-sensitive microcalorimetry. Various data – even if at first glance inconsistent 
with each other – are inter-related in order to add up to a final conclusion concerning particulate 
matter origin. 
 
9.3 Providing evidence of particulate matter  
 
Subjecting numerous (>100) vials to visual inspection revealed the presence of whitish 
particle specimen accumulating at the center of the container bottoms. Bringing the vial volume 
into turbulance by a single limp-wristed agitation, a fine particulate haze spiraled and was visible 
for several seconds before the particles seemed to vanish and to re-dissolve. The particles causing 
that haze appeared to be crystalline in nature and exhibited maximal dimensions of approximately 
100 µm. Analysis by light microscopy substantiated the crystalline impression (Fig. 102). 
 
In case the moderate manual agitation step was repeated, no particles were visible. 
Conversely, vial shaking had no notable impact on the data of light microscopy (Fig. 103). 
Whereas subsequent short-time storage of the vials did not result in visible particle recovery, 
Fig. 102. Light microscopic analysis 
of a vial volume revealing visible 
particulate matter, highlighted by 
black circle (scale bar represents 100 
µm). 
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storage for 6 months at 5 °C enabled the particles in most cases (>80%) to regain visible 
dimensions exceeding ~50 µm. 
 
Although the visible inspection of parenterals renders definite yes/no statements in 
respect of visible particulate matter contamination, these data are subjective values and not to be 
expressed in absolute quantitative terms. Furthermore, one should be aware that consistent levels 
of visible particulate matter does not mandatorily imply consistent quality since the origin of 
visible and subvisible particles can vary (Knapp, 1986). Almost without exception the detection 
of visible specimen in parenterals is associated with the presence of subvisible components – the 
turnaround-statement, however, is not valid. Pertaining to that, the analysis of subvisible 
particulate matter in parenterals by light obscuration is well-established (Boom et al., 2000; 
Backhouse et al., 1987).  
In order to verify the findings above – i.e., shear stress leads to a reduction of particle 
size, but does not relieve the particle contamination per se – the vials were subjected to light 
obscuration analysis (SVSS-C40, PAMAS GmbH, Rutesheim, Germany) (Table 15).  
 
number of particles per 
mL with dimensions of 
vials revealing visible 
particulate matter  
(no shear stress) 
vials revealing visible 
particulate matter  
(shear stress via shaking)
vials without visible 
particulate matter  
≥1 µm 137,592 159,717 18,279 
≥2 µm 44,389 42,321 8,731 
≥10 µm 123 105 291 
Table 15. Light obscuration analysis of immunoglobulin solutions (n=9, Srel <1.6; data in 
cumulative presentation). Note that shear stress has only a humble impact on particle numbers. 
 
According to Table 15, the findings of visible inspection are corroborated: vials exhibiting 
visible particles contain a considerably greater number of particles with dimensions beyond 1 µm 
and 2 µm, respectively, than vials without a visible component. Thereby, the exertion of shear 
Fig. 103. After manual vial shaking 
no visible components were to be 
detected by visual inspection. 
Nevertheless, analysis by light 
microscopy verified the presence of 
particulate matter (highlighted by 
black circle) in the two-digit µm range 
(scale bar represents 100 µm). 
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stress via shaking has virtually no impact on the data, i.e., the extent of particle contamination 
remains constant. Nevertheless, the results are consistent with the outcome of visual and 
microscopic inspection, inasmuch as shaking induces larger particulate entities – i.e., greater than 
2 µm – to disintegrate into smaller particles. Consequently, the number of particles ≥1 µm 
increases. It is not to be expected that vial volumes without a visible fraction contain more 
particles ≥10 µm than the contaminated batches. Anyway, the discrepancies are too minute to 
draw an unambiguous deduction. Interestingly, the assessed particle levels are sufficiently low in 
order not to contravene regulatory standards.  
In summary, the precarious issue of the whereabouts of visible particulate matter 
subsequent to shear stress was clarified: visible particulate specimen disintegrate into smaller 
entities and are amenable to analytics via light microscopy and light obscuration.  
Basically, the size and structure of visible protein entities – i.e., protein precipitates 
following precipitation, aggregate growth and ageing - in agitated volumes is dependent on the 
exerted shear (Byrne et al., 2002). In that realm, whey protein particles were demonstrated to 
disappear when subjected to shear stress. It was hypothesized that - once formed - aggregates 
reach a sufficiently large size, agitation leads to shear induced particle breakage or erosion, which 
in regimes where particles are smaller than turbulent microscale impellers occurs mainly as a 
result of fluid-induced stresses (Spicer et al., 1996). In general, the principal reversibility of the 
formation of protein precipitates back to native state protein is well-documented in the scientific 
literature (De Young et al., 1993) -  and can arrestingly be demonstrated in any laboratory by 
adding 10 mL acetonitrile to albumin solution (10 mg in 10 mL) and redissolving the generated 
protein precipitates by adding 10 mL of water. On the other hand, it is known that precipitates of 
inorganic material such as buffer components or additives are – once formed – highly unlikely to 
redissolve (FDA, 1994). As a consequence, the information above may facilitate to hypothesize a 
tendency of the particle origin to be not proteinic. 
 
9.4 Investigations by SE-HPLC and SDS-PAGE 
 
Since the development of particulate matter in solutions as a consequence of protein 
aggregation is a frequently encountered problem during shelf life studies, manifold analytical 
methods have been applied in order to elucidate that issue. Two techniques turn out to enjoy a 
great acceptance, i.e., SE-HPLC and PAGE (Fletcher et al., 1992). Both methods enable the 
analysis of aggregation and, thus, provide data for clarification of protein precipitates´ origin. It is 
to be outlined that protein aggregation in solution will not necessarily lead to precipitation, as the 
presence of insoluble aggregates will depend largely on the solubilizing properties of the solvent 
and the nature of the aggregates formed (Charman et al., 1993).  
Chapter 9. Particulate matter in parenterals: a case study 
 140
Consequently, vials revealing no visible particles were subjected to SE-HPLC/MALS 
analysis to assess the presence of soluble aggregates (Superose 6HR 10/30, Pharmacia, Germany; 
elution medium PBS pH 7.5, flow 0.5 mL/min) (Fig. 104). 
 
 
As illustrated in Fig. 104, vial volumes free of visible specimen exhibited a marginal 
aggregate fraction (<0.5%). According to MALS, the aggregates are attributed molar masses of 
~302 kDa, pointing out the presence of dimer and the absence of higher-order aggregates. 
Referring to that, the sensitivity of light scattering in terms of detecting even smallest amounts of 
(hmw) aggregate specimen is known (Wyatt, 1998). In case the visible particulate matter is due to 
protein aggregation, vials revealing a visible component are expected to differ from 
inconspicuous vials in aggregate content (Fig. 105).  
Fig. 105. Comparison of vial volumes with (left) and without (right) visible particles. Note that 
both samples appear absolute identical according to MALS90° (▪▪▪▪) and UV280 signals (----). 
 
Because the samples analyzed by SE-HPLC exhibited no discrepancies in MALS and 
UV280 detection, regardless of the findings of visual inspection, a relation of the presence of 
visible particles with protein instability phenomena is deemed unlikely – the more, as the samples 
Fig. 104. Analysis of vial 
volumes without visible 
particulate matter via SE-
HPLC/MALS/UV280. Besides 
monomers (2), remote aggregate 
(1) and fragment fractions (3) 
were detected. Assessed MW 
values were ~150 kDa for the 
monomers and ~302 kDa for the 
aggregates, indicating dimers to 
be the main aggregate specimen.  1,E+04
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were not subjected to processes such as filtration or centrifugation prior to analysis. Data of a 
more comprehensive investigation by means of SE-HPLC are listed in Table 16.  
 
sample aggregate (%) monomer (%) 
experiment a: 
vial volume with visible particles 0.440 99.560 
---- 
vial volume without visible particles 0.439 99.561 
experiment b: 
vial volume with visible particles 0.437 99.563 
---- 
vial volume without visible particles 0.436 99.564 
Table 16. Data on monomer and aggregate content of various vial volumes, derived by SE-
HPLC/UV280 experiments (for all data n=3, Srel <1.1, no sample preparation performed). 
 
Assessing the aggregate content of vials with/without visible particulate matter resulted in 
identical data. Given the background that the presence of particulate matter had no impact on the 
values of AUCUV280 detection, according to SE-HPLC analysis the particle formation in 
immunoglobulin solutions is hardly to be put down to protein instability.  
On the other hand, case studies were reported where protein solutions underwent severe 
protein precipitation that was not reflected in a notable increase in soluble aggregates. E.g., G-
CSF solutions were shown to develop precipitates though the ratio of soluble aggregates – mainly 
dimer - remained constant and did not exceed 3% of total protein, according to SE-HPLC data 
(Bartkowski et al., 2002). It may be hypothesized that lmw aggregates (dimer, trimer, etc.) inhere 
immense reactivity and undergo further aggregation either between themselves or with monomer 
specimen. As a consequence, their steady-state concentrations will remain low and SE-HPLC will 
solely detect a slight decrease in monomer concentration, if any. In the long run, a corresponding 
gain in hmw aggregates may result in visible particle formation. That even minimal amounts - 
<0.1% of total protein, depending on the concentration - of insoluble aggregates can cause 
turbidity and visible particle contamination, matches those phenomena (Hoffmann, 2000). 
Additionally, small quantities of low soluble aggregates can render the formation of protein 
crystals as defects (Bondos et al., 2000).  
The fact that HPLC analysis yields no results on hmw aggregates does not imply PAGE 
to fail in detecting those specimen, too. Recent investigations demonstrated SDS-PAGE to be 
successfully applied in the retrieval of hmw protein specimen (Bondos and Bicknell, 2003). 
Insoluble protein aggregates are considered to immobilize within the pockets of the gel beds 
during analysis and to be still amenable to subsequent staining processes. Results of SDS-PAGE 
analysis of various vial volumes are presented in Fig. 106 (Laemmli method, NU-PAGE 10% 
Bis-Tris-Gel, colloidal blue staining, Invitrogen GmbH, Karlsruhe, Germany).  
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Referring to Fig. 106, no notable difference can be detected between the immuno-
globulin batches. All samples exhibit an intense monomer band assigned ~150 kDa by 
comparison to molecular weight (MW) standards, matching the theoretical value. Furthermore, 
three fragment specimen are unveiled to be present in all solutions: two more pronounced bands 
in the MW sectors of ~70 and ~30 kDa and a vague band in the range of ~50 kDa. Of course, 
the protein specimen reveal greater staining intensities at higher sample loads (8 versus 4 µg). In 
terms of higher-order specimen, samples drawn from particle-contaminated solutions carry the 
impression of revealing slightly higher dimer ratios than particle-free volumes, because the bands 
accounting for dimer (~300 kDa) are more pronounced. Yet, the differences are unimpressive. 
PAGE data back the findings of SE-HPLC, inasmuch as no differences in protein stability could 
be detected between immunoglobulin solutions with and without visible particulate matter, 
respectively – thus disclaiming the particles´ nature to be proteinic. 
 
marker kDa 
200  
116  
66  
22  
37  
protein 
standard
8 µg 
protein 
standard
4 µg 
marker 
without 
particles 
8 µg 
without 
particles
4 µg 
with 
particles 
8 µg 
with 
particles
4 µg 
Fig. 106. SDS-PAGE analysis of immunoglobulin solutions revealing visible particulate matter 
(with particles) and particle-free volumes, resp. (without particles). Molar mass determination is 
enabled by molecular weight standards (marker); immunoglobulin bulk solution was analyzed to 
facilitate evaluation (protein standard); protein load per lane was 8 and 4 µg, resp. 
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Unfortunately, literature inquiries complicate the circumstances: precipitated pellets of 
porcine growth hormone were analyzed by reducing and non-reducing SDS-PAGE but neither 
technique detected the presence of hmw or lmw components, even after subjecting the 
precipitates to SDS solubilization (Charman et al., 1993). Protein concentrations falling below the 
minimal detection limit of PAGE or absolute irreversibility of the precipitation process may be 
cited as explanations therefore. 
Nevertheless, in conclusion, data of SE-HPLC and PAGE exonerate the immunoglobulin 
from inhering insufficient stability – and consequently from being the source of particle 
formation – as no discrepancies between the investigated vial volumes were to be elucidated. 
 
9.5 Microcalorimetric experiments 
 
Microcalorimetry – often referred to as ultra-sensitive differential scanning calorimetry 
(DSC) – measures the difference in heat uptake between a sample solution and an appropriate 
reference such as buffer with increase in temperature. In concerns of protein stability, DSC data 
are often expressed in Tm values. Tm – effectively termed the transition peak – is defined as the 
temperature at which 50% of the protein molecules are unfolded or, in an ideal dynamic 
reversible two-state equilibrium, the temperature at which a protein molecule spends 50% of its 
time folded and the residual time unfolded (Cooper et al., 2001). Hence, in case the presence of 
particulate matter in immunoglobulin solutions were due to alterations in the protein´s tertiary 
structure, DSC data may unveil discrepancies between sample batches with and without visible 
specimen, respectively.  
A thermogram of a particle-free vial volume is depicted in Fig. 107. The assessed Tm 
value of 72 °C is consistent with Tm data of other dissolved G1 immunoglobulins, which were 
determined to be 74 °C (Vermeer et al, 1998). In the course of the experiments (CSC Model 
6100, cell volume 299 µL; Calorimetry Sciences Corp., USA; scan rates 0.5-1 °C/min), various 
vial volumes were ultrafiltrated (Vivaspin 6, polyethersulfone, 20 kDa cut-off, Vivascience AG, 
Fig. 107. DSC data for thermal protein 
unfolding in vial volumes exhibiting no 
visible particulate matter. Tm was 
determined at 72 °C.  
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Hannover, Germany) in order to yield protein-free blank solutions and to provide dilution 
medium, respectively (protein solution from vial volumes diluted down to 0.5-2.5 mg/mL).  
In contrast to the unimodal heat transition of particle-free vial volumes, antibody 
solutions containing visible particulate matter unveiled a different DSC profile (Fig. 108). 
 
 
 
 
 
 
 
 
 
 
According to Fig. 108, the presence of visible particulate matter induces the heat 
transition to exhibit a bimodal pattern: besides the peak representing the unfolding of the 
immunoglobulin (Tm ~70 °C), a heat energy uptake  - beyond Tm and up to 85 °C – was detected. 
If that divergency is due to protein precipitates present in the sample is not to be explained 
plainly: unfolded protein is sticky stuff, and most will aggregate upon thermal denaturation. This 
aggregation is commonly exothermic and irreversible, causing a distortion of the DSC 
endotherm, compounded with noisy traces at higher temperatures because of convection of 
clumpy aggregates in the apparatus cell (Cooper, 2001). Hence, experiment reproducibility is 
generally low.  
In order to scrutinize the origin of the detected bimodal heat transition, antibody bulk 
solution was subjected to heat stressing (60 °C). After 8 hrs, the solution was clear and appeared 
to be free of turbidity and particles when analyzed by visual inspection, but revealed an increase 
in soluble aggregate content by ~4%, verified by SE-HPLC and AF4 analysis. DSC data of heat-
stressed antibody solution is shown in Fig. 109. 
The results are on the main lines in concordance with data of particle-contaminated 
immunoglobulin solutions: protein unfolding is expressed by a Tm of ~71 °C, but the intensity of 
the appendant peak is considerably lower than the signal detected in particle-free batches. 
Furthermore, endothermic heat transitions can be monitored at temperatures above Tm, 
extending to ~88 °C. Repeating the experiments – though facing low reproducibility – 
substantiated the findings, as bimodal heat transitions appeared immanent to the heat-stressed 
solutions. Generally, even in the absence of a priori aggregation phenomena, thermal unfolding is 
rarely completely reversible, since exposure of the unfolded protein to elevated temperatures can 
lead to improper refolding, proline isomerization, deamidation and other chemical changes 
Fig 108. Thermogram of sample vials 
containing visible specimen. In 
addition to a Tm of ~70 °C, an 
endothermic transition can be 
determined, spanning a range from 
~73-85 °C. 
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(Cooper, 2001). It may be assumed that this is the reason why little is published addressing DSC 
analysis of protein solutions which have already underwent aggregation prior to the experiments. 
 
 
 
 
 
 
 
 
 
 
 
Reviewing the DSC results gives rise to the impression the bimodal heat transition of vial 
volumes containing visible particles may be due to protein instabilities and changes in tertiary 
structure. Yet, G1 antibodies were demonstrated to exhibit bimodal heat transitions and multiple 
transition temperatures, what was ascribed to the build-up of the antibody molecules by various 
protein units – i.e., heavy and light chains (Hoffmann, 2000). Moreover, the potential presence of 
molten globule intermediates can affect DSC data, as the kinetically trapped high-energy folded 
states are considered to be reflected in exothermic processes (Epand and Epand, 2003).  
In order to verify a possible influence of changes in protein structure, protein aggregates 
and proteinic particulates on DSC data, another 150 kDa monoclonal antibody (MAB, targeted 
on hepatitis B-virus) was driven into protein precipitate formation via short-term stress at 65 °C. 
Thereby, it was attempted to induce particle contamination comparable to the situation within 
the vial volumes of the immunoglobulin developing visible particulate matter during long-time 
storage at 5 °C (Table 17).  
 
size of particles 
present per mL 
vial volumes 
without visible 
particulate matter 
(shaken) vial 
volumes revealing 
visible particles 
MAK solution  
-  
unstressed 
MAK solution 
-  
thermal stress 
≥1 µm 18,279 159,717 11,333 135,142 
≥2 µm 8,731 42,321 6,867 56,942 
≥10 µm 291 105 383 1,992 
Table 17. Light obscuration data of two immunoglobulin solutions, subjected to various 
conditions (n=9, Srel for all data <1.8). 
 
As outlined by Table 17, the particle contamination of MAK solutions was developed by 
thermal stressing to levels comparable to the situation in particle-containing vial volumes – as far 
Fig. 109. DSC data of heat-
stressed antibody bulk solution. 
Note the bimodal heat transition 
and that the peak attributed to 
thermal unfolding (Tm ~71 °C) is 
eclipsed, compared to the results 
of particle-free solutions (refer to 
Fig. 109).  
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as particles in the one-digit µm range are concerned. In terms of particles greater than 10 µm, the 
contamination levels differ notably. Pertaining to that, protein solutions were demonstrated to 
vary substantially in the contamination levels with particles larger than 10 µm, although they 
contained identical amounts of smaller particles (i.e., <2 µm). The main parameters accounting 
for this phenomenon were found to be protein class and the kind of stress parameter applied for 
particle generation (Mueck, 2002).  
The thermogram of unstressed MAK solution reveals a Tm value of 77 °C and an 
asymmetrical heat transition profile which is typical for immunoglobulins (Fig. 110). 
Similarly to the DSC data of the verum immunoglobulin (refer to Fig. 107), the transition 
peak is flanked by various “shoulders”. This behavior may be attributed to the formation of small 
aggregates (dimers, etc.), as suggested in previous DSC experiments (Fransson et al., 1997). Since 
dimerization was found to be the main aggregation pathway of the immunoglobulin when 
exerted to heat stress, this matches the data derived hitherto. DSC analysis of heat-stressed MAK 
solutions suffering particulate contamination bears out bimodal heat transitions (Fig. 111).  
 
 
Similar to the results on the verum immunoglobulin, the presence of particles in MAK 
solutions reduces the intensity of the unfolding endotherm. Thereby, the value of Tm remains 
constant (77 °C). However, in contrary to the findings of particle containing verum vial volumes, 
Fig 110. DSC data of an unstressed 
monoclonal antibody (MAB, 150 
kDa, Tm ~77 °C).  
Fig. 111. Thermograms of unstressed 
MAK solution inhering minimal particle 
contamination and MAK solution 
revealing severe particle contamination due 
to heat stress. Note that heat transition 
profiles differ considerably. 
unstressed MAK 
heat-stressed MAK 
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the additional endotherm signal causing a bimodal heat transition profile emerges at temperatures 
below Tm, ranging within ~55-75 °C.  
In summary, DSC experiments reveal a tendency to ascribe the presence of visible 
particulate matter in the vial volumes to changes of the protein´s tertiary structure. Subjecting 
particle-free immunoglobulin solutions to thermal stress induces DSC data to exhibit a 
characteristic bimodal heat transition profile similar to that derived from vial volumes containing 
particulate matter. This phenomenon was only partially corroborated by experiments with MAK 
solutions: though heat-stressed MAK reveals a bimodal heat transition curve, the additional DSC 
endotherm was developed at temperatures below Tm, thus hampering unambiguous data 
interpretation. 
 
9.6 Particulate matter analysis by AF4/MALS and filtration 
 
The use of techniques applying light transmission and light scattering for the analysis of 
particulate specimen is well established. Tests for clarity or transparency – based on light 
transmission – are aiming to quantify the amount of light which passes through the formulation 
in the primary container. Some pharmacopoeia tests require a certain level of light transmission 
to be achieved in order that particulate contamination can be checked, e.g., USP XXXIII (Dean, 
2000). Yet, considering that the immunoglobulin solutions reveal an a priori opalescence due to 
the high protein concentration, the application of light transmission tests for the characterization 
of visible particulate matter in vial volumes may be deemed futile. Conversely, the detection of 
even minimal amounts of particles will not be impeded by opalescent solutions, due to the high 
sensitivity of light scattering on µm sized analytes (Wyatt, 1993).  
In order to scrutinize the sensitivity of MALS in the detection of particulate matter, 
parenteral package containers were subjected to various processes that package materials 
normally encounter in the course of manufacturing and production of pharmaceuticals (Fig. 112). 
To provoke particulate matter generation, 20R glass vials were sterilized by dry heat (180 °C, 20 
min), filled with 5 mL Milli-QTM-water, stored at –80 °C for 24 hrs prior to further 24 hrs storage 
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Fig. 112. Particulate matter 
growth in 20R glass vials according 
to successive order of 
manufacturing and production 
processes (data derived by light 
obscuration, n=9, Srel  for all data 
<2.1; refer to text). 
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at 5°C, were exposed to lyophilization applying state-of-the-art process parameters, and finally 
refilled by adding 5 mL Milli-QTM-water. Referring to this, it is known that besides by drug 
instability, particulate matter can emerge in parenterals/package materials during processing, e.g., 
by sterilization, freezing and lyphilization (Gebhardt et al., 1996). According to Fig. 112, the final 
lyophilization step accounts for the lion´s share of particulate contaminates, whereas light 
obscuration data ascribes sterilization and freeze/thaw processes to induce solely minor 
particulate contamination. Conversely, AF4/MALS analysis of the sample batches 
prior/subsequent to the freeze/thaw cycle reveals a notable increase of scattered light intensity 
due to particles in the higher nm range and µm range, which emerged during freeze/thawing (Fig. 
113).  
 
 
According to these results, AF4 seems qualified for the analysis of vial volumes revealing 
particulate matter contamination. Bearing in mind the failure of light obscuration in monitoring 
particulate entities generated by freeze/thaw processes – but AF4 unveiling substantial particulate 
matter originating therefrom -, AF4 appears all the more a good choice in analytical challenges 
where even light obscuration detects notable results – i.e, in the differentiation between 
immunoglobulin solutions with and without visible particulate matter. Concerning that task, AF4 
recently succeeded in the fractionation of particulate samples in the two-digit µm range, thereby 
approaching sample components coming up to visibility (Wahlund and Zattoni, 2002).  
Such micrometer analytes are separated in an elution mechanism referred to as steric- or 
lift-hyperlayer mode - in contrast to submicrometer components, which are fractionated in 
normal mode (Caldwell, 2000). As a consequence, visible particulate matter in the 
immunoglobulin solutions is expected to be separable from dissolved protein specimen. In the 
first Flow-FFF report addressing steric mode separations applied flow rates of 20-40 mL/min 
were reported – causing immense hydrostatic pressure within the system (Chen et al., 1988). In 
Fig. 113. In contrast to light obscuration, the sensitivity of AF4/MALS proves to be sufficient for 
detection of particulate matter induced by manufacturing processes: container volume prior (left) 
and subsequent (right) to freeze/thaw cycle. Since the particles reveal no UV280 absorbance, UV 
spectrophotometry (black curve) fails detection – whereas the sensitivity of MALS90° (grey curve) 
is expressed by intense signals. AF4 parameters: 25% cross flow is reduced to 0% after 13 min, 
forward flow 1 mL/min.  
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contrast, today´s advanced channel set-ups enable steric mode separations to be performed with 
flow rates below 1 mL/min, thus reducing potential shear stress towards zero. Given the 
background of the visible particles´ proneness to physical degradation due to shear, focus step 
and intense field strenghts were avoided during the AF4 experiments (cross flow 10% for 10 
min). However, AF4/MALS could detect no difference between the vial volumes (Fig. 114).  
 
Even if the intense void peak – due to the absence of focusing – is suspected to 
superimpose light scattering signals of particulate matter eluting in steric mode, the samples were 
expected to reveal different void peak intensities, because of varying contents of particulate 
specimen. These data are substantiated by UV/MALS analysis, where the signal charts are shown 
to be virtually interchangeable, regardless of the findings of visual inspection (Fig. 115).  
  
 
It may be argued that due to the dilution (by factor three) of the vial volumes prior to 
AF4 analysis the particulate matter may have redissolved, thus avoiding detection. However, the 
drawbacks of contingent re-dissolution of the particulate specimen are mandatorily associated 
with (semi)-chromatographic methods such as AF4 and HPLC due to the use of elution media. 
Another explanation may be that the cross flow – although of moderate intensity – forces µm 
Fig. 114. Analysis of vial 
volumes with (black line) and 
without visible particles (grey 
line) by means of 
AF4/MALS. The intense 
void peak is due to moderate 
AF4 separation conditions. 
void peak 
monomers aggregates 
Fig 115. UV280 detection 
(exploded view) proves 
particle-free (grey curve) and 
particle-contaminated antibody 
solutions (black curve) to 
reveal equal aggregate ratios 
(0.7%). Similarly, molar masses 
of monomer (150 kDa) and 
aggregate fraction (300-1200 
kDa) were calculated to be 
identical in both solutions.  
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sized particles into close proximity to the membrane, thus giving rise to potential adsorption 
phenomena and consequently burking detection (Schimpf et al., 2000). Pertaining to that, 
running the risk of potential analyte adsorption can be circumvented by performing AF4 analysis 
without exerting field strengths, resulting in a separation mechanism referred to as capillary 
hydrodynamic chromatography (CHDC) (Shiragami, 1991). Thereby, larger analytes are eluting 
prior to smaller analytes, as exemplified by the analysis of vial volumes containing visible 
particulate specimen (Fig. 116).  
Due to the accuracy of the molar mass calculation via MALS, the eluting components can 
be separated into two individual fractions: a fraction containing solely antibody monomers – 
verified by the unimodal mass distribution throughout that fraction – which elutes subsequent to 
a fraction encompassing monomers but mainly higher-order specimen (dimer, aggregates, 
particles, etc.). A quantitative analysis of the different protein solutions is presented in Table 18. 
 
sample AUC≥monomer AUCmonomer ≥monomer (%) monomer (%) 
vial volume without 
visible particles 2.16 11.48 15.83 84.17 
vial volumes with 
visible particles 2.29 11.56 16.50 83.50 
Table 18. AF4 analysis of vial volumes without exerting field strengths (n=6; Srel for all data 
<2.7).  
In vial volumes revealing visible particles the ratio of the fraction “≥monomers” exceeds 
the same fraction detected in particle-free vial volumes by 0.67%. It may be hypothesized the 
visible components for the most part to remain physically intact during separation, thus 
AUC≥m AUCm 
~150 kDa 
Fig. 116. Performing AF4 separation without exerting field strengths results in a characteristic 
elution profile: larger analytes are eluting prior to smaller analytes, i.e., particles and higher-order 
aggregates (AUC≥m) elute earlier than monomers (AUCm). Due to the pronounced break of the 
molar mass marks at t=2 min, a distinct borderline between the 150 kDa monomer fraction and 
higher-order analytes can be set.  
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contributing to the AUCUV280 of the fraction eluting first. Yet, the difference between both vial 
batches is humble. In this concern, MALS for all samples demonstrated the components of the 
fraction “≥monomers” to encompass identical molar mass ranges. 
In summary, AF4 does not disclose stability discrepancies between immunoglobulin 
solutions which vary in the outcome of visible inspection. Both protein solutions are attributed 
identical aggregate ratios by AF4, reaffirming the data derived by SE-HPLC and PAGE. Though 
AF4 was demonstrated to exceed light obscuration in detection sensitivity of process-induced 
particulate matter, operating AF4 conventionally yielded no differences between the vial volumes 
in terms of particle contamination. In contrary, running AF4 in a CHDC-like mode unveiled vial 
volumes with visible particles to slightly exceed particle-free vial volumes in the content of 
fractions that unify any sample components larger than monomer. However, the assessed 
differences remained too low (0.7%) to draw unambiguous conclusions. 
 
In case vial volumes containing visible particulate matter are subjected to sterile filtration 
(0.2 µm), the filtrate appears to be free of visible components. Furthermore, light obscuration 
analysis demonstrates the filtration step to notably reduce the amount of subvisible particles – 
minimizing the number of particles ≥1 µm/mL from a 137,592-level down to ~2000. Assumed 
the particulate matter is of proteinic nature, particles remaining on the filter membrane are 
expected to re-dissolve when exposed to denaturants such as 2% SDS, 6M urea or 6M GdnHCl 
(Allison et al., 1996; Brange et al., 1997). Subsequently, the re-dissolved proteins are amenable to 
analysis by PAGE or UV spectrophotometry. In this realm, the determination of particulate 
matter in parenteral solutions via 0.2 µm-filtration and successive analysis of the remainder by 
means of qualified analytical methods such as element analysis and SEM is long established 
(Winding and Holma, 1976).  
Volumes of five vials (with and without visible particulate matter, respectively) were 
combined and filtered (Minisart®, 0.2 µm, celluloseacetate, Sartorius AG, Goettingen, Germany). 
In order to obviate artifacts by adsorption, the filters were washed five times with 10 mL Milli-
QTM-water. Such washing is considered a state-of-the-art process in protein purification and 
precipitate isolation by means of filters (Kinekawa and Kitabatake, 1996). Subsequently, the 
filters were flushed ten times with the identical volume of 5 mL 2% SDS to re-dissolve protein 
precipitate potentially sticking on the filter membrane. The amount of protein recovered was 
assessed by UV280 spectrophotometry. In order to enable a reasonable data interpretation and to 
evaluate method efficacy, the same process was applied to protein-free buffer medium and 
batches inhering protein precipitate. Therefore, immunoglobulin bulk solution was exposed to 
thermal stress (70 °C, 10 min). The proceedings are summarized in Table 19.  
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samples buffer medium 
vial volume with 
visible particles 
vial volume without 
visible particles 
heat-stressed  
IgG bulk solution 
UV280 absorption 0.0000 0.0325 0.0315 0.4170 
Table 19. UV280 quantification of filter remainders, re-dissolved by means of 2% SDS (n=6, Srel 
for all data <0.9).  
 
According to the data of heat-stressed protein solution, a considerable amount of 
insoluble protein is retained by the filter membrane and amenable to quantification subsequent to 
re-dissolution by SDS. Additionally, the absence of protein in the sample derived from buffer 
volume matches the theory – thus affirming the principal applicability of the experimental set-up. 
In terms of the immunoglobulin batches, data of samples drawn from visible particle-
contaminated solutions are shown to exceed the results of particle-free vial volumes only 
marginally (~3%). Considering the minimal amounts of protein recovered from batches based on 
immunoglobulin vial volumes, that difference is attached minor significance.  
In order to render the re-dissolved batches more distinguishable and to broaden potential 
differences in protein concentration, 1 mL of each batch was concentrated to 0.25 mL by 
ultrafiltration (millipore ultrafree®, cut-off 10 kDa, Vivascience AG, Hannover, Germany) and 
analyzed by SDS-PAGE (Fig. 117). 
 
Basically, the findings derived hitherto are corroborated: because the denaturant solution 
appendant to thermal-stressed protein solution contained the highest amount of protein, the lane 
on the gel exhibits bands representing fragment, monomer and dimer. In contrast, the monomer 
molar mass 
standard 
thermal 
stressed 
IgG 
standard 
with 
particles 
without 
particles 
with 
particles 
200 kDa 
116 kDa 
Fig. 117. PAGE analysis of filter remainders re-dissolved in 2% SDS and concentrated by 
ultrafiltration; staining with colloidal blue. The batch based on thermal-stressed protein solution 
reveals a pronounced monomer band and weak bands representing fragment (~70 kDa) and 
dimer (300 kDa). In contrast, the lanes representing vial volumes are deemed identical, exhibiting 
solely monomer bands. 
66 kDa 
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bands of sample batches basing on immunoglobulin vial volumes appear weak in comparison. 
Generally, PAGE data of batches based on the vial volumes in dispute are absolutely identical in 
qualitative and quantitative terms - this was substantiated by further PAGE analysis of the 
concentrated denaturant solutions, thereby applying silver staining.  
In summary, isolation of the particulate matter present in vial volumes was performed by 
0.2 µm filtration. Identification of the filter remainders was approached by re-dissolution with 2% 
SDS. Neither UV280 spectrophotometry nor SDS-PAGE analysis unveiled any discrepancies 
between immunoglobulin solutions with and without visible particulate matter, respectively. As a 
consequence, the visible particles may not be considered to be of proteinic origin. 
 
9.7 Summary and evaluation 
 
This chapter addresses a case study of an immunoglobulin solution developing visible 
particulate matter within the glass vials sporadically during long-term storage. Information on the 
particles´ origin is of utmost importance, since the potential presence of any insoluble aggregates 
in a protein pharmaceutical is generally not acceptable for product release (Wang, 1999).  
Evidence of the particulate matter in the vial volumes is definitely provided by visible 
inspection as well as by light microscopic and light obscuration analysis. Minimal shear stress – 
e.g., by vial shaking – pretended the visible entities to dissolve, but had virtually no impact on 
light obscuration data. 
In case the particles´ origin is due to protein instability, this is expected to be reflected in 
increased aggregate ratios. However, a comprehensive analysis by SE-HPLC, SDS-PAGE and 
AF4 demonstrated particle-contaminated antibody solutions to equal particle-free solutions in 
aggregate content. Furthermore, detection methods known to be sensitive on (hmw) aggregates 
proved the principal parity of the vial volumes concerning the molar mass dimensions of the 
aggregates, regardless of the degree of particulate matter contamination. 
In contrast, microcalorimetric data of visible particle-contaminated batches resembled 
those of immunoglobulin solutions containing a notable aggregate fraction, induced by thermal 
stressing. Both samples featured characteristic bimodal heat transitions, comprising the transition 
of the unfolding process and a second endotherm at temperatures beyond Tm. Consequently, 
alterations in protein structure and stability may account for the formation of visible components 
in immunoglobulin solutions. 
AF4 separation parameters were developed that proved AF4/MALS to be superior to 
light obscuration in the detection of particulate matter. Yet, AF4 failed in the separation of the 
visible entities applying normal mode conditions. On the other hand, performing AF4 in a 
separation mode without exerting cross flow enabled to yield a fraction encompassing sample 
components larger than monomers. In contrast, the ratio of this very fraction was lower in 
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particle-free vial volumes – matching the findings derived hitherto, but presenting no further 
information on the particle source. 
Finally, the particulate matter was removed from the formulation by 0.2 µm-filtration. 
Assuming the particles to be constituted by insoluble protein aggregates/precipitates, the protein 
remaining on the filter membrane was re-dissolved by 2% SDS solution and analyzed by UV280 
spectrophotometry and SDS-PAGE. However, no differences between each vial volumes could 
be monitored. 
In summary, the visible particulate matter developing in some vials at random during 
storage is in all probability not of proteinic nature, since the majority of the analytical techniques 
applied denies any distinctive features in protein stability. Given the fact that precipitates in 
parenterals can be induced by a variety of sources – e.g., the insolubility of phosphate buffer 
specimen, the precipitation of trace elements or particle formation due to stopper materials – the 
identification of particle nature is commonly considered delicate (Allwood, 2000; Allwood et al., 
1998; McGoff and Scher, 2000). In general, due to the complexicity of the issue, the analytical 
arsenal may be enlarged with sophisticated techniques such as element analysis or high resolution 
mass spectrometry (Anderson et al., 2001) – but none technique per se can guarantee to provide 
unambiguous data. 
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10 Minimizing aggregation in antibody pharmaceuticals: a laboratory case study 
 
10.1 Introduction 
 
Understanding the principles of protein stabilization and armed with the methods to 
gauge changes, the formulation scientist can apply chemical or physical methods to provide a 
pharmaceutical dosage form with acceptable shelf life. Although there is a remarkable move 
towards alternative routes of administration such as nasal, oral, rectal and aerosol dosage forms, 
proteins commonly still are formulated as parenteral injectable products. Referring to the latter, 
ten years ago only few peptides and proteins have demonstrated adequate stability in parenteral 
solutions to provide marketable pharmaceuticals with shelf lifes of one year or more (Hanson 
and Rouan, 1992).  
Contrarily, within the last few years a variety of pharmaceutical proteins have successfully 
been formulated as solutions, for instance erythropoietin-related darbepoetin alpha (AranespTM), 
receptor antagonists (anakinra, KineretTM) and monoclonal antibodies (adalimumab, HumiraTM). 
However, that is not because pharmaceutical formulators suddenly had panaceas to their 
disposal, but due to the mere fact that protein pharmaceuticals per se took center stage of 
research in both science and industries (Walsh, 2003). 
Still, there is no general valid formulation strategy at hand – so proteins in pharmaceutical 
solutions have to be stabilized individually, often on a trial-and-error basis (Wang, 1999). It is the 
aim of this chapter to introduce strategies and pitfalls encountered in the formulation of liquid 
protein pharmaceuticals by means of a laboratory case study. Thereby, the  liquid formulation of 
a pharmaceutical antibody (adalimumab, 147 kDa, 50 mg/mL) was to be optimized in order to 
increase stability during long-time storage. 
The chapter is preluded by a succinct review, wherein latest options of stabilizing 
methods are presented. Due to the complexicity of the matter, a comprehensive list of 
investigations and achievements in protein stabilization can not be provided. Yet, common 
strategies in protein formulation are highlighted and mainstream trends are evaluated. 
Furthermore, attention was paid to the quoted references - as literature on the topic is plentyful, 
even the professional may facing difficulties in keeping track of. It is a further intention of 10.2 to 
leave the mark of protein liquids´ formulation to be a challenging realm. 
 
10.2 Formulation/stabilization of liquid protein pharmaceuticals: a short review 
 
Generally, the successful formulation of a protein into a liquid formulation can not be 
taken for granted. Hence, it is advisable to concomitantly provide a backup formulation by 
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stabilizing the protein via physical methods, usually lyophilization (Carpenter et al., 2002) or 
spray-drying (Andya et al., 1999).  
In case the formulator wishes to reconcile his strategy with published literature, he can 
refer to several reviews targeting protein formulation (Patro et al., 2002; McNally, 2002; Wang, 
1999; Hanson and Rouan, 1992). Additionally, a number of review articles describing protein 
instability have been published. Since those articles commonly are focused on unveiling 
degradation and aggregation pathways - thereby describing parameters opposing protein stability 
-, they are bound to (unintentionally) provide information on how to circumvent protein 
instabilities and thus how to stabilize protein liquids (Arakawa et al, 2001; Reubsaet et al., 1998; 
Kendrick et al., 1998; Constantino et al., 1995; Ò Fágáin, 1995; Chen et al., 1994; Cleland et al., 
1993). 
For many years, the epitome of protein stabilization was the excipient patch, peer with 
stabilization via internal changes, i.e., altering the protein´s structure. However, one paradigm 
shift has certainly proceeded, concerning the chemical modification of proteins in order to 
increase stability. Bearing in mind that many of the 20 amino acids occuring in proteins have 
reactive functional groups such as thiol groups or amino groups – thus rendering the protein 
drug amenable to numerous pathways of degradation and inactivation -, the need for efficient 
conjugation or immobilization procedures has always been an issue in scientific and technical 
literature, reaching the climax about one decade ago (Ò Fágáin, 1995). Several distinct chemical 
modification strategies were deemed to inhere potential to take a front seat in protein 
stabilization techniques, mainly amino acid replacement (Querol et al., 1996), intra- or 
intermolecular cross-linking (Wong and Wong, 1992), surface group modification and 
glycosylation (Liu, 1992), and modifications with polyethylene glycol (PEG, PEGylation) (Katre, 
1993). However, early has it been in the offing that these modifications are not to be performed 
at random, and that for the majority of proteins chemical modifications are associated with 
severe drawbacks concerning long-term stability. Most importantly, these modifications are often 
related to the decrease, and sometimes the complete loss of biologic activity of the protein 
pharmaceutical (Zhang et al., 2002). Meanwhile, PEGylation turned out to to be the remain of 
the former array of auspicious approaches and – considering huge research efforts put in that 
very field (Veronese, 2001) – reciprocation is at hand: e.g., pegfilgrastim (NeulastaTM) was 
approved for treatment of febrile neutropenia by the U.S. Food and Drug Administration (FDA) 
in February, 2002, and peginterferon alpha-2a (PegasysTM) received FDA approval for treating 
hepatits C shortly afterwards, in October, 2002. 
As a consequence of the manifold difficulties connected to chemical modifications, 
today´s stablization of protein liquids is primarily approached by the use of excipients. These 
excipients are also referred to as co-solvents (Timasheff, 1998), co-solutes (Arakawa et a., 1993) 
or chemical additives (Li et a., 1995). Thereby, the selection of excipients in parenteral 
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formulation design is often both rational and empirical. Rational, inasmuch as features and 
stabilizing effects of excipients are known, and they are added to prevent specific problems 
which would likely arise in their absence. On the other hand, the choice of the exact excipient 
used is far from ratonial – it seems to be driven more by an empirically impetus, satisfying one 
question: “Has it been used previously in a similar parenteral formulation?” It may be a surprising 
fact that many prototype formulations have been terminated because one or more of the selected 
excipients was not applied in a previously approved parenteral product (Powell et al., 1998).  
Basically, when proteins are to be used in a clinical setting as a human therapeutic, certain 
criteria restrict the type of excipients that may be used and the conditions under which the 
protein is subjected to long-term storage: excipient components must be safe, i.e., non-toxic and 
non-infective. The solution should be isotonic with respect to the route and mode of 
administration. Moreover, the pH is to be adjusted in appropriate way (Arakawa et al., 2001). 
Taking also into account the impact of excipients and osmolalities on felt pain and burning 
syndroms of the patients during drug administration is considered a matter of course. E.g., 
sodium citrate enjoys the reputation of being an excellent stabilizing buffer, often used in 
concentrations of sizeable 20 mM (Remmele et al., 1998). Unfortunately, at higher concentrations 
sodium citrate is too painful in most instances for subcutaneous use (Powell et al., 1998). 
Similarly, PEGs – though used in liquid protein formulations in amounts up to 65% – were 
proved to inhere drawbacks, as the replacement of PEG by components with lower osmolality 
has effectively reduced the incidence of side effects such as pain and thrombosis (Doenicke et al., 
1992). Facing such requirements, the formulator may anticipate failure ante portas.  
In this realm, the usual proceeding of the formulating scientist is to screen the array of 
excipients available for use – selected on the criterion of what has been used previously. To stay 
with PEGs: the use of lmw PEGs has received approval for numerous parenteral formulations, 
e.g., VepesidTM and RobaxinTM injectable contain both PEG 300 as excipients, and AtivanTM is 
formulated with the use of PEG 400, according to information provided by the manufacturer. 
However, what about PEG 1200, PEG 4000 or hmw PEGs? Concerning to that, it was shown 
that PEG 4000 inhibits the thermal aggregation of lmw urokinase (Vrkljan et al., 1994). 
Furthermore, PEGs were demonstrated to contribute to lactate dehydrogenase stability in 
solution and after freeze-thawing, and the protective effects were maximal with hmw PEGs (Mi 
et al., 2002). Additionally, hmw PEGs such as PEG 8000 were shown to be able to direct 
precipitation, once proceeding, in a manner that protein precipitate is essentially native in 
secondary structures, revealing a virtually identical second-derivative IR spectrum to the native 
dissolved protein control (Kendrick et al., 1998). 
In many cases, problems are associated not only with excipient choice but especially with 
concentrations. E.g., the stabilizer sucrose was demonstrated to reveal virtually no effect on the 
(thermal) stability of megakaryocyte growth factor at low protein concentrations, while at higher 
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protein concentrations (~2 mg/mL) the addition of sucrose increased the protein stability 
substantially. To confuse the matter further on, sucrose exhibited no effect on the reversibility of 
the denaturation (Narhi et al., 1999). Vice-versa situations, where stabilization is facilitated by 
lower excipient concentrations, are also reported. For instance, sorbitol hampers heat-induced 
aggregation of fibroblast growth factor at 55 °C notably below concentrations of 0.5 M, but 
inheres considerably less effect at higher concentrations (Tsai et al., 1993).  
So, facing such inconsistencies, how to decide which class of excipient is to be prioritized, 
which specimen in particular, what are the proper concentrations? Two main approaches are 
prevalently considered state-of-the-art: to apply high-throughput formulation screening (HTS) 
and to perform accelerated stability studies.  
Pertaining to the first, computational HTS can be applied to study the physico-chemical 
features of proteins, thus providing a sound knowledge on protein characteristics (Luo et al., 
2002). Subsequently, various HTS tools may be used in order to identify promising excipients 
that confer physical stability for a given protein. E.g., in self-interacting chromatography the 
protein is immobilized on a chromatographic packing material and elutions are performed with 
the identical protein in mobile phases containing excipients of interest. Compounds that result in 
shortest retention times correspond to those that minimize protein-protein interactions 
(Przybycien and Wilcox, 2002). Naturally, autosampling devices which increase the evaluation 
efficiency of protein liquids are also to be subsumed to HTS, such as autosampling DSC 
instruments (Plotnikow et al., 2002). However, most pharmaceutical formulators will specify HTS 
as a tool of preformulation studies, which nowadays may be considered to interdigitate with the 
virtual formulation process to an increasing extent (McNally and Lockwood, 2002). 
On the other hand, accelerated stability studies (ASS) can be employed to assess the 
influence of excipients – and therefore to predict shelf life of protein formulations. ASS were 
reported to be performed in isothermal and non-isothermal ways (Reithmeier et al., 2001). 
Unfortunately, proteins sometimes act idiosyncratic, and the general consensus is that prediction 
of protein stability based solely on accelerated studies is difficult due to the alleged non-
Arrhenius character of protein degradation – because mechanism and route of degradation may 
depend on temperature (Bartkowski et al., 2002). Yet, dealing successfully with the formulation 
of protein liquids when tests under accelerated storage conditions (e.g., 40 °C) are not applied has 
rarely been reported. Conversely, by arranging ASS in proper way outstanding efficacy may be 
yielded: besides parameters contributing to the stability of recombinant factor VIII, reasons of 
inactivation and main aggregation pathways were elucidated via ASS. Furthermore, simple 
analytical techniques such as HPLC were found to be sufficient in order to monitor and predict 
stability and shelf life, yet in lieu of alternative methods such as one-stage clotting assays (Wang 
and Kelner, 2003). However, it is to be outlined that even the most ingenious HTS and ASS 
studies are no surrogate for real-time stability tests.  
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Evaluation of optimal pH values and buffer components usually accounts for the first 
step towards a stable protein formulation. Since proteins exhibit a stability optimum in a narrow 
pH range – often in a scope of <0.5 pH values -, the assessment of the pH of the formulation is 
a crucial point (Fatouros et al., 1997). In any case, it is advised to distinguish the formulation pH 
by more than 1 unit from the protein´s isoelectric point.  
Common buffer systems are based on phosphate, citrate, succinate, acetate, TRIS or 
histidine, and a variety of other buffer specimen has successfully been applied – but proteins are 
deemed to normally favor one specific buffer system (Piros et al, 2003). For instance, in 
phosphate buffer (10 mM) megakaryocyte growth factor irreversibly precipitated upon unfolding 
under all conditions examined, whereas in imidazole buffer (10 mM) no precipitation was to be 
detected, and unfolding was shown to be (partially) reversible (Narhi et al., 1999). Besides the 
compatibility of the buffer system with the protein, the characteristics of the buffer per se have to 
be scrutinized – as solutions containing components such as sodium phosphate can undergo a 
dramatic decrease in pH at the eutectic point, making those media potentially a poor choice if 
freezing during storage or transport were a matter (Arakawa et al., 2001).  
The use of surfactants remains an important beacon for the field of stabilizing protein 
liquids, whereby the utilization of ionic surfactants may be considered out of date because they 
exhibit a notable affinity to the protein´s polar and nonpolar groups, thus facilitating denaturation 
phenomena (Giancola et al., 1997). Despite a broad variety of nonionic surfactants is at hand, 
derivatives and modifications of virtually solely three surfactants reap the merits, i.e., Tween 
(polyoxyethylene sorbitan monooleate), Pluronic (polyoxyethylene polyoxypropylene block 
polymer) and Brij (polyoxyethylene alkyl ether) (Hillgren et al., 2002; Katakam et al., 1995). The 
observed stabilization of proteins (e.g., albumins) against heat treatment is due to surfactants 
altering aggregation behavior rather than inducing considerable stabilization of the native state. In 
this regard, the binding of nonionic detergents to proteins through hydrophobic surface 
interaction has been shown (Jones and Randolph, 1995). Stabilization by surfactants often 
implicates rather than enhancing conformational stability, the prevention of loss from unfolding 
at air-water or solid-water interfaces, or protection of proteins from aggregation that occurs as a 
result of unfolding, shaking or shear stress, or freezing. However, it is difficult to distinguish 
which of these mechanisms is of primary importance in detergent-induced protein stabilization, 
but nevertheless, due to empiric reasons, the use of surfactants is still on the rise (Arakawa and 
Kita, 2000). 
In contrast to the explicit consent to surfactants, scientists are challenging existing 
paradigms in terms of salts. Hitherto, the addition of salts to protein formulations was deemed a 
must – fostered by the fact that the mechanisms of protein stabilization were thought to be 
elucidated, mainly by sorting things out by means of the Hoffmeister lyotropic series (Timasheff, 
1998). Further models addressed parameters like electrostatic shielding, weakening of ionic 
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repulsion/attraction, an increase of surface tension at water-protein interfaces and preferential 
hydration of proteins (Kohn et al., 1997). Moreover, salts can stabilize via alternative ways, e.g., 
fostering ligand-binding: a >500-fold stabilization of starch phosphorylase against irreversible 
inactivation at elevated temperatures (>50 °C) by adding salts was reported (Griessler et al., 
2000). However, the number of case studies where salts stabilize is put into perspective by studies 
proving salts to have no effect or even to destabilize, what is easily verified by searching the 
review articles. Recently, a full factorial experiment established that all proteins investigated were 
insensitive to sodium chloride concentrations, but greatly stabilized by glycerol (Engel et al., 
2002). Furthermore, as far as tonicity of formulations is concerned, non-electrolytes are often 
preferred to salts as tonicity adjusters due to the potential problems salts cause in precipitating 
proteins (Pikal, 1990). It is to be noted that comprehensive studies - investigating the effect of 
numerous stabilizing additives - were published, wherein the attempt of stabilization via salts was 
virtually turned down (Sebeka et al., 2001). Yet, if that will become the rule is to be doubted, but 
currently the relevancy of protein stabilization via salts struggles to keep pace with other 
approaches, especially those using sugars and polyols. 
Today, sugars and polyols enjoy a great popularity in being used as protein stabilizers. In 
contrast to salts, sugars and polyols contribute to protein stability not only in a non-specific way, 
but they additionally can protect proteins from chemical degradations such as oxidation (Li et al., 
1996). In the majority of published studies, the stabilizing effect of sugars depends on their 
concentration, and 0.3 M (5%) sugar and polyol, respectively, has been proposed as a lower 
concentration limit (Arakawa et al., 1993). The issue is excellently addressed by a comprehensive 
review attributing the stabilization of proteins in aqueous media to the presence of weakly 
interacting cosolvents such as sugars and polyols (McClements, 2002). However, since it was 
published in a field not directly related to pharmaceutics, the article – at least hitherto – was 
attracting little response.  
The three classes of excipients presented above undoubtedly account for the lion´s share 
of substances used for protein stabilization in liquids. Yet, a plurality of other components are 
frequently utilized, with amino acids, metal ions and polymers representing those being most 
widely-used.  
Especially the field of protein stabilization by polymers is in rapid move, since in the last 
decade dramatic improvements in production and purification of tailor-made polymers have been 
achieved. E.g., cyclodextrins (especially hydroxypropyl-β-cyclodextrin) reveal biocompatibility, 
stability and solubilizing features and, hence, are frequently employed as stabilizers (Sharma et al., 
2000). More importantly, efficient syntheses of new sugar-branched stabilizing cyclodextrins have 
meanwhile become a habit (Hattori, 2001). Whereas the stabilizing potential of 
poly(vinylpyrrolidone) – e.g., in terms of antibody solutions - in concentrations of ~1% is known 
since about one decade (Gombotz et al., 1994), other water-soluble polymers such as 
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polyethyleneimine have only recently been proved to effectively stabilize various proteins with 
polymer concentrations down to 0.01% (Andersson and Hatti-Kaul, 1999). Alternatively, 
polymers can be designed with utmost affinity to either potential destabilizers such as metal ions 
or to the designated protein. Although the main application of such polymers is deemed to be 
protein stabilization in gels (Bromberg, 2001) or in aqueous protein analytics (Pessela et al., 2003), 
rational applications in protein liquids are to be expected. 
Of course, protein stability by new excipients can not always be resoundingly successful. 
Heralded as potent and efficacious stabilizers for instance for the stabilization of antibodies 
(Vangala et al., 2000), compatible solutes such as ectoin and hydroxyection fell short of the 
formulators´ expectations, though further applications have been described (Borges et al., 2002). 
This is mainly because compatible solutes normally demand to be used in high concentrations 
(>3 M) and because they are high in price.  
Although a general rule of stabilization can not be provided, in many cases proper 
adjustment of pH as well as an adequate choice of buffer system, surfactant and of one additional 
excipient such as sugar should provide conditions for sufficient protein shelf life. 
 
10.3 General experimental procedures 
 
A pharmaceutical active immunoglobulin (adalimumab, subclass G1, 147 kDa) was to be 
formulated in an adequate solution in order to generate a liquid parenteral dosage form, revealing 
50 mg/mL final drug concentration. Due to previous formulation experiments, a 
phosphate/citrate buffer system was proved to be superior to other buffer systems in terms of 
protein stabilization. Solution pH values of 5.2 and 6.0, respectively, were found to be favored. 
Consequently, dosage form (liquid) and drug concentration (50 mg/mL) were enjoined 
parameters and optimization had to be approached via addition of adequate excipients. All 
excipients used were of highest purity (“pro analysi” grade) and purchased from Merck KGaA, 
Darmstadt, Germany. Mannitol was sourced from Mallinckrodt Baker B.V., Deventer, Holland. 
Analysis of visible particulate matter was conducted according to the regulation of Ph. 
Eur. 2002 (§ 2.9.20 Contamination with particulate matter – visible particles). Subvisible 
particulate matter analysis was realized via light obscuration (SVSS-C40, PAMAS GmbH, 
Rutesheim, Germany). A Superose TM6 10/30 column (Amersham Pharmacia Europe GmbH, 
Freiburg, Germany) was implemented for SE-HPLC analysis (assessment of protein monomer 
content), applying a 0.5 mL/min flow rate of a PBS buffer with pH 7.5, and connected to UV280 
spectrophotometry, refractive index detection and MALS for on-line detection as described in 
Chapter 6. Analysis of each sample was performed at least in triplicate. Except stated otherwise, 
for all SE-HPLC data Srel was below 0.13 and for all light obscuration data below 2.3. 
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Individual protein formulations were prepared via dilution of  adalimumab concentrates 
(~70 mg/mL) with excipient stock solutions. The latter were generated by excipient dissolution 
in phosphate/citrate buffer medium. Prior to sterile filtration (0.2 µm, Minisart®, Sartorius AG, 
Goettingen, Germany), pH adjustement was performed by adding of acid/base specimen of 
buffer components. All formulations were prepared at least in duplicate, and generated via final 
sterile filtration of solution batches into heat-sterilized (180 °C, 25 min) 2R glass vials (Schott 
Glas, Mainz, Germany) under aseptic laminar air flow conditions. Teflon coated butyl-rubber 
closures were sterilized via moist heat (121 °C) according to Ph. Eur. prior to usage. The 
formulations were subjected to 3 m-short-time storage at three different temperatures (5 °C, 25 
°C, 40 °C). 
Adalimumab concentrates were provided by diafiltration of adalimumab bulk solution via 
Vivaflow 50 units (cut-off 50 kDa, Vivascience AG, Hannover, Germany), using 
phosphate/citrate buffer medium for buffer exchange. Popular current processes for 
concentration and buffer exchange of biopharmaceutical solutions are based on IEX, SE-HPLC, 
ultra-/diafiltration and tangential flow filtration (Christy et al., 2002). Diafiltration was applied 
because purification, concentration and buffer exchange are rendered possible within a single-
unit operation with variable flow dynamics, thus minimizing protein stress (Fig. 118).  
 
 
Within one diafiltration cycle, protein concentration was doubled and re-diluted to the 
original concentration, except for the terminal concentration step. Hence, dissolved substances 
not intended for presence can effectively be removed (e.g., a 1.00% concentration can be 
downsized to 0.00098% within ten diafiltration cycles). Subsequent to purification and 
concentration, the adalimumab concentrates were centrifugated (5 °C, 3000 g, 20 min). 
 
10.4 Evaluation of pH optimum 
 
In order to evaluate the optimal solution pH (i.e., pH 5.2 or pH 6.0), three different 
adalimumab formulations were analyzed, varying solely in pH. Stability data of formulations 
containing 1 mg/mL Tween 80 are illustrated in Fig. 119. 
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Concerning the monomer content, no pH is to be favored, as both formulations exhibit 
comparable monomer losses at 40 °C storage, albeit differing slightly in the stability profile. Data 
of 25 °C storage conditions are similar to 40 °C data, whereas at 5 °C all protein solutions 
analyzed in the course of this study did virtually undergo no alterations in monomer content. Yet, 
this is to be expected, since the impact of both thermodynamic forces affecting protein stability 
(i.e., enthalpic and entropic forces) is shifted towards protein stabilization at lower temperatures 
(Wang, 1999; Kristjansson and Kinsella, 1991). Contrarily, a 6.0 solution pH did notably facilitate 
the formation of subvisible particulate matter during 12 w storage, regardless of the storage 
temperature. As the intensity of particulate matter formation is obviously connected with lower 
temperatures, the particles´ origin is prima facie not to be assumed proteinic. In that regard, if 
severe particulate matter formation were merely due to protein instabilities, this prevalently is 
associated with exposure to elevated temperatures during storage tests (Constantino et al., 1995).  
In case the formulations contained 6.16 mg/mL NaCl instead of Tween 80, the findings 
were substantiated (Fig. 120).  
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However, the addition of salt appeared to auxiliarily foster the formation of subvisible 
particles, since the number of particles greater than 1 µm is increased by a similar degree in both 
solutions. Furthermore, after 12 w SE-HPLC data ascribed the pH 6.0 solutions a greater 
monomer content than at pH 5.2 conditions, though the differences were minimal (~0.3%) and 
not corroborated by 25 °C results. 
Hitherto, particle formation appeared to be facilitated by NaCl addition and pH 6.0 
storage and to be opposed by Tween 80 addition and a solution pH of 5.2. Consequently, the 
question arises whether Tween 80 can alleviate particle contamination in solutions containing 
salts such as NaCl (Fig. 121).  
Yet, according to Fig. 121, once the formulations comprised salt, the addition of 
surfactant had no influence in terms of subvisible particle formation. Interestingly, in all samples 
particle numbers were maximal at lowest storage temperature (5 °C), indicating the particle origin 
to be potentially due to inorganic material. Moreover, visible inspection of solutions containing 
salt revealed a slight turbidity after 4 w storage, regardless of the storage temperature. It is known 
that precipitation of visible inorganic components can be the result of storage at cold 
temperatures, even if the storage is temporarily. E.g., sodium phosphate buffers may yield the 
relatively insoluble Na2HPO4*12H2O at 4°C (Borchert et al., 1986). However, in terms of 
particulate matter being an evaluating criterion, a solution pH of 5.2 is to be prioritized. 
The matter has to be approached differently as far as data of monomor content is 
concerned – as both solution pH values render identical monomer contents during storage and in 
case of NaCl-containing formulations (without Tween 80!) a pH of 6.0 appears to reveal even 
slightly higher stability. Yet, it is commonly accepted that at pH values towards neutral or even 
basic conditions proteins are prone to a broader variety of potential degradation mechanisms 
(Wang, 1999). E.g., carbonyl-amine reactions of un-ionized protein amides, (base-catalyzed) β-
eliminations and deamidations are facilitated by higher pH values as well as various oxidation 
reactions (Akers and DeFelippis, 2000).  
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Hence, in summary, a solution pH of 5.2 is to be considered superior to a 6.0 value in 
terms of adalimumab long-time stability.  
 
10.5 Stabilization by excipients 
 
10.5.1 Surfactants 
 
Interestingly, in terms of stabilizing protein liquids Tween 20 appears to inhere an 
absolute competitiveness - if not a minor superiority - on Tween 80 (Bam et al., 1998; Johnston, 
1996). Yet, Tween 80 enjoys a by far greater popularity among the pharmaceutical formulators, 
according to the listings of recently FDA approved parenterals or compendia such as Physicians´ 
Desk Reference. In order to scrutinize the stabilizing potential of surfactants on adalimumab, 
various amounts of Tween 80 were added to a protein solution containing 6.16 mg/mL NaCl. 
Generally, Tween 80 is assumed to stabilize proteins – inter alia - via binding through 
hydrophobic surface interaction. As the protein´s surface characteristics are decisively influenced 
by the presence of salts, the effect of NaCl absence additionally was surveyed (Kheirolomoom et 
al., 1998) (Fig. 122).  
 
 
Pertaining to the data presented in Fig. 122, Tween 80 proved unable to bring any 
stabilizing influence to bear. If 0.03% Tween 80 was added, this even resulted in decreasing the 
monomer content after 12 w storage at 40 °C. In this realm, in the majority of articles addressing 
this topic the stabilizing impact of Tween 80 was shown to be related to increasing 
concentrations of surfactant, this being valid in the range from 0.001 to 1% (Arakawa et al., 
2000). Thus, the data above seem agonizing - the more, as the analysis of the formulations in 
terms of subvisible particulate matter seemed to meet into a coherent picture (Fig. 123):  
At all storage temperatures, the addition of Tween 80 led to a substantial growth of 
subvisible particle numbers, carried to the extremes at concentrations of 0.03% and, hence, 
backing the findings of SE-HPLC. Interestingly, the absence of NaCl proved to notably decrease 
Fig. 122. Influence of Tween 
80 on protein formulations 
containing 6.16 mg/mL NaCl 
(storage temperature 40 °C). 
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the formation of subvisible particles, regardless of the storage temperature. Similarly to the 
findings above, the addition of 0.1% Tween 80 to solutions of interleukin-1β (100 µg/mL) was 
demonstrated to have no stabilizing effect in the pH below 7 (Gu et al., 1991). The potential of 
Tween 80 to destabilize proteins was also reported. E.g., 0.1 and 0.01% Tween 80, respectively, 
were shown to facilitate precipitation of bovin somatotropin at 54 °C, whereas without Tween 80 
the protein revealed enhanced stability (Akers and DeFelippis, 2000).  
In contrast to the minor stabilizing impact on liquid solutions during storage, Tween 80 
proved to confer notable stability towards adalimumab during freeze-thaw cycles (Fig. 124). 
  
Protein solutions were repeatedly subjected to stress via freezing (-80 °C, 12 hrs) and 
thawing (5 °C, 12 hrs), and the effect of Tween 80 was determined. The number of freeze-thaw 
(f/t) cycles applied was closely correlated to a gain in subvisible particulate matter. However, 
whereas the exertion of 5 f/t cycles on solutions with 0 or 0.03% Tween 80 content was reflected 
in a ~10-fold increase in particle contamination (particles ≥1 µm), the situation virtually remained 
unchanged in 0.1% Tween 80 solutions. Seconding these findings by SE-HPLC analysis led to 
similar results (Fig. 125).  
In close accordance to the results of numerous studies published where f/t cycles were 
exerted on other proteins, the stability of adalimumab decreases when exposed to repeated f/t 
stress and no surfactant is present. Conversely, the addition of surfactant shields the protein 
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against deleterious parameters associated with freezing/thawing, as the content of native 
monomer – what was verified with MALS – remained unchanged.  
 
 
Until the mid-1990s, this phenomenon was accounted to the protein´s exposure to ice-
water interfaces, as studies on individual proteins have demonstrated the greater denaturation 
during f/t cycles when proteins are frozen under conditions assumed to generate a large ice 
surface area than when conditions leading to less surface area are employed (Hsu et al., 1995). 
Yet, earlier studies demonstrated Tween 80 to inhere potential to protect adalimumab against f/t 
stress in concentrations of 0.001%, well below the CMC (Fraunhofer, 2002). Consequently, 
parameters of ice-water interfaces are not to be considered solely responsible for f/t denaturation 
of adalimumab, what was corroborated recently in proving sodium phosphate buffers to undergo 
pH shifts up to 3 pH units due to crystallization of the disodium salt (Pikal-Cleland et al., 2002). 
Generally, formulators should be aware of the potential for Tween 80 to affect adversely 
the oxidative stability of proteins, despite its stabilizing impact on proteins. Unfortunately, it 
inheres the tendency to produce peroxides which can oxidize methionine and cysteine residues. 
This phenomenon was reported in studies involving the formulation development of Neupogen® 
(Herman et al., 1996) and recombinant human ciliary neurotrophic factor (Knepp et al., 1996).  
In summary, the addition of 0.1% Tween 80 to adalimumab solutions is to be preferred. 
Though 0.1% Tween was demonstrated to improve the protein stability in stored liquids only 
marginally, the stabilizing effects during processes such as freezing and thawing are substantial. 
Anyway, addition of Tween 80 may emerge as great benefit, as freezing is a common unit 
operation in the production, storage and transport of protein pharmaceuticals (Cao et al., 2003). 
Additionally, the use of 0.1% Tween 80 in pharmaceuticals is well-accepted, demonstrated by the 
FDA approval of OrthocloneTM (murine IgG2a) as early as 1986.  
Besides Tween 80, the nonionic surfactant Solutol® HS15 was investigated in its potential 
to stabilize adalimumab. The protecting features of Solutol® in concentrations of 0.03 and 0.1% 
were shown recently in terms of aviscumin parenterals (Steckel et al., 2003). Hence, the influence 
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of Solutol® on adalimumab solutions in terms of particulate matter contamination were 
compared to protein solutions containing 0.1% Tween 80 (Fig. 126). 
In contrast to solutions with 0.03% and 0.1% Solutol®, adalimumab solutions with 1% 
Solutol® and 0.1% Tween 80, respectively, exhibited a notable increase of particulate matter 
during storage. This positive influence of low Solutol® concentrations was not reflected in data of 
SE-HPLC analysis. After 12 w storage (40 °C), all solutions containing Solutol® revealed a loss in 
monomer content of ~0.5% in comparison to the reference (0.1% Tween 80). Especially the 
formation of hmw aggregates during storage is to be considered critically, as those are generally 
deemed as pre-stage specimen of potentially arising visible particulate matter (Fig. 127). 
 
This experiment is suitable to illustrate the great advantages offered by MALS in the 
early-stage detection of hmw protein aggregates (Fig. 128). Due to its high sensitivity on large 
analytes, minimal concentrations thereof are sufficient to induce an immense response at the 
detector. E.g., the formation of hmw aggregates after 1 w storage (40 °C) could be verified by 
MALS - but was virtually not seizable by UV280-detection.  
As a consequence, Solutol has to be deleted from the list of potential stabilizers, as the 
formation of hmw ranges already in early stages of accelerated shelf life studies is generally not 
acceptable. The more, as even minimal amounts of protein (<0.1%) are known to contingently 
account  for precipitation  (Hoffman, 2000).  The findings  above fall  into place  with other data, 
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where higher concentrations (>1%) of Solutol® HS15 were shown to destabilize solutions of 
serpine-related protease inhibitor and avail visible particulate matter phenomena (Schmidt, 2003).  
 
10.5.2 Polyols 
 
Many sugars (e.g., sucrose, glucose, raffinose, trehalose) and polyols (e.g., glycerol, 
sorbitol, mannitol) are subsumed under the caregory of protein stabilizing co-solvents (Ebel et 
al., 2000). It is widely believed that those substances act primarily through a steric exclusion 
mechanism. E.g., polyols such as sorbitol are often used in order to stabilize parenterals, for 
instance in a number of lyophilized vaccine pharmaceuticals such as MumpsvaxTM, MeruvaxTM II 
and AttenuvaxTM or intravenous administrable solutions such as CardeneTM.  
Yet, in contrast to other excipients such as surfactants, sugars and polyols normally 
demand to be added in higher concentrations (>0.5 M) in order to deploy their complete 
stabilizing potential (McIntosh et al., 1998). As a consequence, sorbitol was added to adalimumab 
solutions in concentrations of 50 and 100 mg/mL, respectively, and subjected to 12 w storage 
(Fig. 129). 
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As far as particulate matter is concerned, sorbitol apparently decreased the tendency for 
particle formation during storage, compared to solutions where no sorbitol was present. Thereby, 
the amount of added sorbitol did virtually not result in any differences. In terms of monomer 
content, the stabilizing effect of sorbitol was found to be closely concentration-dependent (Fig. 
130).  
According to Fig. 130, the addition of 100 mg/mL sorbitol increases the content of 
monomer by ~1.5% during 12 w storage at 40 °C. Reducing the amount of excipient leads to a 
reduction of adalimumab stability. The findings are corroborated by recent investigations on the 
stability of horse immunoglobulins, where 180 mg/mL sorbitol were demonstrated to be 
superior to the addition of 90 mg/mL in terms of protein stabilization against heat stress 
(Rodrigues-Silva et al., 1999). That the the stabilizing impact of sugars and sugar-derived polyols 
is concentration-dependent has repeatedly been reported (Chan et al., 1996; Fatouros et al., 
1997). Interestingly, the addition of 4 mg/mL salt detracts notably from the stabilizing potential 
of sorbitol (- 0.25% monomer). However, inasmuch this observation can be correlated to the fact 
that NaCl was shown to foster the formation of subvisible particles in other adalimumab 
solutions during storage can – at present – not be explained sufficiently (refer to Fig. 123). On 
the other hand, the absence of NaCl in adalimumab solutions containing 0.1% Tween 80 leads to 
only a minimal increase in monomer content during shelf life experiments (refer to Fig. 122).  
How does this match to the findings illustrated above? Trying to get to the bottom of the 
stabilization mechanism prevalently ascribed to polyols and sugars may be helpful: the 
steric/preferential exclusion mechanism of polyols has already been mentioned. Additionally, 
recent measurements of the influence of temperature on preferential interaction coefficients 
hypothesize the stabilization mechanism of some co-solvents to be highly temperature-dependent 
(Xie and Timasheff, 1997a). In this realm, at higher temperatures it was found that the stabilizing 
mechanism was due to a greater preferential accumulation of these excipients by the native state 
than by the denatured state (Xie and Timasheff, 1997b). Can sorbitol be thought to contribute to 
adalimumab stabilization in a manner to thermodynamically favor native state-sorbitol 
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interactions more than denatured state-sorbitol interactions? Is is to be noted that this is not in 
complete accordance with the stabilizing mechanism of preferential exclusion, where the majority 
of stabilizing input is due to thermodynamically infavorable interactions of hydrophobic protein 
sites – once denaturation occurred – with the surrounding water molecules. 
Now the salt: at low concentrations, salts affect electrostatic shielding (according to 
Debye-Hueckel), leading to potential stabilization when there are major repulsive interactions 
leading to protein unfolding (Wang, 1999). At high concentrations salts are inducing preferential 
hydration of proteins, by keeping hydrophobic protein spots away from the water molecules 
(Kohn et al., 1997). Bearing in mind the amounts of NaCl added (4 mg/mL), both NaCl and 
sorbitol may be thought to figuratively compete for the native state adalimumab, with NaCl 
slightly in the fore. Hence - the stabilizing potential of sorbitol assumed to exceed that of NaCl -, 
NaCl addition has to be expected to detract from adalimumab stability, as demonstrated. 
Generally, if the derived hypothesis is to be come into consideration at all, the observations are 
expected to be continuable with other sugar-derived polyols. Corresponding data in terms of 
mannitol are presented in Fig. 131.  
Basically, the findings on sorbitol are substantiated by addition of mannitol to 
adalimumab solutions: (1) solutions enriched by 80 mg/mL mannitol exceed mannitol-free 
solutions in protein monomer content by ~1.5% after 12 w storage (40 °C), (2) the stabilizing 
input of mannitol is oriented towards a concentration-dependent profile, (3) and NaCl reduces 
the forfending features of mannitol. Interestingly, these data are corroborated by identical 
experiments performed at 25 °C. 
In order to prevent misconceiving: the addition of sorbitol or mannitol to protein 
solutions is not always associated with a gain in protein stability. For instance, sorbitol offered no 
advantage against precipitation of porcine growth hormone when evaluated during thermal or 
interfacial stress conditions – in contrast to Tween 20 and hydroxypropyl-β-cyclodextrin, 
respectively (Charman et al., 1993). 
In summary, it may be concluded that adalimumab is stabilized via preferential 
accumulation of both sorbitol and mannitol by the native state. This mechanism is interfered by 
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NaCl, which was shown to impede protein stabilization via polyols – the findings that NaCl does 
not detract from adalimumab stability when added to protein solutions containing 0.1% Tween 
80 is consistent with the conclusions above, as in that case the protecting polyol contribution can 
not be interfered.  
 
excipients (mg/mL) % monomer % aggregate % fragment 
aggregate share (%) in the 
amount of monomer  loss 
no excipient 95.32 1.68 3.02 35.7 
sorbitol 50 96.49 1.40 2.11 39.9 
sorbitol 50 
NaCl 4 96.13 1.38 2.49 35.7 
sorbitol 100 96.80 1.21 1.99 37.8 
mannitol 40 96.37 1.42 2.21 39.1 
mannitol 40 
NaCl 4 96.26 1.40 2.34 37.4 
mannitol 80 96.81 1.28 1.91 39.9 
 
Table 20. Impact of excipient addition on adalimumab stability after 12 w storage at 40 °C. Data 
derived via SE-HPLC. 
 
According to Table 20, the amount of native monomer assessed in each adalimumab 
formulation is dependent on the addition of polyols and on the excipient composite. 
Commensurately, the amounts of aggregate and fragment fractions vary. Thereby, the aggregate 
share in the amount of monomer loss remains constant, regardless of the excipients added, if any. 
In other words, the ratio of adalimumab aggregates and fragments are in firm balance (i.e., ~38% 
aggregates and ~72% fragments), and this equilibrium is not influenced by the addition of 
polyols and salts. In this concern, it is prevalently accepted that the major consequence of protein 
denaturation is aggregation (Wang, 1999). Then, if sorbitol and mannitol were contributing to 
adalimumab stability solely via native state stabilization, this should be reflected in alterations of 
the aggregate share. Since this is not the case, there has to be a further mechanism of adalimumab 
stabilization by sorbitol/mannitol, resulting in an impediment of fragmentation processes. 
In this realm, protein fragmentation is often due to electron transport processes and ion 
desorption, to be observed in protein oxidation by means of vial headspace O2 (Goolcharran et 
al., 2000) or induced during protein analytics, e.g., in electrospray mass spectrometry (Thomson, 
1997). It was reported earlier that mannitol in concentrations above ~10 mg/mL is able to inhibit 
oxidative degradation via complexation of metal ions (Li et al., 1996). Recently, mannitol was 
demonstrated to reveal free radical quenching features, since the ˙OH radical mediated 
fragmentation of serum albumin was effectively hampered by mannitol (Jaiswal et al., 2002).  
In case mannitol/sorbitol were indeed revealing potential to protect adalimumab from 
oxidative degradation, this were deemed a valorizing characteristic: generally, special care has to 
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be taken in choosing the right means of protein stabilization against oxidation. E.g., chelates such 
as Fe(III)-EDTA – commonly used in reducing oxidative fragmentation – were demonstrated to 
induce rather than prevent oxidation (Zhao et al., 1996).  
In conclusion, it was shown that adalimumab can effectively be stabilized by adding 
mannitol or sorbitol. Besides contributing to protein stability by native state protection, those 
substances were unveiled to stabilize the protein via a further mechanism, thereby reducing 
fragmentation during long-term storage.  
 
10.5.3 Salts  
 
Beyond doubt, NaCl is the most-used salt in the formulation of protein parenterals. 
Whereas NaCl was evidenced to detract from adalimumab stability in the presence of polyols and 
not to increase protein stability if representing the exclusive excipient, it was often found to 
prevent proteins from degradation, even in a concentration-dependent manner (Mayr and 
Schmid, 1993). Generally, in pondering on the potential stabilizing effect of salts acting according 
to the Hoffmeister lyotropic series provides a rough rule of thumb. Hence, using the anionic 
acetate instead of chloride as counterion in sodium salts may be promising.  
As illustrated in Fig. 132, the individual solutions reveal different protein stability.  
 
 
Obviously, the adalimumab solution containing NaCl is stacked against protein stability, 
since as early as after 4 w storage (40 °C) formulations containing NaCl and sodium acetate, 
respectively, exceed the NaCl enriched batch in monomer content by ~0.25%, adding up to a 
>0.4% difference after 12 w. Consequently, sodium acetate is deemed to contribute more to 
adalimumab stability than sodium chloride. Due to the Hoffmeister series, acetate ions are 
attributed a greater ionic strength than chloride ions. Consequently, acetate enhances 
hydrophobic interactions and reduces solubility of the protein´s hydrophobic spots, thus 
resulting in preferential hydration (Wang, 1999) – providing a sound explanation fo the data 
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above, which are corroborated by the results of 25 °C storage. Nevertheless, the addition of 
sodium acetate has no share in additional protein stabilization, since the salt-free formulation 
inheres identical monomer content. 
In comparison to both other formulations, acetate containing formulations exhibit a 
greater number of particles beyond 1 µm (~180,000/mL versus <6,000/mL). 
One main aspect in this realm attends the cationic counterion of the phosphate buffer 
system, as extreme pH shifts (~3 pH units) were reported to occur in sodium phosphate buffer 
during freezing, what can negatively affect protein stability (Pikal-Cleland and Carpenter, 2001). 
Yet, an indispensable prerequesite for sodium phosphate buffer use is its basic compatibility with 
adalimumab in liquid – not frozen – state (Fig. 133).  
 
 
As illustrated in Fig. 133, the stability of adalimumab dissolved in potassium phosphate 
buffer equals that determined in sodium phosphate buffers. Data of storage tests performed at 25 
°C substantiated these findings. Additionally, both buffer systems equaled in particulate matter 
contamination. Hence, potassium phosphate is considered to be preferred in liquid protein 
formulations.  
In summary, it can be concluded that the addition of NaCl should be avoided in case of 
adalimumab solutions. If the presence of salts is favored – e.g., by reasons of osmolality – the 
addition of sodium acetate proved to be superior to sodium chloride. Similarly, potassium based 
phosphate buffer systems equaled sodium phosphate buffer systems in terms of adalimumab 
stability. Given the background of the substantial pitfalls associated with sodium phosphate 
buffers in f/t processes, it is to be dissuaded from its use. 
 
10.6 Summary 
 
This chapter was dedicated to the formulation of liquid protein parenterals. Concerning 
to theory, prevalent strategies in liquid protein formulation were highlighted, actual mainstream 
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trends were outlined and both assets and drawbacks of the most popular excipients were 
displayed within a short literature review. 
In practical realm, a laboratory case study was demonstrated, encompassing protein bulk 
preparation and studies on pH optima and stabilizing excipients. Thereby, the influence of 
processing parameters such as freeze/thawing were taken into consideration, e.g., in case of 
surfactant concentration and choice of cationic counterion of the phosphate buffer system. 
Primarily, a solution pH of 5.2 and the addition of 0.1% Tween 80 were found to be 
favored against other alternatives. Protein stability and particulate matter contamination after f/t 
studies and (accelerated) storage tests were evaluating criteria. 
Furthermore, polyols such as mannitol and sorbitol were demonstrated to substantially 
contribute to protein stability with virtually identical potency. Preferential accumulation at the 
native state protein was found to be not the only stabilization pathway, as both protein 
aggregation and fragmentation were impeded. 
NaCl was evidenced to detract from protein stability, once polyols were present. Yet, the 
addition of sodium acetate was shown to inhere no deleterious impact on protein stability.  
The data merge in a conclusive pattern and can be transferred into the suggestion of a 
promising formulation, comprising the parameters potassium phosphate buffer, pH 5.2, 0.1% 
Tween 80 and the addition of ~50 mg/mL mannitol or sorbitol – aiming at final osmolality 
values of~300 mosM/kg. 
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11 Summary, conclusions and prospective 
 
Due to enormous progress in recombinant DNA techniques and methodology, a 
multitude of biosynthetic, pharmaceutically relevant polypeptides and proteins became available 
in the past decade and have been employed in numerous pharmaceutical products. 
Concomitantly, substantial progress was made in pharmaceutical formulation development of 
peptides and proteins, inasmuch as many challenges in formulating these compounds in products 
with optimal therapeutic effects and shelf life were successfully approached. Additionally, new 
drug delivery systems – e.g., based on polymeric materials – will most likely enlarge the spectrum 
of future proteinic dosage forms, where today solutions and lyophilized products take center 
stage. Yet, due to the proneness of proteins to degradation - what can affect pharmaceutical 
relevant features such as biological activity and immunogenicity -, scrutinizing the homogeneity 
of protein formulations is of utmost importance. Hence, the development and implementation of 
new analytical techniques in order to keep pace is highly desired. It was the aim of this thesis to 
evaluate the applicability of asymmetrical flow field flow fractionation (AF4) in pharmaceutical 
protein analytics, to compare AF4 performance with established state-of-the-art methods and to 
reveal the effectivity of inherent AF4 characteristics in demanding analytical tasks. 
 
The Theoretical Section encompasses Chapter 2, wherein the family of field-flow 
fractionation techniques is introduced, as well as Chapter 3 (attending to protein aggregation) 
and Chapter 4, which provides an insight into multi-angle light scattering. The Theoretical 
Section is summarized in Chapter 5. 
 
Chapter 6 attends to the general applicability of (semi-)chromatographic AF4 in protein 
analysis. The correlation of cross flow progression with increased resolution was exemplified by 
the separation of human serum albumin (HSA), thereby rendering the (base-line) separation of 
HSA specimen into monomer, dimer, trimer and tetramer possible. Due to the AF4 feature to 
discretionarily alter the resolution power within one separation run, the fractionation of higher-
order aggregates and insoluble, precipitated protein was successfully performed.  
System variables and parameters of fractionation were investigated, revealing that sample 
loads differing more than two orders of magnitude did not negatively affect data reproducibility. 
Whereas up to now cross flow intensity was deemed to predominantly account for contingent 
sample loss during AF4 experiments, analysis of proteins with varying hydrophilicity proved the 
preceding focusing step to contribute notably for that phenomenon. How to overcome potential 
drawbacks such as sample-membrane interactions by adequate choice of the ultrafiltration 
membrane as well as carrier liquid composition was illustrated. 
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Given the background that effective AF4 fractionations are due to differences in analyte 
size – i.e., in diffusion coefficients -, the separation of equal-sized proteins is prima facie 
considered to be impractical. Yet, the retaining impact of sample-membrane interaction was 
evidenced to decrease the effective diffusion coefficient, resulting in successful fractionations of 
proteins differing ~1% in size (i.e., G-CSF, 19.6 kDa versus IFN-α2a, 19.4 kDa). In this realm, 
the normal mode elution order of smaller analytes eluting prior to larger ones was shown to be 
invertible, exemplified by the elution of a 40 kDa analyte prior to IFN-α2a. 
AF4 potency in analysis of insoluble high molecular weight (hmw) aggregates was 
compared with data derived by established methods such as light obscuration and Coulter 
technique, verifying the competitiveness of AF4. 
A comparative study of AF4 with size exclusion chromatography (SE-HPLC) unveiled 
SE-HPLC to inhere higher recovery rates and AF4 to exhibit greater resolution. Coupling both 
techniques with multi-angle light scattering (MALS) detection systems disclosed SE-HPLC to 
induce artifacts concerning hmw aggregate quantification. Moreover, in contrast to SE-HPLC, 
AF4 was capable of seizing undissolved and precipitated protein specimen, thus making AF4 a 
promising alternative in the analysis of protein pharmaceuticals. 
 
AF4´s ability to separate undissolved sample components proved to be an indispensable 
feature in the analysis of a pharmaceutical protein formulated within siliconized disposable 
syringes, which was attended to in Chapter 7. During long-term storage, visible particulate 
matter developed sporadically within the syringe volumes, raising the question of the particles´ 
origin. Since protein instabilities were not to be accounted for being the particle source – verified 
by several analytical methods -, silicone oil detachment and subsequent coalescence came into 
question, as the barrel siliconization process was lacking a final heat curing step. Thus, an AF4 
application was developed, intending to separate µm sized silicone oil droplets. The task was 
approached by analysis of silicone oil emulsions, followed by the fractionation of ultrasound-
stressed syringe volumes containing detached and coalesced silicone oil after stress exertion. 
Unambiguously, detached silicone oil was evidenced by AF4 to account for visible particulate 
matter in the syringe volumes, corroborated by MALS and refractive index detection as well as 
light microscopy and syringe frictional drag analysis. Subsequently to artificially induced protein 
aggregation of particle-containing syringe volumes, AF4 was able to separate silicone oil droplets, 
protein monomer and aggregates as individual fractions within one single run. Finally, AF4 
enabled access to data on protein drug stability and insights into protein adsorption tendencies 
on coalesced silicone oil specimen – thereby providing valuable data which otherwise would have 
required a variety of various analytical techniques.  
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In Chapter 8 the suitability of AF4 in overall-characterization of gelatin nanoparticles 
was explored. The efficacy of providing hmw gelatin bulk material by various desolvation steps 
was evaluated by SE-HPLC and AF4. Due to the absence of shear degradation phenomena, AF4 
was demonstrated to enable more moderate separation conditions than SE-HPLC, verified by 
on-line determination of analyte molecular weight via MALS.  
Gelatin nanoparticles were characterized by means of AF4/MALS with respect to size 
and size distributions and the data were compared to results of photon correlation spectroscopy 
(PCS) and scanning electron microscopy (SEM). Because of the precedent separation step via 
AF4, data derived by MALS revealed a greater veracity than PCS results, where the size 
assessment of nanoparticles relied on batch experiments. Whereas PCS attributed unloaded and 
DNA plasmid loaded nanoparticles virtually unimodal size distributions, both AF4/MALS and 
SEM demonstrated the nanoparticles to span a broad size range. Furthermore, loaded and 
unloaded nanoparticles were unveiled to exhibit only minimal differences in size, thus providing 
information on the interplay of nanoparticles and plasmid strands. 
For the first time, the separation of nanocolloidal drug carrier and designated 
pharmaceutical payload was established. Additionally to drug carrier characteristics, data on the 
loading efficacy could be yielded. Furthermore, nanoparticle shelf life stability and extent of 
potential drug decomplexation could be determined.  
Bearing in mind colloidal, polymer-based drug delivery carriers gaining increasing 
importance, that very AF4 application is expected to accommodate the demand for accurate 
analytics, as the pharmaceutical product can be characterized in both qualitative and quantitative 
terms. 
 
In Chapter 9 a case study of particulate matter analysis of a pharmaceutical antibody 
solution is presented, wherein individual vials of one production lot developed visible 
components at random during long-term storage. In order to (a) provide evidence on the 
presence of the contamination, (b) to attempt particulate entitiy quantification and (c) to elucidate 
particles´ nature, a multiplicity of analytical techniques were applied, encompassing particle 
counting (optical inspection, light obscuration, light microscopy), protein characterization 
techniques (SE-HPLC, polyacrylamide gel electrophoresis, AF4, microcalorimetry) and particle 
separation techniques (sterile filtration, AF4). 
Attempts to isolate the particulate components by AF4 or filtration techniques provided 
no further indications of the particle´s origin. 
Virtually no alterations in protein characteristics were monitored between contaminated 
and particle-free vial volumes, respectively. Solely, microcalorimetric data of contaminated vial 
volumes resembled those of immunoglobulin solutions exposed to heat stress prior to analytics.  
Consequently, protein instabilities were assumed not to cause the visible contamination.  
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The topic of liquid protein parenterals, protein instability and particulate matter was 
completed by presenting a formulation process of an immunoglobulin into a liquid formulation 
in Chapter 10. Prevalent strategies and mainstream trends of liquid protein formulation were 
introduced by reviewing latest publications on the issue.  
Parameters revealing decisive influence on the protein´s long-term stability such as solution 
pH as well as type and concentration of excipients were evaluated by means of accelerated 
stability studies at various storage temperatures. Additionally, processing parameters, e.g., 
freeze/thawing, were assessed evaluating criteria in terms of surfactant and buffer choice.  
The addition of NaCl was shown to detract from protein stability and to facilitate the 
formation of particulate matter. Non-deleterious alternatives of salt additives were discovered.  
On the other hand, the addition of polyols such as mannitol and sorbitol was demonstrated 
to notably contribute to the immunoglobulin stability. Preferential accumulation at the native 
state protein was thought to be the mechanism for reducing aggregation phenomena of the 
protein. Besides, the extent of fragmentation was reduced by polyols, indicating a second 
pathway of stabilization, which was hypothesized to be hampering of oxidation processes. Due to 
detailed investigations, a proposal pertaining an optimal formulation could be made in the course 
of that case study. 
 
This thesis has shown that asymmetrical flow field-flow fractionation (AF) can effectively 
be used to monitor protein stability in a broad variety of pharmaceutical formulations. Especially 
in the characterization of the most common outcome of physical instability – i.e., protein 
aggregation – the potential of AF4 has comprehensively been demonstrated. Moreover, AF4 
applications and separation tasks within pharmaceutical analytics considered hitherto impractical 
or at least highly challenging were successfully performed. Facing increasingly complex liquid- or 
colloidal-based formulations, with this knowledge practice and research in pharmaceutical 
analytics can take a notable step forward. 
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